Antibody_ID	HC_germline	CDR_H3	LC_germline	CDR_L3	Antigen_target	Neutralization	Source	Reference
CR3022	IGHV5-51	AGGSGISTPMDV	IGKV4-1	QQYYSTPYT	RBD	No	SARS_infection	Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
S110	IGHV3-30	AKDRFQFARSWYGDYFDY	IGKV2-30	-	S_protein	-	SARS_infection	Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S124	IGHV2-26	ARINTAAYDYDSTTFDI	IGKV1-39	-	RBD	-	SARS_infection	Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S309	IGHV1-18	ARDYTRGAWFGESLIGGFDN	IGKV3-20	-	RBD	Yes	SARS_infection	Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S315	IGHV3-7	ARDLWWNDQAHYYGMDV	IGLV3-25	-	RBD	Yes	SARS_infection	Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S303	IGHV3-23	ARERDDIFPMGLNAFDI	IGKV1-5	-	RBD	No	SARS_infection	Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S304	IGHV3-13	ARGDSSGYYYYFDY	IGKV1-39	-	non-RBD	Yes	SARS_infection	Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S305	IGHV1-18	ASDYFDSSGYYHSFDY	IGKV3-11	-	non-RBD	-	SARS_infection	Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S310	IGHV1-69	ATRTYDSSGYRPYYYGLDV	IGLV2-23	-	non-RBD	No	SARS_infection	Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
P1A-1C7	IGHV1-46	length=15	IGKV1-39	length=10	RBD	No	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C10	IGHV1-69	length=16	IGKV1-5	length=9	RBD	No	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C11	IGHV1-69	length=16	IGKV1-5	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C6	IGHV3-13	length=19	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D3	IGHV3-13	length=18	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C2	IGHV3-23	length=10	IGKV1-36	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1B2	IGHV3-30	length=12	IGLV2-14	length=10	RBD	No	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C1	IGHV3-33	length=17	IGKV1D-13	length=9	RBD	No	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D1	IGHV3-53	length=12	IGLV2-8	length=10	RBD	No	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D5	IGHV3-53	length=15	IGKV1-33	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D6	IGHV3-53	length=15	IGKV1-33	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A10	IGHV1-2	length=19	IGKV2-40	length=9	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A4	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B2	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G1	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G12	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A10	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B10	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D6	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D12	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1F10	IGHV1-2	length=19	IGKV2-40	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F8	IGHV1-2	length=14	IGKV3-20	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G9	IGHV1-2	length=14	IGKV3-20	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C3	IGHV1-46	length=15	IGKV1-5	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C10	IGHV1-69	length=11	IGKV3-11	length=8	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G10	IGHV1-69	length=11	IGKV1-39	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F11	IGHV1-69	length=17	IGLV1-40	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D9	IGHV2-5	length=16	IGLV1-47	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E2	IGHV2-5	length=12	IGKV1-5	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E4	IGHV2-5	length=11	IGLV2-14	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F4	IGHV2-70	length=14	IGLV1-44	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A3	IGHV3-11	length=12	IGKV1-9	length=9	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D6	IGHV3-15	length=24	IGLV1-44	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B12	IGHV3-15	length=13	IGLV6-57	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F9	IGHV3-15	length=16	IGKV1-NL1	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D5	IGHV3-23	length=14	IGLV3-21	length=11	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B4	IGHV3-30	length=22	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F2	IGHV3-33	length=11	IGLV2-11	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G4	IGHV3-33	length=11	IGLV2-11	length=11	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C8	IGHV3-33	length=13	IGKV2D-30	length=9	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1B3	IGHV3-48	length=16	IGKV3-20	length=10	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B11	IGHV3-48	length=16	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B12	IGHV3-48	length=16	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C4	IGHV3-48	length=16	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E11	IGHV3-48	length=16	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2H7	IGHV3-48	length=16	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G12	IGHV3-48	length=16	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1E5	IGHV3-48	length=16	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A10	IGHV3-53	length=15	IGKV1-33	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F5	IGHV3-53	length=14	IGKV1-NL1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D7	IGHV3-53	length=12	IGKV2D-30	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G1	IGHV3-66	length=11	IGKV3-20	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1E1	IGHV3-66	length=9	IGKV3-11	length=10	RBD	No	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1F11	IGHV3-66	length=11	IGKV3-20	length=8	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A8	IGHV3-9	length=23	IGLV2-14	length=10	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B10	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C10	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D3	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2H4	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A5	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A8	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B1	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C12	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A6	IGHV3-9	length=23	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A9	IGHV3-9	length=17	IGLV1-40	length=11	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A1	IGHV3-9	length=17	IGLV1-40	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G11	IGHV3-9	length=17	IGLV1-40	length=11	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E12	IGHV3-9	length=17	IGLV3-20	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2F6	IGHV4-38	length=20	IGLV2-8	length=10	RBD	Yes	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1B10	IGHV4-39	length=20	IGLV1-47	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B9	IGHV4-39	length=9	IGKV1-NL1	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2F11	IGHV4-39	length=9	IGKV1-NL1	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G8	IGHV4-39	length=11	IGKV1-5	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A1	IGHV4-59	length=14	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D11	IGHV4-59	length=22	IGLV3-25	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F11	IGHV4-59	length=15	IGKV1-39	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A7	IGHV5-51	length=17	IGLV3-1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A12	IGHV7-4-1	length=16	IGKV1-39	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G5	IGHV7-4-1	length=12	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P3A-1F1	IGHV3-13	length=17	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P3A-1G8	IGHV3-64	length=19	IGLV1-44	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A10	IGHV1-46	length=26	IGLV1-40	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F6	IGHV1-69	length=15	IGLV2-23	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E11	IGHV2-5	length=18	IGLV1-36	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A2	IGHV3-23	length=14	IGLV1-51	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A8	IGHV3-23	length=11	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2C1	IGHV3-23	length=16	IGKV2-28	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-1H5	IGHV3-30	length=21	IGKV1-39	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1G2	IGHV3-30	length=21	IGKV1-39	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2B3	IGHV3-30	length=21	IGKV1-39	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-1H6	IGHV3-30	length=21	IGKV1-39	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1G5	IGHV3-30	length=22	IGLV3-21	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2E10	IGHV3-30	length=21	IGKV1-39	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E3	IGHV3-30	length=21	IGKV1-39	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D9	IGHV3-30	length=21	IGKV1-39	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F4	IGHV3-30	length=22	IGKV2-30	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E7	IGHV3-43D	length=20	IGKV3-1	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F10	IGHV3-7	length=13	IGKV3-21	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D1	IGHV3-9	length=13	IGKV1-12	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D2	IGHV4-39	length=16	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E12	IGHV4-59	length=11	IGLV1-44	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2C12	IGHV5-51	length=15	IGLV1-44	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1A8	IGHV3-23	length=11	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1C6	IGHV3-30	length=20	IGKV1-33	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1A5	IGHV5-51	length=18	IGLV1-47	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1D5	IGHV6-1	length=16	IGKV3-20	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A1	IGHV1-24	length=15	IGKV2-28	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C8	IGHV1-46	length=22	IGKV1-33	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D5	IGHV1-46	length=24	IGLV1-40	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C8	IGHV1-46	length=15	IGLV2-23	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E9	IGHV1-46	length=22	IGLV2-14	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B8	IGHV1-46	length=16	IGLV2-23	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A11	IGHV1-69	length=14	IGKV1-39	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C10	IGHV1-69	length=22	IGLV6-57	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A2	IGHV1-8	length=21	IGLV1-40	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C11	IGHV1-8	length=17	IGLV3-21	length=13	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F11	IGHV1-8	length=15	IGKV4-1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B9	IGHV1-8	length=15	IGKV1-36	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C12	IGHV2-5	length=16	IGKV3-11	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C12	IGHV2-5	length=19	IGKV4-1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C3	IGHV2-5	length=12	IGLV6-57	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C1	IGHV3-11	length=13	IGLV3-21	length=13	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C4	IGHV3-13	length=20	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G8	IGHV3-13	length=13	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D3	IGHV3-13	length=16	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B10	IGHV3-13	length=16	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D8	IGHV3-13	length=18	IGLV3-19	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G10	IGHV3-13	length=18	IGLV3-19	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H6	IGHV3-15	length=18	IGLV3-19	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D6	IGHV3-23	length=13	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E12	IGHV3-23	length=14	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D12	IGHV3-23	length=24	IGLV1-47	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B6	IGHV3-30	length=20	IGKV1-33	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E6	IGHV3-30	length=20	IGKV1-33	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B1	IGHV3-33	length=14	IGKV3-15	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C5	IGHV3-33	length=14	IGKV3-15	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H7	IGHV3-33	length=14	IGKV3-15	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G9	IGHV3-33	length=12	IGLV5-37	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G11	IGHV3-33	length=17	IGLV2-14	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B8	IGHV3-53	length=9	IGKV1-9	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D2	IGHV3-53	length=15	IGLV1-40	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D1	IGHV3-53	length=11	IGKV1-9	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C9	IGHV3-7	length=14	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E4	IGHV3-7	length=14	IGKV3-20	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G12	IGHV3-7	length=12	IGLV6-57	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D12	IGHV3-7	length=18	IGKV2-28	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F1	IGHV3-74	length=12	IGLV6-57	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C10	IGHV3-9	length=14	IGLV3-21	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E8	IGHV3-9	length=13	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A2	IGHV3-9	length=14	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D6	IGHV3-9	length=14	IGLV1-40	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B12	IGHV3-9	length=17	IGLV1-51	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A6	IGHV3-9	length=27	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D9	IGHV3-9	length=16	IGKV3-15	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D10	IGHV3-11	length=21	IGLV2-14	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A1	IGHV3-53	length=11	IGKV3-20	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C8	IGHV3-53	length=11	IGKV1-9	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D10	IGHV4-31	length=12	IGLV6-57	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G5	IGHV4-31	length=14	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A12	IGHV4-39	length=17	IGKV4-1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C7	IGHV4-39	length=16	IGLV2-23	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F7	IGHV4-39	length=18	IGLV2-23	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F9	IGHV4-39	length=14	IGLV2-23	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A5	IGHV4-4	length=14	IGLV2-14	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C6	IGHV4-4	length=22	IGLV1-40	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A10	IGHV4-4	length=21	IGKV1-39	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B9	IGHV4-59	length=22	IGKV4-1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A7	IGHV4-59	length=22	IGKV4-1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B1	IGHV4-59	length=22	IGKV4-1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B6	IGHV4-59	length=22	IGKV4-1	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C10	IGHV4-59	length=17	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E5	IGHV4-59	length=12	IGLV6-57	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G4	IGHV4-59	length=12	IGKV1D-16	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G7	IGHV4-61	length=20	IGLV2-14	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B10	IGHV5-51	length=12	IGKV2-28	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C9	IGHV5-51	length=11	IGLV3-19	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D11	IGHV5-51	length=13	IGLV1-44	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B4	IGHV5-51	length=13	IGLV1-44	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H3	IGHV5-51	length=13	IGLV1-44	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E1	IGHV5-51	length=12	IGLV3-21	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B11	IGHV7-4-1	length=20	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D7	IGHV7-4-1	length=10	IGKV6-21	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C9	IGHV7-4-1	length=10	IGKV6-21	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D11	IGHV7-4-1	length=10	IGKV6-21	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A3	IGHV1-3	length=11	IGLV6-57	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A8	IGHV1-46	length=20	IGLV3-21	length=13	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B5	IGHV1-46	length=13	IGLV3-21	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1C6	IGHV1-46	length=16	IGLV3-21	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1C1	IGHV3-13	length=21	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A5	IGHV3-33	length=15	IGKV1-33	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A12	IGHV3-33	length=19	IGLV1-51	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B1	IGHV3-74	length=15	IGLV1-36	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B3	IGHV3-9	length=24	IGLV3-1	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B12	IGHV4-34	length=16	IGLV1-51	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B8	IGHV5-51	length=19	IGLV3-1	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A7	IGHV7-4-1	length=14	IGLV3-21	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A10	IGHV7-4-1	length=15	IGLV3-21	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E10	IGHV1-46	length=15	IGKV3-11	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D2	IGHV1-8	length=21	IGLV1-40	length=12	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D8	IGHV3-23	length=20	IGKV3-15	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D7	IGHV3-33	length=13	IGKV1-39	length=10	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D1	IGHV3-53	length=11	IGKV1-9	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E8	IGHV3-9	length=16	IGKV3-15	length=11	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D5	IGHV4-39	length=14	IGLV2-23	length=8	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E6	IGHV4-59	length=16	IGKV3-20	length=9	RBD	-	SARS-2_infection	Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
BD-494	IGHV3-53	ARDLVVYGMDV	IGKV1-9	QQLNSYPFT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-498	IGHV3-66	ARDLVVYGMDV	IGKV1-9	QQLNSYPLT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-500	IGHV3-53	ARDAMSYGMDV	IGKV1D-39	QQSYSTPPDT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-503	IGHV3-53	ARDAAVYGIDV	IGKV1D-39	QQSYTTPLFT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-504	IGHV3-66	ARDLISRGMDV	IGKV1-9	QQSYTTPLFT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-505	IGHV3-53	ARDRVVYGMDV	IGKV1D-33	HQYDNLPPT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-506	IGHV3-53	ARDLVSYGMDV	IGKV1-9	QQLNSYPLT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-507	IGHV3-53	ARDLVVYGMDV	IGKV1-9	QQLNSNPPIT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-508	IGHV3-53	ARDAQNYGMDV	IGKV1D-39	QQSYSTPPYT	RBD	Yes	SARS-2_infection	Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CC12.1	IGHV3-53	ARDLDVYGLDV	IGKV1-9	QQLNSYPPKFT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.2	IGHV3-53	ARDYGDLYFDY	IGKV3-20	QQYGSSPRT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.3	IGHV3-53	ARDFGDFYFDY	IGKV3-20	QQYGSSPRT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.4	IGHV1-2	ATESWVYGSGSYSSGAFDI	IGLV2-8	TSYAGSNNFV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.5	IGHV1-2	ARGPRYSGTYFDY	IGLV2-14	SSYTSSSTQV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.6	IGHV1-2	ARGPRYSGTYFDY	IGLV2-14	SSYTVSSTQV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.7	IGHV1-2	ARGPRYSGTYFDF	IGLV2-14	SSYTISSAQV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.8	IGHV1-2	ARGPRYSGTYFDY	IGLV2-14	SSYTSSSAQL	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.9	IGHV1-2	ARGPRYSGTYFDY	IGLV2-14	SSYTSSSAQV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.10	IGHV1-2	ARGPRYSGTHFDY	IGLV2-14	SSYAGSSTQV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.11	IGHV1-2	ARGPRYSGTYFDY	IGLV2-14	SSYTSSSAQL	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.12	IGHV1-2	ARGPRYSGTYFDY	IGLV2-14	SSYTSGSTQV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.13	IGHV3-53	ARDPYGYSSIWDGQGGH	IGKV1-33	QQYDNLPIT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.14	IGHV3-21	ARGGYCSDGSCYVQDRLIYYYSGLDV	IGKV2-30	MQGTHWPPT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.15	IGHV3-48	ARDRRRRYCTNGVCYRPEEIDY	IGLV1-40	QSYDSSLSGVV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.16	IGHV3-33	ARDPFPGAVAGTGYLQY	IGLV3-21	QVWDSSSDPWV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.17	IGHV3-30	AKSSGSYYYYYYGMDV	IGLV3-21	QVWDSSSDHPVV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.18	IGHV1-46	ARLHCGGDCYLDY	IGLV6-57	QSYDSSNHEEIWV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.19	IGHV3-23	AKGSGSGSYPNYYYYYGMDV	IGLV3-21	QVWDNNSDHLV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.20	IGHV3-30	AKDQAYYDILTGYLNPPKNYYYYGMDV	IGLV1-47	AAWDDSLSGRVV	non-RBD	No	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.21	IGHV1-24	ATAFSIFGVVPPDY	IGLV1-44	AAWDDSLNGPV	RBD	No	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.22	IGHV1-24	ATGFAQNMVLLTPY	IGKV3-15	QQYNNWPPIT	non-RBD	No	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.23	IGHV4-39	ARQGDCSTTSCAYDY	IGLV3-25	QSADSSGTYLVV	non-RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.24	IGHV3-30	AKDRTGNYYYGMDV	IGKV1-39	QQSYSTPWT	non-RBD	No	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.25	IGHV3-23	AKDRYYEFWSGYSNWFDP	IGLV1-44	AAWDDSLNGPV	non-RBD	No	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.26	IGHV5-51	ARVNYYDSSGYPSFHFDY	IGLV7-43	LLYYGGAQRWV	non-RBD	No	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.27	IGHV1-2	AREMPAAMGYYYYGMDV	IGLV2-23	YSYAGSSTFVFV	non-RBD	No	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.28	IGHV3-23	AKANKYSSSEFDF	IGLV1-47	AAWDDSLSGWV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.29	IGHV7-4-1	AVYYYDSGSPGWFDP	IGKV1-39	QQSYSTPPT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.30	IGHV1-69	ARDFRYCSSTRCYFWFDP	IGKV1-39	QQSYSTPRT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.31	IGHV1-46	ARWYDSTGSIDY	IGKV1-17	LQHNSYPILT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.32	IGHV3-9	AKDQGYSYGNYFDY	IGLV3-21	QVWDSSSDHPYV	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.33	IGHV1-69	ALRNQWDLLVY	IGKV3-20	QHYGSSLWT	RBD	Yes	SARS-2_infection	Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
COVA1-01	IGHV4-39	ARVSSGYYFTPFDY	IGKV3-20	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-02	IGHV3-30	ARARGGSYNDAFDI	IGLV2-14	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-03	IGHV3-30	AKDGQYYDFWSGYLGARTNPHYYYYMDV	IGKV1-27	-	non-RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-04	IGHV1-69	ARIPGYDSSGYYRGDY	IGKV3-11	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-05	IGHV1-24	ATSRVRGVSNWFDP	IGLV2-23	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-06	IGHV3-9	AKDMGEAVAGTHYGMDV	IGLV3-1	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-07	IGHV1-69	ARVGAYDSSGYSNDY	IGKV3-11	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-08	IGHV3-30	AREDYYDSSGSFDY	IGLV2-14	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-09	IGHV4-59	ARHSQGWLQQAVAFDI	IGKV1-39	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-10	IGHV3-66	ARGGYYYDPSGYYSRSFSFDY	IGLV2-14	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-11	IGHV3-30	ARSASGSYYGAFGY	IGLV3-1	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-12	IGHV1-2	ARDLVWATVSGTMDV	IGLV2-8	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-13	IGHV3-7	ARETPTSTYSSGWYNYYYYMDV	IGKV1-5	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-14	IGHV4-59	ARRGEVNGYRGAFDI	IGKV3-20	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-15	IGHV3-30	ARPRGGNYLAGFDP	IGLV2-14	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-16	IGHV1-46	ARPPRNYYDRSGYYQRAEYFQH	IGKV1-33	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-17	IGHV1-2	AREAVAARPGNFDY	IGLV1-51	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-18	IGHV3-66	ARVEWAAAGTFY	IGLV7-46	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-19	IGHV3-21	ARWKSDYYDSSGYYPAAFDI	IGKV3-15	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-20	IGHV3-21	AGDQNLYCSGDSCYYHYYGMDV	IGLV3-21	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-21	IGHV3-30	ARDSEYYDILTGYLAPTHYYYYYMDV	IGKV3-15	-	non-RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-22	IGHV1-18	ARDLVDTAMVQTLDDYGMDV	IGLV3-1	-	non-RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-23	IGHV5-51	ARYYYDSRGYTSIDF	IGLV3-25	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-24	IGHV3-33	ARGPPPDDSSGWTMGYFDY	IGLV1-51	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-25	IGHV4-39	ARLNYDFWSGYYSYALYYMDV	IGKV1-5	-	non-RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-26	IGHV4-31	ARQQLDYYDSSGCFDY	IGKV1-9	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-27	IGHV3-30	ARAMGSYRSPFDY	IGKV3-20	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-01	IGHV3-13	ARGGDRYPVGYFDL	IGKV1-39	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-02	IGHV4-39	ARRSTSRWGYYYMDV	IGKV1-39	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-03	IGHV3-48	AREANSDFWSGYLGYFDY	IGKV3-11	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-04	IGHV3-53	ARDLERAGGMDV	IGKV3-20	QQYGSLYT	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-05	IGHV5-51	ARHMRPSIAARPGYQYYMDV	IGKV1-33	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-06	IGHV4-59	ARGGWSLDS	IGKV3-20	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-07	IGHV3-53	AREAYGMDV	IGKV3-20	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-08	IGHV3-30	ARVIGGNYFGAFDI	IGKV3-15	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-09	IGHV4-34	ARGRNYVLQFSEWPHPRAHFDN	IGKV4-1	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-10	IGHV3-23	AKGLRGQQLVIPTEYFQH	IGKV3-20	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-11	IGHV3-21	ARGPRGCSSTSCYGSYFDY	IGKV3-20	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-12	IGHV3-53	ARDQPLPDILTGYYTGPLDY	IGKV3-15	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-13	IGHV1-69	ARDLDTMGGMDV	IGKV3-20	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-14	IGHV1-69	ARVRYYDSSGYYEDY	IGKV3-11	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-15	IGHV3-23	AKDTGYCGDDCYIKLIRGGPDY	IGKV2-30	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-16	IGHV1-69	ASSDSSGFVGSRGFDY	IGKV1-17	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-17	IGHV1-69	ASFGDDSGDEGVR	IGKV3-11	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-18	IGHV1-69	ARVYSYDSSGYYLEY	IGKV3-11	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-19	IGHV1-18	ASVVGGRIAAAGCLGY	IGKV3-20	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-20	IGHV3-53	ASPLLLTPPDYYYYMDV	IGKV1-17	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-21	IGHV4-4	ARWKYNDRFDY	IGKV1-5	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-22	IGHV1-69	ARGPRYCSSTSCYAGVYFDY	IGKV1-33	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-23	IGHV1-2	ARDGFGDVEEMATIKDAFDI	IGKV3-20	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-24	IGHV5-10	ARPNPAGGYDSSGWVDAFDI	IGKV1-39	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-25	IGHV1-24	ATGPTIAAAATNWFDPG	IGLV2-14	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-26	IGHV3-15	TTDRGDSYGYYYCMDV	IGLV3-1	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-27	IGHV1-8	ARVVGSSWYPVDAFDI	IGLV2-14	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-28	IGHV3-30	AKDKAPPCSSGWYYFDY	IGKV3-15	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-29	IGHV4-30	ARGVEDPVVPAAIPWCWFDP	IGKV1-39	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-30	IGHV3-30	ASLPVVPAAIGPLPAFDI	IGLV3-21	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-31	IGHV1-2	RKMLTIFGKVNQTMLLISGAKGQ	IGKV2D-29	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-32	IGHV1-69	ARTHSYDNSGQYFDY	IGKV3-11	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-33	IGHV5-10	ARLKVITIFGVVRDDYGMDV	IGLV2-23	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-34	IGHV3-30	ARSASGSYYGAFDY	IGLV2-14	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-35	IGHV3-33	ARDGSNESCSGGFCSDS	IGLV3-21	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-36	IGHV5-51	ARHNPDYYDSSGPLDY	IGKV1-5	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-37	IGHV1-24	ATSPAVMSVGWVDP	IGLV1-40	-	non-RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-38	IGHV4-39	ARQVRQWLEDDAFDI	IGKV1-17	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-39	IGHV3-53	ARAHVDTAMVESGAFDI	IGLV2-23	-	RBD	Yes	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-40	IGHV4-4	AGRYCSGGRCGWFDP	IGLV2-23	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-41	IGHV3-21	ARVQKDIVVVPVALADYYYYGMDV	IGKV3-15	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-42	IGHV4-31	AKEGSGGGSQNWFDL	IGKV3-11	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-43	IGHV1-18	ARFDYGYPYSSWSVLSIDY	IGKV1-17	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-44	IGHV3-30	AREGSRQWLVIYFDY	IGKV1-39	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-45	IGHV1-2	ARGDGDYYDSSGYYRPTLYNWLDP	IGKV3-20	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-46	IGHV4-39	ARHPSGLYQLLN	IGKV1-33	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-47	IGHV3-9	AKVATYYYDRSGYYYGGALDY	IGKV4-1	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-01	IGHV4-59	ARGPAATYYYYMDV	IGKV1-39	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-02	IGHV3-7	ARDWEEQWLVAFDY	IGLV3-1	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-03	IGHV3-23	AKEIAVAGCFDY	IGLV3-25	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-04	IGHV3-33	ARVGSVKSTAGYDFWSGDPFDY	IGLV3-21	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-05	IGHV1-24	ATAYSVDTAMVRGVGY	IGLV1-44	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-06	IGHV1-69	ARDAPDYYDSSGPTYFDY	IGKV4-1	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-07	IGHV3-9	AKMGPDPAHDYGRKNDAFDI	IGKV3-20	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-08	IGHV3-9	AKAEPEVGGYDYYMDV	IGKV1-39	-	non-RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-09	IGHV4-59	ARGPAATYYYYMDV	IGKV1-39	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-10	IGHV5-51	ARRGYTYGADFYGLDV	IGKV4-1	-	RBD	No	SARS-2_infection	Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
B5	IGHV1-2	-	IGKV3-20	-	RBD	Yes	SARS-2_infection	Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
B38	IGHV3-53	AREAYGMDV	IGKV1-9	QQLNSYPPYT	RBD	Yes	SARS-2_infection	Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
H2	IGHV3-9	-	IGKV1-39	-	RBD	Yes	SARS-2_infection	Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
H4	IGHV1-2	ARVPYCSSTSCHRDWYFDL	IGKV2-40	MQRIEFPLT	RBD	Yes	SARS-2_infection	Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
1M-1D2	IGHV3-64	ARGAEYYDFWSGYYSAYFDY	IGLV1-47	SMGAQPDLCA	RBD	Yes	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-13A3	IGHV3-30	ARGGGSYYYWFDP	IGKV4-1	QQYYST	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-13D11	IGHV4-34	ARAGYSSSWYGVRGVDP	IGKV3-20	QQYGSSRSWT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14B2	IGHV3-30	AKGSDIVVVPVGNWFDP	IGKV1-39	QQSYSTFTLYT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-10B11	IGHV3-66	ARATWLRGVMDV	IGLV6-57	QSYDSSNHWV	RBD	No	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14E4	IGHV4-61	ARVQRYYPDSSGFYGRRFDI	IGKV1-39	QQSHSFPFT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14E5	IGHV3-30	ARSGGGSYRGPFDY	IGKV1-9	QQLNSYVT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2D4	IGHV3-23	AKIGLGLGGLLRRYFDY	IGKV3-11	QQRTNWPL	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2G12	IGHV3-11	DANYDYVVAQTGYGR	IGKV1-39	QQNYSTWT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-4G4	IGHV1-46	ARERGDSSGYYEIITTANRRFGMDV	IGLV2-23	CSYAVSSTWV	RBD	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2D1	IGHV4-39	ARGDRIQLWLLDAFDI	IGLV1-47	CSTGAQPEWLG	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-7E9	IGHV1-69	ARIPGWDRGTDRNWNDD	IGKV3-11	QQRSNWPPAFT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-8E7	IGHV1-69	ARTYSFDSSGYYYDY	IGKV3-11	QQHSNWPPKIT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-8H10	IGHV3-30	ARAFYDSNWSVGSYFDS	IGKV4-1	QQYYNNQWT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-9F10	IGHV3-9	AKDSVRREYTHARVPFDN	IGKV1-39	QQSFVSPRT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-9H1	IGHV3-30	AKSSKIFYLGESREVDY	IGKV1-17	LQHKSYPLT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-12D7	IGHV3-9	AKDVRYCSSTSCYFSAFDI	IGKV1-39	QQSYSTPRT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-2F8	IGHV5-51	ARRGDGLYYYGMDV	IGKV2-28	MQALQTPQT	S_protein	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-3H3	IGHV4-59	ARDRIAPVGKFFGWYFDL	IGKV3-15	QQYNKWPPWT	S2	Yes	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-4A2	IGHV4-39	ARELFTAVAGKGGIDY	IGKV4-1	HQYYNTPRT	S1	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-4A10	IGHV3-64	ARSSSRGFDY	IGKV4-1	QQYYSSPYA	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A1	IGHV3-30	AKDFKGGSSSWYTPEIEYGMDV	IGKV3-11	QQRSNWPPT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A2	IGHV7-4-1	ARLIRHEAHTYCSGGSCYSPDYYYGMDV	IGKV1-39	QQSYSTPPT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A3	IGHV3-48	ASNPPLGEPYFDI	IGKV1-39	QQTYRPPWT	S_protein	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A7	IGHV3-30-3	ARWGGGMQYLDV	IGKV2-28	MQTLQTPYT	S1	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A8	IGHV7-4-1	ARAGPNYDFWSGYYQTFDY	IGKV1-33	QQYDNLPLT	S1	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A9	IGHV1-24	ATATAMDGYYYYYGMDV	IGKV2-24	MQATQFPYT	S_protein	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-B1	IGHV5-51	ASAGSSWYGDAFDI	IGKV4-1	QQYYSTYGS	S_protein	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-C4	IGHV1-24	ATATIFGVANNWFDP	IGLV1-51	GTWDSSLSVVV	S_protein	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-C9	IGHV3-30	AKDLGYYDILTGQLGGYYYYYGMDV	IGLV1-44	AAWDDSLNGVV	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
4A8	IGHV1-24	ATSTAVAGTPDLFDYYYGMDV	IGKV2-24	TQATQFPYT	NTD	Yes	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
9A1	IGHV3-30	AKVSAIFWLGQGLSPIDV	IGKV3-15	HQYSKWPVT	S2	No	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
8D2	IGHV3-7	ARDWDYDILTGSWFGAFDI	IGKV1-17	LQHNSYPLT	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
8D9	IGHV3-7	ARPTIGYSYGSDY	IGLV3-1	QAWDSSTGV	S2	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
10C10	IGHV3-7	ARDWDYDILTGSWFGAFDI	IGKV1-17	LQHNNYPLT	S_protein	-	SARS-2_infection	Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CV1	IGHV4-38-2	-	IGLV1-44	-	non-RBD	Yes	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV2	IGHV3-30	-	IGKV3-15	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV3	IGHV7-4-1	-	IGKV1-39	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV4	IGHV3-30	-	IGKV1-5	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV5	IGHV1-46	-	IGKV4-1	-	RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV7	IGHV3-30	-	IGKV1-5	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV8	IGHV1-18	-	IGKV3-20	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV9	IGHV4-39	-	IGLV2-14	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV10	IGHV4-59	-	IGKV3-20	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV11	IGHV4-31	-	IGKV3-11	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV12	IGHV3-30	-	IGKV2-30	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV13	IGHV7-4-1	-	IGKV1-39	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV15	IGHV3-7	-	IGLV2-11	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV16	IGHV5-51	-	IGKV3-20	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV17	IGHV1-2	-	IGLV2-23	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV18	IGHV1-24	-	IGLV1-51	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV19	IGHV1-2	-	IGKV3-20	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV21	IGHV3-15	-	IGKV3-11	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV22	IGHV3-21	-	IGLV4-69	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV23	IGHV1-3	-	IGLV3-25	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV24	IGHV1-24	-	IGLV1-51	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV25	IGHV4-30-4	-	IGKV3-15	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV26	IGHV3-30-3	-	IGKV1-17	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV27	IGHV3-30	-	IGLV2-14	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV30	IGHV3-53	-	IGKV3-20	-	RBD	Yes	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV31	IGHV1-24	-	IGLV1-51	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV32	IGHV1-2	-	IGLV1-51	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV33	IGHV1-18	-	IGLV1-40	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV34	IGHV3-30-3	-	IGLV3-12	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV35	IGHV4-38	-	IGLV1-44	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV36	IGHV1-2	-	IGLV3-25	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV37	IGHV1-18	-	IGKV1-33	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV38	IGHV3-30	-	IGKV3-11	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV39	IGHV3-30	-	IGKV2-30	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV40	IGHV1-18	-	IGKV1-17	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV41	IGHV3-30	-	IGKV3-15	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV42	IGHV1-18	-	IGKV1-39	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV43	IGHV3-30	-	IGLV6-57	-	RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV44	IGHV1-46	-	IGLV3-25	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV45	IGHV1-18	-	IGLV1-40	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV46	IGHV3-30	-	IGKV2-30	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV47	IGHV1-18	-	IGKV1-17	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV48	IGHV1-69	-	IGKV2-30	-	non-RBD	No	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV50	IGHV3-33	-	IGLV3-10	-	non-RBD	-	SARS-2_infection	Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CA1	IGHV1-18	AREGYCSGGSCYSGYYYYYGMDV	IGKV3-11	QQRRNWGT	RBD	Yes	SARS-2_infection	Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CB6	IGHV3-66	ARVLPMYGDYLDY	IGKV1-39	QQSYSTPPEYT	RBD	Yes	SARS-2_infection	Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
515-1	-	ARDFISRPRGYR	-	-	RBD	Yes	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
505-5	-	ARDFISRPRGYR	-	-	RBD	Yes	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
413-2	-	ARDNNYRNYYYYMDV	-	-	non-RBD	Yes	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
414-2	-	ARESRDYYDSSGLASRYFDL	-	-	RBD	No	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-49	-	AKDSSSWYNYYGMDV	-	-	RBD	Yes	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
505-3	-	ARDFISRPRGYR	-	-	RBD	Yes	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-15	-	ARVWYYYGPRDY	-	-	RBD	Yes	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
105-38	-	ARVQWLRGEFDY	-	-	RBD	No	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
415-5	-	ARAVYYYDSSGYPYAEDYFDY	-	-	RBD	No	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-20	-	ATAPVRRLGWFDP	-	-	RBD	No	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
105-9	-	TRDPWGTTYFDY	-	-	RBD	No	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-63	-	ARMEAPKLTLDP	-	-	RBD	Yes	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
414-1	-	ARGALGCSSTSCYPNNFDY	-	-	RBD	Yes	SARS-2_infection	Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
C105	IGHV3-53	ARGEGWELPYDY	IGLV2-8	SSYEGSNNFVV	RBD	Yes	SARS-2_infection	Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533
COV072_P3_HC_50-P1369	IGHV3-23	ANHPLASGDEYYYYYMDV	IGKV3-20	QQYGSSRALT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_24-P1369	IGHV3-23	ANHPLASGDDYYHYYMDV	IGKV3-20	QQYGSSRALT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_66-P1369	IGHV3-23	ANSPCSSASCKSGYYYYYMDV	IGKV3-20	QQYGSSRSLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_49-P1369	IGHV1-46	ARSRPTPDWYFDL	IGLV3-21	QVWDSSSDHPGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_81-P1369	IGHV1-46	AKSRPTPDWYFDL	IGLV3-21	QVWDGGSDHPGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_17-P1369	IGHV1-69	ARVNQAVTTPFSMDV	IGKV3-15	QQYNNWPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_21-P1369	IGHV1-69	ARANQPVTTPFSMDV	IGKV3-15	QQYNNWPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_51-P1369	IGHV3-23	AKDPLITGPTYQYFHY	IGLV3-21	QVWDSSSDRPGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_93-P1369	IGHV3-23	AKDPLITGPTYQYFHY	IGLV3-21	QVWDSSSDRPGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_53-P1369	IGHV3-30-3	ARDSDVDTSMVTWFDY	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_83-P1369	IGHV3-30-3	ARDSDVDTAMVTWFDY	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_80-P1369	IGHV3-66	ARDLGDYGMDV	IGKV1-9	QQLNSYPPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_36-P1369	IGHV3-66	ARDLYYYGMDV	IGKV1-9	QQLNSYSYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_12-P1369	IGHV3-7	ARALQGPWLGADY	IGLV6-57	QSYDSSKGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_33-P1369	IGHV3-7	AGGTWLRSSFDY	IGLV6-57	QSYDSSNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_25-P1369	IGHV4-4	ARGGDTAMGPEYFDY	IGLV2-14	SSYTSSSTLL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_53-P1369	IGHV4-4	AKGGDRAMGPEYFDY	IGLV2-14	SSFTSSSTLL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_9-P1369	IGHV1-18	ARDGITGTIEYYFDY	IGKV3-11	QQRSNWPPGVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_44-P1369	IGHV1-18	ARVLGIIVAGSLN	IGLV6-57	QSYDSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_34-P1369	IGHV1-24	ATNAEIAARKGGMDV	IGKV2-28	MQALQTPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_40-P1369	IGHV1-46	ARDLGYIPASDAFDI	IGLV2-11	CSYAGSYTRYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_10-P1369	IGHV1-46	ARDIALVPAAMGLDY	IGKV1-39	QQSYRTRLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_42-P1369	IGHV1-58	AAVDCNSTSCYDAFDI	IGKV3-20	QQYDISPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_31-P1369	IGHV1-69	AKVSLTLPIAAAPRFWFDS	IGKV3-15	QQYHNWPPALT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_30-P1369	IGHV1-69	ARGVVAATPGNFDI	IGKV3-15	QQYNNGLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_48-P1369	IGHV1-69	ARDLLDPQLDDAFDI	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_40-P1369	IGHV1-69	ARGGYSYGQLYYFDY	IGKV3-20	QQYANSRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_77-P1369	IGHV1-69	ARFSNYCTSTSCYDY	IGLV1-40	QSYDSSLSGSV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_58-P1369	IGHV3-11	ARDRGYSGYGLDRFDY	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_64-P1369	IGHV3-11	ARDNITMVRGVIVRPNDGGYYYALDV	IGKV1-39	QQSYSTRALT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_55-P1369	IGHV3-15	TTDYSIRYYYGMDV	IGLV3-25	QSADSSGTYEV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_38-P1369	IGHV3-21	ARAKLEIAHYGGSPGFDY	IGLV3-1	QAWDSSTGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_36-P1369	IGHV3-21	ARMGLELPGLDYGMDV	IGLV1-36	AAWDDSFNGPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_94-P1369	IGHV3-23	AKVDYGEYVFSNAFDI	IGLV2-23	CSYAGTSTYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_5-P1369	IGHV3-23	AKSKTVERLPYCGGDCFSAIDY	IGKV1-33	QQYDNLPPFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_92-P1369	IGHV3-23	AKAGPAAAYGWYYYYMDV	IGKV1-27	QKYNSALGFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_15-P1369	IGHV3-30	AKGPRFGWSYRGGPGFDI	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_45-P1369	IGHV3-30	ASSSGYLFHSDY	IGKV1-5	QQYNSYPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_31-P1369	IGHV3-30	AKGPRFGWSYRGGSGFDI	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_3-P1369	IGHV3-30	AKQLGLYCSGGNCYSGALDY	IGKV1-33	QQYDNLPFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_37-P1369	IGHV3-30	AKQNGLYCSGGSCYLGYFDY	IGKV1-33	LQYDNLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_56-P1369	IGHV3-30	AKAGGRDYYDSSGYYLLDHYYGMDV	IGLV1-40	QSYDSSLSGFYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_63-P1369	IGHV3-30	AKGGAYSYYYYMDV	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_69-P1369	IGHV3-30-3	ARDSDTAMVDYFDY	IGKV1-39	QQSYSTFMYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_74-P1369	IGHV3-30-3	AKVDLKYSYGLYYFDY	IGKV1-39	QQTYITPPS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_12-P1369	IGHV3-30-3	ASSSGYLFHFDY	IGKV1-5	QQYNSYPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_54-P1369	IGHV3-30-3	ARNDGSSGWYPERGGGFDY	IGLV1-40	QSYDSSLSGLWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_94-P1369	IGHV3-30-3	ARALSFIAVAGIDY	IGLV6-57	QSYDSTTHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_91-P1369	IGHV3-30-3	ARADLGYCTNGVCYVDY	IGLV6-57	QSYDSSNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_23-P1369	IGHV3-30-3	ARVRLGAYYNYFGMDV	IGKV2-28	MQALQTFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_68-P1369	IGHV3-30-3	AKKGQPYCGGDCYFYYFDY	IGKV1-33	QQYDNLPPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_72-P1369	IGHV3-33	ARDGTGIAAAGTANPPFDY	IGKV1-33	QQYDNLPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_25-P1369	IGHV3-33	ATSLFGIISLDY	IGKV1-6	LQDYNYPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_54-P1369	IGHV3-33	ARDWEIVVAGMDV	IGKV2-30	MQGTHCPFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_71-P1369	IGHV3-33	ARGEWDSGSYQYYDYYMDV	IGLV8-61	VLYMGSSNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_78-P1369	IGHV3-43	AKGLNYRPQYYYYYGMDV	IGKV2-28	MQALQTPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_26-P1369	IGHV3-53	ARSFYFDAFDI	IGKV1-9	QQLNSYPLLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_67-P1369	IGHV3-53	TRDPVPGRGDAY	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_1-P1369	IGHV3-53	ARVVGYDFWSGYDGGYFDY	IGLV2-23	CSYAGSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_89-P1369	IGHV3-53	ARDLYYYGMDV	IGKV1-9	QQLNSYPT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_22-P1369	IGHV3-64D	VKDITMIVDVFEY	IGKV1-39	QQSYTTPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_47-P1369	IGHV3-66	ARDIAGRLDY	IGKV1-33	QHYDSLSRLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_59-P1369	IGHV3-66	ARDLVVYGADY	IGKV1-9	QQLNSYPPP	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_16-P1369	IGHV3-66	ARDLQYYGMDV	IGKV1-9	QQPDSFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_14-P1369	IGHV3-66	ASHLMPDAFDI	IGLV2-23	CSYGGSSTSFYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_37-P1369	IGHV3-7	ARDQVSWYNLDAFDI	IGKV2-30	MQGTHWPKT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_5-P1369	IGHV3-7	ARDTGRITFGGGDDAFDI	IGLV3-21	QVWDSSSDHRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_86-P1369	IGHV4-30-4	VRVVMSGIAAAGQNDY	IGKV1-33	QQYDILPPMYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_32-P1369	IGHV4-30-4	ARTYYYDSSGYYFQYYFDC	IGKV3-20	QQYGSSPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_67-P1369	IGHV4-31	ATNYDDYVPAEYFQD	IGKV3-11	QQRSNWPPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_88-P1369	IGHV4-31	ARSCSSTSCPFDY	IGKV1-33	QQYDNLPFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_71-P1369	IGHV4-31	ARGVVLITDYYFDY	IGLV3-25	QSADSSGTR	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_73-P1369	IGHV4-34	AREGAVAGGDFDY	IGLV3-21	QVWDGTSDHPGWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_74-P1369	IGHV4-39	ARRPPGDYYYMDV	IGKV1-39	QQSYSIPQIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_76-P1369	IGHV4-59	ARGRGLPPWFDP	IGLV6-57	QSYDSSNVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_18-P1369	IGHV4-59	ARPDMSSSSSPHYWYFDL	IGLV3-21	QVWDSSSGHFHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_84-P1369	IGHV5-51	ARRGGSYYNNGDGMDV	IGLV3-1	QAWDSSTPHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_4-P1369	IGHV6-1	ARSGSYYISHGMDV	IGKV3D-15	QQYNNWPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B4-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSALYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F6-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSALYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_G8-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSALYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A2-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSALYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B2-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSALYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B12-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSALYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C10-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSVLYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_D10-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSALYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_E1-1369	IGHV5-51	ARGVAVDWYFDL	IGLV1-40	QSYDSSLSALYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F3-1369	IGHV4-59	AREVVVQSAKDWSHYYYYMDV	IGKV3-11	QQRSSWFVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A6-1369	IGHV4-59	AREVVVSSPKDWSHYYYYMDV	IGKV3-11	QQRSTWFVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B11-1369	IGHV4-59	AREVVVQSAKDWSHYYYYMDV	IGKV3-11	QQRSSWFVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_D11-1369	IGHV4-59	AREVVVQSAKDWSHYYYYMDV	IGKV3-11	QQRSSWFVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_F10-1369	IGHV4-59	AREVVVQSAKDWSHYYYYMDV	IGKV3-11	QQRSSWFVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B11-1369	IGHV1-69	ARDSEYSSSWYSRGYYGMDV	IGKV2-28	MQALQTPPT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A11-1369	IGHV1-69	ARDSEYSSSWYSRGYYGMDV	IGKV2-28	MQALQTPPT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_E2-1369	IGHV1-69	ARDSEYSSSWYSRGYYGMDV	IGKV2-28	MQALQTPPT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B7-1369	IGHV3-7	ARQPESTIWYYFDY	IGLV3-25	QSADSSGSYVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F5-1369	IGHV3-7	ARQPESTIWYYFDY	IGLV3-25	QSADSSGSYVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_H2-1369	IGHV3-7	ARQPESTIWYYFDY	IGLV3-25	QSADSSGSYVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_D12-1369	IGHV4-34	ARRRSFSRPSSIDY	IGKV2-28	MQALQTLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B6-1369	IGHV4-34	ARRRSFSRPSSIDY	IGKV2-28	MQALQTLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_H7-1369	IGHV4-34	ARRRSFSRPSSIDY	IGKV2-28	MQALQTLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_E6-1369	IGHV1-58	AANHCSGGSCYDGFDI	IGKV3-20	QQYGSSPWM	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_H6-1369	IGHV1-58	AAPYCSGGSCNDAFDI	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A10-1369	IGHV3-15	TTDPHCSSTSCPIFYYYYMDV	IGLV3-21	QVWDSSSDQGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C4-1369	IGHV3-15	TTDPHCSSTSCPIFYYYYMDV	IGLV3-21	QVWDSSSDQGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_E9-1369	IGHV3-30	AKSPMGYCTNGVCYPDS	IGLV6-57	QSYDINSRWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_G5-1369	IGHV3-30	AKSPMGYCTNGVCYPDS	IGLV6-57	QSYDINSRWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F10-1369	IGHV4-34	ARAGFGVVITYGSGTDPLFDY	IGLV1-40	QSYDSSLSGSRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_H3-1369	IGHV4-34	ARAGFGVVITYGSGTDPLFDY	IGLV1-40	QSYDSSLSGSRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_A5-1369	IGHV1-2	AREYLERYFDGGQRWISYYYMDV	IGLV2-14	SSYTPNSTLVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_A9-1369	IGHV1-46	AREIPDILEVVAATGSLDD	IGLV2-8	SSYAGITNLV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_A11-1369	IGHV1-69	ARDSEYSSSWYSRGYYGMDV	IGLV2-8	YSYGGNNNAV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B1-1369	IGHV1-69	ARDSGYSGYGSTYYMDV	IGLV1-40	QSYDSSLSGSV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F11-1369	IGHV1-69	ARDSEYSSSWYSRGYYGMDV	IGKV2-28	MQALQTPPT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_G11-1369	IGHV1-69-2	ARSGPDYFDY	IGKV3-15	QQYNNWPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C12-1369	IGHV3-13	ARGTTFNHYYYMDV	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C3-1369	IGHV3-15	TTDVGADSSSAYYYYYMDV	IGKV3D-20	QQYGSSPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_E11-1369	IGHV3-21	ARDVASNYAYFDL	IGKV3-15	QQYDNWPL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_H12-1369	IGHV3-23	AKDTGSMIVELLGY	IGLV1-40	QSYDTSLRVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B8-1369	IGHV3-49	TRARSVTMVWYRYYMDV	IGKV2D-29	MQSIQLPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C2-1369	IGHV3-64	AREGPFLPSLYSSSRDAFDI	IGLV3-21	QVWDSSSDPHYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_C8-1369	IGHV3-64	ARGPIAAAGSYFDY	IGLV3-21	QVWDSSSDPHWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F9-1369	IGHV3-66	ARDLAVYGMDV	IGKV1-9	QQLNSYPPVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_C3-1369	IGHV3-66	ARDGEGQRETDY	IGKV1-33	QQYDNLPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_G3-1369	IGHV3-74	TRDDSSWPHFFDN	IGKV1-39	QQSYSSPLWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B7-1369	IGHV3-74	TRDDSSWPHFFDN	IGKV3-15	QQYDNWPL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_H10-1369	IGHV4-34	ARAYVSSVSEDYFDY	IGKV1-39	QQSYTTPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B9-1369	IGHV4-34	ARHWMPRDYYYYGMDV	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_E3-1369	IGHV4-34	ARGAKGDSDWYFDL	IGKV3-11	QQGDNWPRMYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_F8-1369	IGHV4-59	ARHYDILTALSWFDP	IGLV1-51	GTWDSSLSAYWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_H11-1369	IGHV4-59	ARLLSTEWLFNWFDP	IGLV3-1	QAWDSSTAYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A9-1369	IGHV5-51	ARGIAVDWYFDL	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_9-P1369	IGHV3-53	ARDWGEYYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_36-P1369	IGHV3-53	ARDYGDYYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_40-P1369	IGHV3-53	ARDWGEYYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_13-P1369	IGHV3-53	ARDYGDYYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_93-P1369	IGHV3-53	VRDYGDFYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_11-P1369	IGHV4-34	ARKPLLYSDFSPGAFDI	IGKV3-20	QQYHTTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_42-P1369	IGHV4-34	ARKPLLYSNLSPGAFDI	IGKV3-20	QQYGTTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_84-P1369	IGHV4-34	ARKTLLFSDFSPGAFDI	IGKV3-20	QQYGTTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_31-P1369	IGHV4-34	ARKPLLHSDLSPGAFDI	IGKV3-20	QQYVTTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_53-P1369	IGHV4-34	ARKPLLYSDFSPGAFDI	IGKV3-20	QQYTTTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_29-P1369	IGHV3-53	ARGEGWDLPYDY	IGLV2-8	SSYAGSNNFVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_35-P1369	IGHV3-53	ARGEGWDLPYDY	IGLV2-8	SSYAGSNNFVL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_4-P1369	IGHV3-53	ARGEGWELPYDY	IGLV2-8	SSYEGSNNFVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_63-P1369	IGHV1-18	ARGEAVAGTTGFFDY	IGLV1-47	AAWDDSLSGFVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_68-P1369	IGHV1-18	ARGEAVAGTTGFFDY	IGLV1-47	AAWDDSLSGFVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_13-P1369	IGHV1-2	ARDVIVSMVRGVIFRMDV	IGLV1-44	AAWDDSLNGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_27-P1369	IGHV1-2	ATAHPRRIQGVFFLGPGV	IGLV1-44	AAWDDSLNGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_79-P1369	IGHV1-46	ARANHETTMDTYYYYYYMDV	IGLV2-14	SSYTSSSTSVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_91-P1369	IGHV1-46	ARANHETTMDTYYYYYYMDV	IGLV2-14	SSYTSSSTSVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_53-P1369	IGHV1-58	AAPHCSSTSCFDAFDI	IGKV3-20	QQYGNSPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_81-P1369	IGHV1-58	AAPYCSGGSCSDAFDI	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_42-P1369	IGHV3-30-3	ARDPIWFGELLSPPFVHFDY	IGLV1-51	GTWDSSLSAGGVYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_89-P1369	IGHV3-30-3	ARDPIWFGELLSPPFVHFDY	IGLV1-51	GAWDSSLSAGGVYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_22-P1369	IGHV3-30-3	AREDYYDSSGSFDY	IGLV2-14	SSYTSSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_88-P1369	IGHV3-30-3	AREDYYDSSGSFDY	IGLV2-14	SSYTSSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_49-P1369	IGHV3-30-3	ASGYTGYDYFVRGDYYGLDV	IGLV4-69	QTWGTGILV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_84-P1369	IGHV3-30-3	ASGYTGYDYFVGGDYYGMDV	IGLV4-69	QTWGTGILV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_19-P1369	IGHV3-33	ARGVNPDDILTGVDAFDI	IGKV1-5	QQHNSSPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_38-P1369	IGHV3-33	ARGVNPDDILTGVDAFDI	IGKV1-5	QQHNSSPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_15-P1369	IGHV3-49	TRWDGWSQHDY	IGKV2-28	MQVLQIPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_69-P1369	IGHV3-49	TRWDGWSQHDY	IGKV2-28	MQVLQVPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_32-P1369	IGHV3-53	AREGMGMAAAGT	IGKV1-33	QQYDNLPQT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_73-P1369	IGHV3-53	AREGMGIAAAGT	IGKV1-33	QQYDNLPQT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_62-P1369	IGHV3-53	ARGDGELFFDH	IGLV1-40	QSYDSSLYAV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_73-P1369	IGHV3-53	ARGDGELFFDQ	IGLV1-40	QSYDSSLYAV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_46-P1369	IGHV4-4	VRDGGRPGDAFDI	IGLV2-14	NSYTSSSTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_57-P1369	IGHV4-4	VRDGGRPGDAFDI	IGLV2-14	NSYTSSSTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_36-P1369	IGHV4-59	ARVEDWGYCSSTNCYSGAFDI	IGLV1-36	AAWDDSLNGAWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_71-P1369	IGHV4-59	ARVEDWGYCSSTNCYSGAFDI	IGLV1-36	AAWDDSLNGAWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_77-P1369	IGHV4-61	ARERPGGTYSNTWYTPTDTNWFDT	IGLV3-21	QVWDSSRDHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_72-P1369	IGHV4-61	ARERPGGTYSNTWYTPTDTNWFDT	IGLV3-21	QVWDSSRDHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_75-P1369	IGHV5-51	ARSFRDDPRIAVAGPADAFDI	IGKV1-5	QQYNSYPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_90-P1369	IGHV5-51	ARSFRDDPRIAVAGPADAFDI	IGKV1-5	QQYNSYPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_52-P1369	IGHV1-18	ARAIAVAGTSGEFDY	IGLV1-44	AAWDDSLNGHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_58-P1369	IGHV1-18	ARSQGWLQLNDY	IGLV6-57	QSYDSSTPNCV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_7-P1369	IGHV1-18	ARVGHARGVITGGDYFYYGMDV	IGKV3-20	QQYGSSPT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_18-P1369	IGHV1-2	AREPQINPYYDILTGYRAFDY	IGKV3-20	QQYGSSLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_45-P1369	IGHV1-2	ARGHDYVWGSYRYHNV	IGLV2-14	SSYTSSSTLL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_60-P1369	IGHV1-2	ARDLAFSMVRAPGDY	IGLV2-23	CSYAGSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_5-P1369	IGHV1-2	ARELIAVAGIFDY	IGLV3-21	QVWDSSWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_94-P1369	IGHV1-2	ARAPLFPTGVLAGDYYYYGMDV	IGLV2-23	CSYAGSSTLV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_83-P1369	IGHV1-2	ARYKGTTVNTNYYYGMDV	IGLV3-1	QAWDSSTVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_21-P1369	IGHV1-46	ARGPRSPSDWCSGGSCYDDQNWFDP	IGKV1-39	QQSYSTLIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_24-P1369	IGHV1-46	ARDFELWFGELRGWFDP	IGKV3-15	QQYNNWPPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_40-P1369	IGHV1-46	ARDPSPIIARPGMGYWFDP	IGLV1-40	QSYDSSLSAVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_17-P1369	IGHV1-69	ASFHVAYGDYIPFDY	IGKV3-20	QQYGRSPTWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_78-P1369	IGHV1-69	ARAGLLTKNIVATIGCFDP	IGKV4-1	QQYYSTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_28-P1369	IGHV1-69	ARDSSGYYYVSNWFDP	IGLV1-40	QSYDSSLSGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_95-P1369	IGHV1-8	ARGGRYCSSTSCYSHVGFDP	IGKV1-9	QQLNSYPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_92-P1369	IGHV3-11	ATYRSYLPLVQVDY	IGLV6-57	QSYDSSKHAV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_38-P1369	IGHV3-13	ARVRYDSSGYFWSLDY	IGKV1-39	QQSYSTPQYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_61-P1369	IGHV3-13	ARGVSGVVRGVIRSFYYYGLDV	IGKV1-39	QQSYITPGWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_55-P1369	IGHV3-21	ARGQLLPFADY	IGLV6-57	QSYDSSKSWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_47-P1369	IGHV3-21	TRGSRGYYDRSGYYTPLDPYYGMDV	IGLV1-40	QSYDSSLSGSYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_49-P1369	IGHV3-23	AKEEVLPAVEYFQH	IGLV3-21	QVWDGSSDHHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_80-P1369	IGHV3-23	VETNLWFGEDNYYYYYGMDV	IGKV3-20	QQYGSSPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_68-P1369	IGHV3-30	ATGGGSYFSPRIYFDY	IGKV1-33	QQYDNLPPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_51-P1369	IGHV3-30	AKQAGPYCSGGTCYPGTLDY	IGKV1-33	QQYDNVPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_43-P1369	IGHV3-30	AKAGYSYGYPQQYFDY	IGKV1-5	QQYNSYSYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_3-P1369	IGHV3-30	AKSLGPYCSGGNCYSSYFDY	IGKV1-5	QQYNSYST	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_44-P1369	IGHV3-30	AKKGGGAYCGGDCYLGEFDY	IGKV3-20	QQYGTSPST	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_22-P1369	IGHV3-30	AKGGYYYYNSDSYQAEIDY	IGLV1-51	GTWDSSLSAFV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_76-P1369	IGHV3-30	AKSWWLSENWFDP	IGKV3-15	QQYNNWPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_16-P1369	IGHV3-30	AKGGLYDSSGYYPHYGMDV	IGKV1-33	QQYDNLPLA	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_91-P1369	IGHV3-30	AKDPLPFRDFFYYYMDV	IGLV2-14	SSYTSSSTLGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_10-P1369	IGHV3-30-3	ARDQDLDTAMVTLFDY	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_65-P1369	IGHV3-30-3	ARDSPSQIVVVPVFDY	IGKV1-39	QQSYSTLALT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_35-P1369	IGHV3-30-3	ARETQGGYYGSGSYYASPFDP	IGLV3-21	QVWDSSSDHPVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_24-P1369	IGHV3-30-3	ARDFYHNWFDP	IGLV6-57	QSYDSSNQWVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_34-P1369	IGHV3-33	ARDRGLRLGGPKYYFDY	IGLV2-14	SSYTSSSVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_2-P1369	IGHV3-48	AREGARVGATYDTYYFDY	IGKV3-11	QQRNNWPPEWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_64-P1369	IGHV3-48	ARVAIRVVVPSATYYFDY	IGKV3-11	QQRSNWPQGFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_41-P1369	IGHV3-48	ARDPQRDPADYFDY	IGLV3-21	QVWDSSRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_11-P1369	IGHV3-48	ARDQGYCSSTSCYDGYYYYMDV	IGKV1-39	QQSYSAPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_44-P1369	IGHV3-53	ARDLRGPGTFDI	IGKV1-33	QQYDNLPRVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_88-P1369	IGHV3-53	AREVAAFDI	IGKV1-9	QQLNSYPPG	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_18-P1369	IGHV3-53	ARDLSAAFDI	IGKV1-9	QQLNSYPPA	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_59-P1369	IGHV3-53	ARTMDGDYFDY	IGKV1-27	QKYNSAPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_30-P1369	IGHV3-53	ARTDIVVVPAARGFYFDY	IGKV1-5	QQYNSYGT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_15-P1369	IGHV3-53	ARESGDTTMAFDY	IGKV1-9	QQLNSDSYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_23-P1369	IGHV3-53	ARDLGTGLFDY	IGKV1-9	QQLDSYPPGT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_82-P1369	IGHV3-53	ARDYGDFYFDY	IGKV3-15	QQYYNWPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_95-P1369	IGHV3-53	ARDYGDLYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_86-P1369	IGHV3-53	ATDLTSGRGP	IGKV1-6	LQDYNYPKT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_78-P1369	IGHV3-53	ARDLVVWGMDV	IGKV1-9	QLLNSYPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_46-P1369	IGHV3-7	AIQLWLRGGYDY	IGLV2-8	SSYAGSNNYVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_32-P1369	IGHV3-7	AVQLWLRGNFDY	IGLV6-57	QSYDSSNHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_9-P1369	IGHV3-73	TKPHAHCGGDCYSRDWFDP	IGKV1-39	QQSYSTPPFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_50-P1369	IGHV3-9	AKGLIAELVGGGWYFDY	IGKV3-11	QQRSNWPPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_74-P1369	IGHV3-9	AKALSSTGFLVVYFDY	IGKV3-15	QQYNNWLSLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_25-P1369	IGHV3-9	AKDDREGFGDYFDY	IGLV3-21	QVWDSSSDHYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_54-P1369	IGHV3-9	AKDSLVRRNFYYYYMDV	IGLV1-40	QSYDSSLSGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_93-P1369	IGHV4-31	AWRYSSSWYTVDNKKGDYYFDY	IGKV2-28	MQALQTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_20-P1369	IGHV4-39	AGMYYDILTGYSEGAFDI	IGLV2-23	CSYAGSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_25-P1369	IGHV4-39	AGGTNPQWLDSTFDY	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_64-P1369	IGHV4-39	ASAPYLNWNDWIFDY	IGLV2-14	SSYTSSSTLV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_28-P1369	IGHV4-59	ARLQWLRGAFDI	IGLV6-57	QSYDSSNLV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_58-P1369	IGHV4-59	ARYGWGYDSSGYYFDY	IGLV2-23	CSYAGSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_2-P1369	IGHV4-59	ARATTPFSGVDY	IGLV6-57	QSYDTSNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_10-P1369	IGHV4-59	ARILRGVAENWFDP	IGLV3-21	QVWDNNSDHRGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_48-P1369	IGHV4-61	ATRGGYYDSSGYYALAFDI	IGLV2-14	SSYTSSSTVWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_45-P1369	IGHV5-10-1	ARHISSGWYDY	IGKV1-33	QQYDNLPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_39-P1369	IGHV5-10-1	ARHRHPGITMIVALDY	IGKV1-33	QQYDNVPL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_87-P1369	IGHV5-10-1	ATETNSETTDMFTGYSFDP	IGLV1-44	AAWDDSLSGYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_1-P1369	IGHV5-51	ARGGPPGGVKLELTDY	IGLV1-44	AAWDDSLNGPVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_92-P1369	IGHV5-51	ARLHPTYYDILTGYYIDY	IGLV2-23	CLYAFSSIV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_37-P1369	IGHV5-51	ALTTVTTGRWFDP	IGKV2-30	MQGTHWLWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_26-P1369	IGHV5-51	ARRPSSYSGWFDP	IGLV1-44	AAWDDSLNGLV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_100-p1369	IGHV3-23	ARESDCGSTSCYQVGWFDP	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_164-p1369	IGHV3-23	ATERIAVAGTRMYNWFDP	IGKV1-39	QQSYSAPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_25-p1369	IGHV3-23	ASEEDYSNYVGWFDP	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_91-p1369	IGHV3-23	ARESDCGSTSCYQVGWFDP	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_115-p1369	IGHV3-66	ARDTLGRGGDY	IGKV1-33	QQYDNLPRS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_133-p1369	IGHV3-66	ARDTFGRGGDY	IGKV1-33	QQYDNLPRS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_34-p1369	IGHV3-66	ARDTLGRGGDY	IGKV1-33	QQYDNLPRS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_106-p1369	IGHV3-9	AKGVEYSSSSNFDY	IGKV1D-12	QQTNSFPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_132-p1369	IGHV3-9	VKGVEYSSSSNFDY	IGKV1D-12	QQTNSFPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_6-p1369	IGHV3-9	VKGVEYSSSSNFDY	IGKV1D-12	QQANSFPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_116-p1369	IGHV1-2	ARERYFDLGGMDV	IGLV2-23	CSYAGSSTRL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_77-p1369	IGHV1-2	AREPYFDLGGMDV	IGLV2-23	CSYAGSSTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_138-p1369	IGHV1-8	ARGFSLTWYFDL	IGLV3-21	QVWDSTGGHPDVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_176-p1369	IGHV1-8	ARGFSLTWYFDL	IGLV3-21	QVWDSTSDHPDVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_104-p1369	IGHV3-21	ARVQVGARGWVDY	IGLV6-57	QSYDSINWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_111-p1369	IGHV3-21	ARVQVGARGWVDY	IGLV6-57	QSYDRINWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_158-p1369	IGHV3-23	AKEPIGQPLLWWDY	IGKV3-11	QQRSNWPRG	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_78-p1369	IGHV3-23	AKEPIGQPLLWWDY	IGKV3-11	QQRSNWPRG	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_130-p1369	IGHV3-9	AKGSSSGWTRPLDY	IGLV3-21	QVWDSSSDPVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_44-p1369	IGHV3-9	AKGSSSGWTRPLDY	IGLV3-21	QVWDSSSDPVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_72-p1369	IGHV1-18	ARRPRDYYDRSGYYYVPGYFDY	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_90-p1369	IGHV1-18	ARRVEDNGDDGGDYYYYYGMDV	IGLV3-25	QSADSSGTLVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_71-p1369	IGHV1-2	ARDLEYCSSTSCYTSTTFDY	IGLV3-21	QVWDYGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_52-p1369	IGHV1-2	ASGIGHNWNYVSTPNGMDV	IGLV6-57	QSYDSGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_10-p1369	IGHV1-2	ARDFAMGTVTGTFVY	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_4-p1369	IGHV1-2	AREKVATMFALPPYGMDV	IGKV3-11	QQRSNWPPIA	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_127-p1369	IGHV1-46	ARPLLPGETGSLNRLDY	IGKV1-39	QQSYSTLWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_2-p1369	IGHV1-46	AREGVGGTSYFDY	IGLV3-21	QVWDSSSDPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_113-p1369	IGHV1-46	ARGPERGIVGATDYFDY	IGKV3-20	QQYVSSPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_153-p1369	IGHV1-69	ASEWEIFGFDY	IGKV1-39	QQSYSTPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_55-p1369	IGHV1-69	TSGQGAGVNRGVVITTLGY	IGKV4-1	QQYYSTPCS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_42-p1369	IGHV1-69	ARDDGQQLWSYFDY	IGKV4-1	QQYYSTLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_30-p1369	IGHV1-69	ARDGLSGHFPHNWFDP	IGLV1-40	QSYDSSLRGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_136-p1369	IGHV1-69	ARREAYGPRDYYYYYGMDV	IGLV9-49	GADQGSGSNFVGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_99-p1369	IGHV1-69	ARVLGYYDSSGSNDAFDI	IGLV1-40	QSYDSSLSGSV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_152-p1369	IGHV1-8	ARGGRYCSDVSCYSGTGFDY	IGLV1-47	AAWDDSLSGYWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_156-p1369	IGHV3-11	ARDLPPRRFDI	IGKV1-33	QQFDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_137-p1369	IGHV3-13	ARGDSGSYLGVWYFDL	IGKV1-39	QQSYSSPPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_75-p1369	IGHV3-13	ARDRGSSGWYGWYFDL	IGKV1-39	QQSYSTPPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_123-p1369	IGHV3-13	ARGDYNILTGYYFDY	IGKV1-39	QQSYNTPQVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_65-p1369	IGHV3-13	ARDRDSSWSFDY	IGKV1-39	QQSYSTPPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_81-p1369	IGHV3-13	ARGTFFYGSGSYNWFDP	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_166-p1369	IGHV3-15	TTLSDYGDLSSVY	IGKV1-39	QQSYSTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_50-p1369	IGHV3-15	TTDLGYCSSTNCYYYY	IGLV3-21	QVWDSSSDHPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_92-p1369	IGHV3-15	TTDDPGSYYYGMDV	IGLV7-46	LLSYSGARV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_140-p1369	IGHV3-21	AKEEYYGMDV	IGKV1-12	QQANRFPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_40-p1369	IGHV3-30	ARAGTTNSDYFDY	IGLV3-21	QVWDSSSALWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_43-p1369	IGHV3-30	AKQLYYYGSGSYVFDY	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_149-p1369	IGHV3-30	AKGGYSYGYSLYYFDY	IGLV2-14	SSYTSSSTLV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_157-p1369	IGHV3-30	AKAQYSYGYVVYYFDY	IGLV6-57	QSYDSSNVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_21-p1369	IGHV3-30	AKDTPGGDDILTGWGLYGMDV	IGKV1-39	QQSYSTPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_122-p1369	IGHV3-33	ARDMGTLVTHFDY	IGKV1-39	QQSYSSPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_98-p1369	IGHV3-33	ARDVGRVTTWFDP	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_48-p1369	IGHV3-48	ARASGLRSYYYYGMDV	IGKV1-39	QQSYSTPAT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_79-p1369	IGHV3-48	ARVVGSGSYYYYGMDV	IGKV1-39	QQSYSTPAT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_3-p1369	IGHV3-49	TRDLSYYYDSSGRGSHLFDY	IGKV3-15	QQYNNWWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_121-p1369	IGHV3-53	ARSLWLRGSFQH	IGLV6-57	QSYDSSSWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_134-p1369	IGHV3-53	ARDLMAYGMDV	IGKV1-9	QQLNSYPQGT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_68-p1369	IGHV3-53	ARDGGHYGMDV	IGKV1-9	QQLNSYPPA	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_183-p1369	IGHV3-53	ARESYGMDV	IGKV3-20	QQYVTSPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_74-p1369	IGHV3-66	ARDYGDFYFDY	IGKV3-15	QQYNNWPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_27-p1369	IGHV3-7	ARGDYDFWSGYYDY	IGLV3-25	QSADSSSWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_142-p1369	IGHV3-7	ATAPWLRGGFDY	IGLV6-57	QSFDSTNLWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_45-p1369	IGHV3-74	TRDDSSWPHFFDN	IGKV1-33	QQYDNLPPKLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_126-p1369	IGHV3-74	TRDDSSWPHFFDN	IGKV1-39	QQSYISPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_1-p1369	IGHV3-9	AKIADIVRAYDFWSGQHFDAFDI	IGLV1-44	AAWDDSLVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_15-p1369	IGHV3-9	AKDGGSGTTEYEAYYFDY	IGLV1-44	AAWDDSLNGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_20-p1369	IGHV3-9	AKDMGRDDSSGSLLFDY	IGLV3-21	QVWDSSSDHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_159-p1369	IGHV3-9	AKDIGSKRSTSENYGMDV	IGLV3-21	QVWDSSSDSVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_103-p1369	IGHV4-39	ASLRGAYYDFWSGPRDGGWFDP	IGLV2-23	CSYAGSSLWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_23-p1369	IGHV4-61	AREIPSTWYFDL	IGLV1-47	AAWDDSLSGYWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_101-p1369	IGHV4-61	ARDIPPTWYFDL	IGLV3-21	QVWDSTSDHLFWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_8-p1369	IGHV5-51	ARPVTYDWYFDL	IGKV1-12	QQANSFPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_124-p1369	IGHV5-51	ARVPSSSDYGDYGGFEY	IGKV1-39	QQSYSTPCS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_28-p1369	IGHV5-51	ARMVTSGTYYYDNSGYSSSGPFDY	IGKV1D-13	QQFNN	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_12-p1369	IGHV5-51	ARLSDRWYSPFDP	IGKV3-15	QQYNNWPPGGFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_174-p1369	IGHV5-51	ARLPSGRYNWFDP	IGLV1-44	AAWDDSLNGHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_189-p1369	IGHV5-51	ARLPQEEKRFLEWLPPANVRKQIPYYYGMDV	IGLV1-40	QSYDSSLSGPYWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_43-P1369	IGHV3-53	AREGEVEGYNDFWSGYSRDRYYFDY	IGLV2-14	SSYTSSSTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_57-P1369	IGHV3-53	AREGEVEGYYDFWSGYSRDRYYFDY	IGLV2-14	SSYTSSTTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_58-P1369	IGHV3-53	AREGEVEGYYDFWSGYSRDRYYFDY	IGLV2-14	SSYTSISTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_26-P1369	IGHV3-53	AREGDVEGYYDFWSGYSRDRYYFDY	IGLV2-14	SSYTSSSTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_41-P1369	IGHV3-53	AREGEVEGYYDFWSGYSRDRYYFDY	IGLV2-14	SSYTSSSTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_49-P1369	IGHV3-53	AREGEVEGYYDFWSGYSRDRYYFDY	IGLV2-14	SSYTSSTTRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_16-P1369	IGHV3-66	ARDSSEVRDHPGHPGRSVGAFDI	IGLV2-23	CSYAGASTFV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_12-P1369	IGHV3-66	ARDSSEVRDHPGHPGRSVGAFDI	IGLV2-23	CSYAGASTFV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_65-P1369	IGHV3-66	ARDSSEVRDHPGHPGRSVGAFDI	IGLV2-23	CSYAGASTFV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_57-P1369	IGHV3-66	ARDSSEVRDHPGHPGRSVGAFDI	IGLV2-23	CSYAGASTFV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_10-P1369	IGHV1-18	ARDRGGHDFWSGYGFYYYYGMDV	IGKV1-27	QKYNSAPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_95-P1369	IGHV1-18	ARDRGGHNFWSGYGYYYYYGMDV	IGKV1-27	QKYNSAPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_34-P1369	IGHV3-21	ARERGYYGGKTPPFL	IGLV6-57	QSYDSSNYWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_24-P1369	IGHV3-21	ARERGYDGGKTPPFL	IGLV6-57	QSYDSSNYWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_91-P1369	IGHV3-30	AKNVGTGYNVMYYFDY	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_87-P1369	IGHV3-30	AKQAGPYCSGGSCYSAPFDY	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_69-P1369	IGHV3-30	AKVGLGYSSGWYGEEIDY	IGKV1-39	QQSYRTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_68-P1369	IGHV3-30	AKVGMEYSSGWYGEEIDF	IGKV1-39	QQSYRTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_64-P1369	IGHV3-30	AKDPFPLAVAGTGYFDY	IGLV3-21	QVWDSSSDPWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_77-P1369	IGHV3-30	AKDPWELRQGNYFDY	IGLV3-21	QVWDSSSDPWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_65-P1369	IGHV3-53	ARDYGDYYFDY	IGKV3-15	QQYNNWPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_27-P1369	IGHV3-53	ARDFGEFYFDY	IGKV3-15	QQYNNWPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_3-P1369	IGHV3-66	ARDSSEVRDHPGHPGRSVGAFDI	IGLV2-23	CSYAGASTFV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_90-P1369	IGHV3-66	ARDSSEVRDHPGHPGRSVGAFDI	IGLV2-23	CSYAGTSTFV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_24-P1369	IGHV3-66	ARIANYMDV	IGKV3-15	QQYNNWPPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_94-P1369	IGHV3-66	ARIANYMDV	IGKV3-15	QQYNNWPPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_8-P1369	IGHV5-51	ARLSDRWYSPFDP	IGLV7-46	LLSYSGARPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_91-P1369	IGHV5-51	ARLSDRWYSPFDP	IGLV7-46	LLSYSGARPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_77-P1369	IGHV1-18	ARVPRGYYDRSGYYYLPHYLDY	IGKV1-33	QQYDSLPGCS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_78-P1369	IGHV1-18	ARDSAYSGYDFFEAPRDY	IGKV1-39	QQSYRTPPL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_21-P1369	IGHV1-18	ARPSSSLTSYFDY	IGLV3-21	QVWDSSSDRHWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_53-P1369	IGHV1-18	ARVPASYGDDDYYYYYGMDV	IGLV3-25	QSADSSGTLWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_27-P1369	IGHV1-2	ARGPLFHRLVYDFWSGYHDGFDM	IGLV2-14	NSYTSSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_10-P1369	IGHV1-2	ARTPRVYDPTLPNQWLVGEYYCDY	IGLV2-11	CSYAGSYTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_60-P1369	IGHV1-2	ARGTEYNWNSAHFDP	IGLV2-14	SSYTSSSTSWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_29-P1369	IGHV1-2	VRGGTWNYVGGEV	IGLV2-14	TSFTSSSDSWI	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_61-P1369	IGHV1-46	ASSSSTPDYYGMDV	IGKV1-9	QQLNSYPLCS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_48-P1369	IGHV1-46	ARASTSTTNWNDALSLGC	IGLV1-40	QSYDSGLSGSGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_78-P1369	IGHV1-46	ARGGSSRYCSSTSCYSFGVDNFDY	IGLV3-21	QVWDSSSDHYYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_43-P1369	IGHV1-69	ARVGYGYYFDY	IGKV3-11	QQRSNWPS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_89-P1369	IGHV1-69	ARDLRYCSGGRCLWWFDP	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_15-P1369	IGHV1-69	ARYTYYYDRSGYYRPDYFDY	IGKV1-13	QQFNSYQLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_54-P1369	IGHV3-15	TTTNDYGDYSPAY	IGKV1-39	QQSYSTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_72-P1369	IGHV3-15	TSQVWLRGPGDY	IGLV6-57	QSYDSSLNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_17-P1369	IGHV3-21	AREAEWEAFDI	IGLV2-11	CSYAGSYTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_84-P1369	IGHV3-21	ARDVASNYAYFDL	IGKV1-39	QQSYSTPPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_67-P1369	IGHV3-21	ARERYGDN	IGLV4-69	QTWGPWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_84-P1369	IGHV3-21	ARVVANWFDP	IGKV4-1	QQYYSTPQPSWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_40-P1369	IGHV3-21	AREAARRYDFWSGLNWFDP	IGKV4-1	QQYYSTMLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_36-P1369	IGHV3-23	AKSGGRHYYDSSGYYRLPLDDAFDI	IGLV1-40	QSYDSSLSGSWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_52-P1369	IGHV3-30	ARAEWLRGAFDI	IGLV6-57	QSYDSTNHWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_70-P1369	IGHV3-30	ARAGWELLRIRYYFDF	IGKV1-33	QQYDNLPPT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_31-P1369	IGHV3-30	YALFERGNWNDAEY	IGKV2-30	MQGTHWPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_30-P1369	IGHV3-30	AKDLGSSLYYDAFDI	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_20-P1369	IGHV3-30	AKVDGSYYYYYYGMDV	IGLV2-14	SSYTSSSTAWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_22-P1369	IGHV3-33	AREQEANYYDISGYYHWGESLGY	IGKV1-9	QKVNSHPPGLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_70-P1369	IGHV3-33	ARGGRYYDSSGYNGTYEFDY	IGKV3-15	QQYNNWPPVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_50-P1369	IGHV3-33	ARDRKYSSGWSVVNFDY	IGLV1-36	AAWDDSLNGWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_59-P1369	IGHV3-33	ARDGLNWNVPHYGMDV	IGKV1-12	QQANSFPPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_58-P1369	IGHV3-53	ARVGGAHSGYDGSFDY	IGLV2-23	CSYAGSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_8-P1369	IGHV3-53	ARDRVIYGMDV	IGKV1-33	QQYDNLPQT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_11-P1369	IGHV3-53	ARAISESPRYGVY	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_14-P1369	IGHV3-53	ARVLPFGDYFDY	IGLV1-40	QSYDINLSAWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_91-P1369	IGHV3-66	ARDSSEVRDHPGHPGRSVGAFDI	IGKV4-1	QQYYSTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_51-P1369	IGHV3-66	ARDSTPGYGDY	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_47-P1369	IGHV3-66	ARDYGDFYFDY	IGKV3-15	QQYNNWPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_71-P1369	IGHV3-66	ARDLRDQDGYSYGAFDY	IGLV2-14	SSYTSSSSWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_16-P1369	IGHV3-74	ASAFWQRGNFDY	IGLV6-57	QSYDSSILWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_25-P1369	IGHV3-74	ARPTAVAAAGNYFYYYGMDV	IGLV2-14	SSYRSSSTLV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_86-P1369	IGHV4-30-2	ARFTNPNYYDSSGYYGFDY	IGLV2-8	TSYAGSNNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_39-P1369	IGHV4-31	ARVKGWLRGYFDY	IGLV6-57	QSYDSGSHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_83-P1369	IGHV4-4	ARVAAFLDY	IGKV1-NL1	QQYYSTRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_38-P1369	IGHV4-4	ARTWIQPHNWFDP	IGKV1-16	QQYNSYPLFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_72-P1369	IGHV4-4	ARGPPRLLWFGESPPTYWYFNL	IGKV4-1	QQYYSTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_38-P1369	IGHV4-59	ARYQLAPGSGSYYNWGGYPRESEYYFDY	IGLV2-11	CSYAGSYTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_5-P1369	IGHV4-59	ARHDTIFGVGQYYFDY	IGLV2-23	CSYAGSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_35-P1369	IGHV4-59	ARHSWLRGMADY	IGLV6-57	QSYDSSIWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_49-P1369	IGHV4-59	ARLKQQLVGFGWFDP	IGLV1-40	QSYDHSLNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_23-P1369	IGHV6-1	ARDILRDTSWPHDAFDI	IGLV2-14	SSYTSSSTPFYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A4-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B5-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C12-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_E4-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F1-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B7-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B9-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E1-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E11-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F6-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_A6-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_B12-p1369	IGHV3-30	AKEGRPSDIVVVVAFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C8-p1369	IGHV1-2	ASPASRGYSGYDHGYYYYMDV	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F12-p1369	IGHV1-2	ASPASRGYSGYDHGYYYYMDV	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_H9-p1369	IGHV1-2	ASPASRGYSGYDHGYYYYMDV	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E5-p1369	IGHV3-11	ARRGDGSSSIYYYNYMDV	IGLV1-44	AAWDDSLNGPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F8-p1369	IGHV3-11	ARRGDGSSSIYYYNYMDV	IGLV1-44	AAWDDSLNGPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G5-p1369	IGHV3-11	ARRGDGSSSIYYYNYMDV	IGLV1-44	AAWDDSLNGPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A11-p1369	IGHV3-30-3	ARDGIVDTAMVTWFDY	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D1-p1369	IGHV3-30-3	ARDQGMATTYFDY	IGKV1-39	QQSYNTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H7-p1369	IGHV3-30-3	ARDGIVDTALVTWFDY	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B5-p1369	IGHV1-2	ARDSPFSGLGASNDY	IGLV2-8	SSDAGSNNVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_B5-p1369	IGHV1-2	ARDSPFSALGASNDY	IGLV2-8	SSDAGSNNVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F9-p1369	IGHV1-58	AAPHCSGGSCLDAFDI	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F10-p1369	IGHV1-58	AAPHCSGGSCYDAFDI	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_E9-p1369	IGHV3-15	TTGPHYDSSGYSYTVDS	IGKV2-28	MQGLQTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G2-p1369	IGHV3-15	TTGPHYDDSGYSYTVDY	IGKV2-28	MQALQTPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G4-p1369	IGHV3-30	AKASGIYCSGGDCYSYYFDY	IGKV1-5	QQYNSYST	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B2-p1369	IGHV3-30	AKASGIYCSGGNCYSYYFDY	IGKV1-5	QQYNSYST	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F2-p1369	IGHV3-9	AKGRVVYAIDPDSVSPFDY	IGLV2-14	SSYTSRSTLGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E2-p1369	IGHV3-9	AKPRKRGDYYGSGSYDY	IGLV2-14	SSYTSSSTVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B10-p1369	IGHV4-39	ARHAAAYYDRSGYYFIEYFQH	IGKV1-5	QQYNNYRYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H11-p1369	IGHV4-39	ARHAAAYYDRSGYYFIEYFQH	IGKV1-5	QKYNSYRYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_E4-p1369	IGHV1-18	ARTDGTPAEYFQY	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G7-p1369	IGHV1-2	ARGGQDELTGAFDI	IGLV3-21	QVWDSGWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D10-p1369	IGHV1-2	AKSPYYYDSSGYLGGFDY	IGLV2-23	CSYAASSTYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C7-p1369	IGHV1-2	ARDLGYSYVQGYFDY	IGLV2-23	CSYAGSNTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B12-p1369	IGHV1-2	ARDLGFSRLQFLFDY	IGLV2-23	CSYAGSSIVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F4-p1369	IGHV1-2	ASTGYYILTGYEFGAMDV	IGLV2-14	SSYTSSSTV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D7-p1369	IGHV1-2	ARDRPLWFGVEYGMDV	IGLV2-14	SSYTSSSTLV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C1-p1369	IGHV1-2	ATTEGQQLPHPPYYYYYYYMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G5-p1369	IGHV1-46	ARDRAETEGSETYYYDSSGYYLLGY	IGKV1-39	QQSYSTPPS	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D3-p1369	IGHV1-46	ARSSVTGTPPFDY	IGLV3-21	QVWDSSSDHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G8-p1369	IGHV1-46	ARVPREGTPGFDP	IGLV3-21	QVWDSSSDHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E4-p1369	IGHV1-46	LVGISTIVVVRPAVWTS	IGLV5-52	GTWHSNSRV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F12-p1369	IGHV1-69	ARVLYYYDSSGYPNLEYFQH	IGKV1-33	QQYDNLPSFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B3-p1369	IGHV1-69	ARGNRLLYCSSTSCYLDAVRQGYYYYYYMDV	IGLV1-44	ASWDDSLNGPL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_C11-p1369	IGHV1-69	ARVGYYYDRSGFPRTEDYFDY	IGLV1-40	QSYDSSLSGVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G6-p1369	IGHV1-69	ARDEGYCSGGSCYGYYYGMDV	IGKV1-33	QQYDNLPMYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B2-p1369	IGHV1-69	ARGNRLLYCSSTSCYLDAVRQGYYYYYYMDV	IGKV3-11	QQRSNWPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D2-p1369	IGHV3-11	ARGLVYTPYRFGY	IGKV1-33	QQHDNVVT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_B4-p1369	IGHV3-11	ARGRTWELVDY	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A12-p1369	IGHV3-11	ARGKWLRGSFDY	IGLV6-57	QSYDSSNHWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A10-p1369	IGHV3-13	ARVGYDSSGYSGWYFDL	IGKV1-39	QQSYSTPPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_A2-p1369	IGHV3-13	ARGGGETITTVFDY	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D3-p1369	IGHV3-13	ARGSYSNYVGYMDV	IGKV1-39	QQSYSTPGLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D10-p1369	IGHV3-15	TTDQIYGDYLRMPVPFDY	IGLV1-47	ATWDDSLSGPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_H6-p1369	IGHV3-15	TTGPQYDDNGYSYTVDY	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_D12-p1369	IGHV3-21	AREVKRVVAAPEYYFDY	IGLV1-44	AEWDDSLSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_D11-p1369	IGHV3-21	AREVKRVVAAPEYYFDY	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C3-p1369	IGHV3-21	ARDRNRYDFWSGYYRLVGFDP	IGLV2-8	SSYAGSNNHV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F11-p1369	IGHV3-23	AKVWSISLDAFDI	IGLV3-21	QVWDSSSDL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C4-p1369	IGHV3-23	AKDGGRQWLVELLDY	IGKV1-39	QQSYSSPPT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G9-p1369	IGHV3-23	AKDRAAAHWATDY	IGKV1-33	QQYDNRLFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F7-p1369	IGHV3-23	AKDDSSGYHYYFDY	IGKV1-39	QQSYNTPPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D1-p1369	IGHV3-23	AKDSGTAMVEIFDY	IGKV1-39	QQSYSSTLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_E1-p1369	IGHV3-23	AKDLRSTTFYVYYFDY	IGLV2-14	SSYTSSSTPDV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F8-p1369	IGHV3-23	AKVPIHYCSNGVCYFDY	IGLV6-57	QSYDSSNRWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_D4-p1369	IGHV3-23	AKVVGSGTPPDYYYYYYMDV	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D4-p1369	IGHV3-30	ARATCSGGSCLFGQNAFDI	IGKV2-30	MQGTHWPPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G9-p1369	IGHV3-30	ARDYGSSWYQVPDY	IGKV1-39	QQSYSTPPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H9-p1369	IGHV3-30	AREFGDPEWYFDY	IGKV1-5	QQYNSYWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G8-p1369	IGHV3-30	AKNQNSYGYLSYFDY	IGKV1-33	QQYDNLPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E12-p1369	IGHV3-30	AKASGEYCGGGSCYRGVFDY	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_H4-p1369	IGHV3-30	AKVMGPYCSGGSCYSGYFDY	IGKV3-11	QQRSNWPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C4-p1369	IGHV3-30	AKAGGPYCSGGSCYSSYFDY	IGKV3-20	QQYGSSPAIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G2-p1369	IGHV3-30-3	ARDCGGDCYPTTDAFDI	IGKV1-39	QQSYSTPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H10-p1369	IGHV3-30-3	ARDHDYGEIVDAFDI	IGKV1-39	QQSYSTLMYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B1-p1369	IGHV3-30-3	ARDSEDCSSTSCYLDY	IGKV4-1	QQYYSTPFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_E6-p1369	IGHV3-30-3	ARGPGWQWPELDY	IGLV1-44	AAWDDSLNGPV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_A5-p1369	IGHV3-30-3	ATEDYYDSSGSFDY	IGLV2-11	CSYAGSFWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_C12-p1369	IGHV3-30-3	ARSKSYTSWGYYHMDV	IGLV2-14	SSYTSSSTWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D8-p1369	IGHV3-33	ARDGTSITLITEGDAFDI	IGKV1-12	QQANSLPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B11-p1369	IGHV3-33	ARDPSVVVTAIDFDY	IGKV2-30	MQGTHWPWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C9-p1369	IGHV3-33	AREHTPTDIVVVNVEY	IGKV2-30	MQGTHWPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_H8-p1369	IGHV3-33	AREKDIVATDFDY	IGLV1-40	QSYDSSLSGPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E10-p1369	IGHV3-33	AREYFYDSSDYYFEYYFDY	IGLV2-11	CSYAGSYTYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A4-p1369	IGHV3-33	ARDHSLGVRGDGYGMDV	IGKV1D-13	QQFNNYPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G11-p1369	IGHV3-33	ARDGAVVRFLEWPTVGYYYYYMDV	IGKV2-28	MQALQTPIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_G10-p1369	IGHV3-33	ARDMMIRGVAWYYYMDV	IGLV2-14	SSYISSNTV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H2-p1369	IGHV3-48	ARDSGGDIVVIPAVNGFDY	IGLV3-25	QSADSRGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A8-p1369	IGHV3-48	AREAHDGALTDYGDYLNWFDP	IGLV3-21	QVWDSSSDHLYWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A3-p1369	IGHV3-53	ARDLYSSGGTDI	IGKV3-20	QQYGSSPGT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_G1-p1369	IGHV3-53	ARDLYSSGGTDI	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A2-p1369	IGHV3-53	ARGYGDYYFDY	IGKV1-9	QHLNG	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F7-p1369	IGHV3-53	ARDYGDFYFDY	IGKV1-NL1	QQYYSTPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C8-p1369	IGHV3-53	ARDWGDYYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A10-p1369	IGHV3-53	ARDYGDFYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B12-p1369	IGHV3-53	ARDLSVFGMDV	IGKV1-9	QQVNSYSH	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_C9-p1369	IGHV3-53	ARDLGERGMDV	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_H7-p1369	IGHV3-7	ARYCSGGSCHPPGQWLSDAFDI	IGKV1-39	QQSYSTWT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F1-p1369	IGHV3-7	ARLRWLRADFDY	IGLV6-57	QSYDSGNVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C10-p1369	IGHV3-7	ARYYDILTGYYVDYYYMDV	IGLV3-25	QSADSSGTYVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_H10-p1369	IGHV3-74	TRDDSSWPHFFDN	IGKV1-39	QQSYSTRT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D8-p1369	IGHV3-74	ARAWAMRQTTLTPEWIDY	IGKV3-20	QQYGSSPYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D9-p1369	IGHV3-74	ARAWAMRQTTLTPEWIDY	IGLV3-25	QSADSRKVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_G3-p1369	IGHV3-9	AKGGEGFRNWNDGLDYFDY	IGLV1-44	AAWDDSLNGYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A5-p1369	IGHV3-9	AKDGRSGDQWPELYYFDY	IGLV3-21	QVWDSSSDHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_E10-p1369	IGHV3-9	AKAGVRGIAAAGPDLNFDH	IGKV3-11	QQRIT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_F9-p1369	IGHV3-9	AKGSSSSYHNWFDP	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D6-p1369	IGHV3-9	AKDGAGTENWFDP	IGLV3-21	QVWDSSSDPHVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G3-p1369	IGHV3-9	AKDMLGNYYYYAMVV	IGLV2-14	SSYTSSSTLEGV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E6-p1369	IGHV4-31	ARTMYYYDSSGSFDY	IGKV2-28	MQALQTPHT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G1-p1369	IGHV4-31	ASGELSAFGELFPHDY	IGKV3-11	QQRSNWLFT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_G7-p1369	IGHV4-31	ARVHVVRGVANYPYFDY	IGLV2-11	CSYAGSYTPWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D5-p1369	IGHV4-31	ARGSYSNYNGGLDY	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A9-p1369	IGHV4-31	ARVATDYGDSFDY	IGLV7-43	LLYYGGAWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_A8-p1369	IGHV4-4	ARAPPGDFYDSSGYFSAFDI	IGLV2-14	SSYRGSSTPYV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B6-p1369	IGHV4-4	ARDNGYVWGSYRPDAFDI	IGLV6-57	QSYDSRNVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D4-p1369	IGHV4-4	ARVVGYSSRGANYYMDV	IGLV1-40	QSYDSSLSDSL	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_H5-p1369	IGHV4-59	ARVPSVGDCSSTSCLYWYFDL	IGKV1-5	QQYNSYST	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F4-p1369	IGHV4-59	ARYGMGELLTLRSEYYFDY	IGLV2-11	YSYAGSYTFV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_C4-p1369	IGHV4-59	ARSYDSSGLSYNWFDP	IGLV1-40	QSYDSSLSGYVV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_E2-p1369	IGHV4-59	ARGGYYYDSSGYEYYYYYGMDV	IGLV1-47	AAWDDSLSGYWV	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C5-p1369	IGHV4-61	ARETYYYDSSGYYISDAFDI	IGKV1-5	QQYNSFSYT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H4-p1369	IGHV5-51	ARQWRGYYDRSGYYHFDAFDI	IGKV3-15	QQYNNWLGT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C6-p1369	IGHV5-51	ARHWYYGDYGNYSYYYLDV	IGKV3-15	QQYNNWPLT	RBD	-	SARS-2_infection	Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
8.10E+009	IGHV2-70	ARVQVAAAGSPYDY	IGKV1-39	QQTYSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81D2	IGHV3-53	ARFRYGDYPDY	IGKV1-33	QQYDNLPSFT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81A2	IGHV4-34	GVPYCSSSSCYRYYGMDV	IGKV1-9	QQLNSYPQAT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81C8	IGHV3-33	ARDGVDFGMVTLFDY	IGKV1-39	QQSYNTPPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81A1	IGHV4-59	ARDQGYSSGWNDAFDI	IGLV2-23	CSYAGSRFWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81A11	IGHV1-69	AREAGTTDWYFDL	IGLV1-40	QSYDSSLSVVV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81C3	IGHV4-39	ARHPRFSWRGNDSGYFDY	IGLV2-14	SSFTSSSTPYV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81C7	IGHV2-5	AHSMVRGVLFGADFDY	IGLV1-36	AAWDDSLNGPV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81D5	IGHV5-51	ARRWDGVGFDI	IGLV3-19	NSRDSSINHYV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81F2	IGHV4-34	ARGWTVPPLWVLNWFDP	IGKV2-28	MQALQTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81G8	IGHV3-7	ARSPHYYGGFDY	IGLV6-57	QSYHNSVWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8.10E+002	IGHV1-24	AITSVARGLRGYFDT	IGLV1-47	AAWDDSLSRVV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8.10E+011	IGHV1-24	AITSLARGLKGYFDS	IGLV1-47	AAWDDSLSGVI	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81A6	IGHV3-9	AKDIGCSSTSCSYYHYYGMDV	IGKV2-28	MQALQTPT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81B2	IGHV3-66	ARDGRAVAGTD	IGKV1-33	HQYDNLPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81B7	IGHV1-18	ARDYGWFGELSTEGQFDY	IGKV3-11	QQRRDFT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82A6	IGHV4-39	ARFITDGYSSGSDS	IGKV1-39	QQSYSTPRLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82C4	IGHV1-58	AADRMRIVGGKGYYYGMDV	IGKV1-5	QQYNSYSPGDT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82G8	IGHV4-59	ARRSMGYCSGGNCYSGFDP	IGKV1-39	QQSYSTPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82B6	IGHV4-61	AMTYYDYIWGRVDPQFDP	IGKV2-30	CMQGTHWPPT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82B7	IGHV1-18	ARDYGWFGELSTEGQFDY	IGKV3-20	HQYASSPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82C6	IGHV4-39	ARFITDGYSSGSDS	IGKV2-30	MQGTHWPMYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82F6	IGHV3-30	AKQASPYCSGGSCYSGNFDY	IGKV1-33	QQHDNVPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82A5	IGHV1-18	ARVQWLRLDY	IGKV1-12	QQAKGFPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82C12	IGHV2-5	AHRPAGFWSAHFDY	IGKV1-39	QQSYSTPAWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D3	IGHV3-66	AREGLLVGPTGRGLGMDV	IGKV1-33	QQYADLPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D4	IGHV2-70	ARMVVRGVMLDY	IGKV1-39	QQSYSPPHS	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51A3	IGHV1-18	ARDLAWFGELSESPIEY	IGKV3-11	QQRGNSIT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D2	IGHV2-5	AHRLAPDYDFLTGYYNGDDAFDV	IGKV1-39	QQSYNTLALS	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51A1	IGHV3-66	ARDLNIAGGFDI	IGKV1-9	QHLNIDPIT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.10E+013	IGHV3-7	ARLMYYYGNFDY	IGKV1-8	QQYYGYPT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D12	IGHV5-10-1	ARLPFCDSASCGRAHYYYGMDV	IGKV3-15	QQYNNWPET	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51F11	IGHV1-69	ATGRYTYGYGYYFDY	IGKV3-20	QQYGSSRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.10E+011	IGHV1-18	ARARQLVLNWYFDL	IGKV4-1	QQYYITPQLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.10E+008	IGHV3-13	ARVGYYGSGSYPLYWYFDL	IGKV1-39	QQSYSAPPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D7	IGHV5-51	ATRTGWTNDAFDI	IGKV1-39	QQSYSTPCT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51F5	IGHV2-70	ALGRAGTMDY	IGKV1-39	QQSYSPPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.10E+004	IGHV3-9	AKDMVAGPHYYGMDV	IGLV1-44	AAWDDSLNGWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51B1	IGHV5-51	ARHPSNFYDSGGDYYAMDV	IGLV2-23	CSYAGSSSWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52C1	IGHV3-66	ARLASDGSGSYLDYFDY	IGLV1-40	QSYDSSLSGSWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52G1	IGHV3-9	AKDLSSGWDLFDY	IGLV3-21	QVWDTSGDPLV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52C6	IGHV1-69	ATDGGGGSYYYAHYYYGMDV	IGLV8-61	VLYMGSGIVV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.20E+008	IGHV5-51	VRSDGDYVIGHDY	IGLV1-44	ATWDDSLNGRV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52B6	IGHV3-48	ARGRDDYGDYRGGDFDY	IGKV3-11	QQRSNWPPIT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52F7	IGHV3-9	AKDIGVMVPGVTPYGMDV	IGKV2D-30	MQGTHWPPGT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52B8	IGHV1-69	ARGPAYVSGTYYWNAFDI	IGKV3-15	QHYNNWPLYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.20E+010	IGHV3-30	ARDPPPGNMGSMAQHLVLLVVFDI	IGKV1-39	QQSYTTLALT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52G9	IGHV3-66	ARDPMRPGMDV	IGKV1-33	QQYDNLPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53H3	IGHV3-66	ARYYGPQGRAFDI	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53C5	IGHV1-69	ARGRYTYGTEGYFDN	IGKV1-5	QQYNNLYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53G1	IGHV3-33	AKGGFGYASGWYYLDY	IGKV1-33	QQYGNLPPIA	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53B2	IGHV3-13	ARAYYDTSGYYNYFDH	IGKV3-15	QHYNNWPLYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53H5	IGHV3-53	ARGYGSGSYGWFDP	IGKV3-15	QHYNNWPLYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53H6	IGHV3-53	AREGLGMDV	IGKV3-15	QHYNNWPLYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53F9	IGHV3-53	AREGLVGTTLTFDY	IGKV2D-30	MQGTHWPPGT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53G6	IGHV2-70	ARFLVGGFKAWFDP	IGLV1-51	GTWDTSLNVWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53C10	IGHV3-43	ARESPKLTGYFDY	IGLV3-21	QVWDSSSDPYV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.30E+012	IGHV1-46	ARDQAFIVATLGPDY	IGLV8-61	VLYMGSGIWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.30E+013	IGHV3-53	AKMLWLRGWFDP	IGLV6-57	QSYDTSNHWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53F12	IGHV3-66	ARDAVGSYYYGMEV	IGKV3-15	QHYNNWPLYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
54H2	IGHV5-51	ARQESGWSFDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
54F10	IGHV3-53	ARDLEERGAMDV	IGKV3-20	QQYGSSLWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
54G7	IGHV3-66	ARAGWLRGRFDP	IGLV3-21	QVWDSTTDLPHWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55G3	IGHV2-70	ARTRLGITAFDI	IGKV1-39	QQSYTTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55A8	IGHV1-69	ARGTEYGDYDVSHD	IGKV1-5	QQYNSYSHT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55C9	IGHV3-53	AREGLVGTALAFDY	IGKV1-39	QQSYSTPPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55G9	IGHV3-13	ARVGYDSSGYYWYLDL	IGKV1-39	QQSYTTPLFT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55G11	IGHV3-30	GKGAGPYCGGGSCYPTKVDY	IGKV1-33	QQYDNLLWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56C3	IGHV3-33	AKDGSGSYYNSGALDY	IGKV1-33	QQYDNLPPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56H3	IGHV3-66	ARDYGDYYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56B4	IGHV1-18	ATDDPDIVLVPAAMSLDY	IGKV1-39	QQSYNTLALS	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56D7	IGHV3-66	ARDLDYYGMDV	IGKV1-9	QQLNSYPPIT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56H7	IGHV4-59	ATDYYDSSGYRYGMDV	IGKV1D-12	QQANSFPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56A8	IGHV1-69	ASFGSLWDLRDY	IGKV3-20	QQYGTSRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.60E+009	IGHV3-23	AKDVGSRLIYDVFDY	IGKV1-39	QQSYSTPPYS	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56A10	IGHV2-70	TRTATVVKDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56B11	IGHV2-70	ARMIPIPALDY	IGKV1-39	QQSYSTPHT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56B12	IGHV2-70	AREEAAGTKLDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56C12	IGHV3-30	AKDPTSLYCSGGSCYNNWFDP	IGKV1-39	QQTYSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.60E+002	IGHV3-30	AGGGVLVTSDPDAFDI	IGLV1-44	AAWDDSLNGWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56A3	IGHV3-30	AKRGGTYCSGGICYGGYFDY	IGLV1-40	QSYDSSLSDWGV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56F3	IGHV1-46	ARDYSRITMIRGAGDY	IGLV1-51	GTWDSSLSAQV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56H9	IGHV3-53	ARGPYPSSSWA	IGLV2-14	SSFTSSSTPYV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56H11	IGHV4-4	AGEQHIVTTIIDY	IGLV1-44	ATWDDSLNGRV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57B2	IGHV3-30	AGGGVLVTSDPDAFDI	IGKV1-33	QQSDNVPVT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57C4	IGHV3-15	STTNDYGDYSANY	IGKV1-39	QQSYSTPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.70E+008	IGHV5-51	ARIEYYNDSSGYYQF	IGKV3-20	QQYGSSWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57H7	IGHV1-8	ARGLWFGDLTRTKYNWFDP	IGKV1D-13	QQFNNFLLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57A8	IGHV3-23	AKGQRGSPDFFDY	IGKV1-5	QQYNSYSPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57B8	IGHV3-53	ARDLVTWGLDY	IGKV1-9	QLLNTDPIT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57A9	IGHV1-3	ARAGWELNY	IGKV4-1	QQYYSFWA	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57G9	IGHV2-70	ARITPHLVYDY	IGKV1-39	QQSYSIPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57A6	IGHV5-51	ARQESGWSFDY	IGLV3-19	NSRDSSGNHWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57F7	IGHV4-34	ARDDSSSSGVGTGMDV	IGLV1-44	AVWDDSLNGWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57F8	IGHV2-5	AHTTWYYYGSGWFDP	IGLV1-44	AAWDDSLNGHV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57A11	IGHV1-18	ARVQEFWLDP	IGLV3-21	QVWDSSSDHPL	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.70E+012	IGHV1-8	ARGLWFGDLTRTKYNWFDP	IGLV1-44	AAWDDSLNGWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58G1	IGHV3-53	ARDLENGGLDV	IGKV1D-12	QQTNSFPT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58D2	IGHV3-11	ASPLLSHNYGSGSYYNVYWYFEL	IGKV3-11	QQLGT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58A4	IGHV4-59	ARTLGAYYDILTGFRTPGGWFAP	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58B5	IGHV3-23	AKEPSFGLWFGELSG	IGKV3-20	QQYGSSLPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58G6	IGHV1-58	AAPNCNSTTCHDGFDI	IGKV3-20	QQYDNSPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58G9	IGHV3-13	ARGSLRGGILSGYAFDI	IGKV1-39	QQSYSSPPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.80E+003	IGHV4-39	ARYYGPGTYYDAFDI	IGLV2-14	SSYTSSSTWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58A3	IGHV3-30	ARDWVHYGSGSYPPDY	IGLV2-18	SSYTSSSTWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58H3	IGHV5-51	ARHPVLRGNIDY	IGLV1-40	QSYDSSLRGSV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H2	IGHV3-66	ARDKWEGTFDY	IGKV1-9	QQLNSYPRMT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510A4	IGHV2-70	ARVQVAAAGSPYDY	IGKV2-28	MQALQMGT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510G4	IGHV4-31	ARDYGGNSNYFHY	IGKV1-33	QQYDTLPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H4	IGHV3-66	AETGWDGMDV	IGKV3-11	QQRSNWPGT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510A5	IGHV3-9	AKDRGYEILTPASFDY	IGKV1-39	QQSYSTPPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510F6	IGHV2-5	AHSLPSKYSYSYGSFDY	IGKV1-39	QQSYSAPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510D7	IGHV1-69	ATGRYTYGYGYYFDY	IGKV3-20	QQYGSSRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.10E+012	IGHV3-23	AKGELLWFGELLENWFDP	IGKV1-12	QQADSFPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H10	IGHV2-70	ARIQRGIAADY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510B1	IGHV5-51	ARLPPHFGSGSYYGNAFDI	IGLV1-47	ATWDDSLTGPV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510G2	IGHV7-4-1	ASTVGRGSGTYYYGNYYSYSMDV	IGLV2-14	TSYTGSSTSVV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H7	IGHV4-59	ARHCPWQQLVSNWFDP	IGKV1D-13	QQFNNFLLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H6	IGHV1-46	ARTGFLIPSKGGGMDV	IGLV2-14	SSYTSSSSLQI	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510C4	IGHV3-48	ARDPGEWESLDLDY	IGLV1-40	QSYDSSLSGNWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511A1	IGHV4-31	AREKIRSIAAAGTVYYYGMDV	IGKV3-15	QQYNNWPPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511B4	IGHV4-59	ASTYWDSSGYYYGVDY	IGKV1D-12	QQANSFRLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.11E+009	IGHV5-51	ALAVGRGIPTSYFDY	IGKV1-33	QQYHNLPIT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511G7	IGHV3-33	AKGGNYGDYLRGFDY	IGKV1-33	QQYHNVPPA	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.11E+011	IGHV1-18	AREGAGLIIAYDY	IGKV6-21	HQSSSLPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511D11	IGHV1-18	AVLDYCSGGSSSSGYYNYGMDV	IGKV3-20	QQYGRSPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511H11	IGHV3-13	VRGDHSSGWYGTYYYYMDV	IGKV1-39	QQSYSSPPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511D12	IGHV3-66	ARDLDIAGAFDI	IGKV1-9	QLLNSFPIT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511A5	IGHV4-31	ARIYRGTMVVVFSDLHWYFDL	IGLV3-21	QVWDSSADHYV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
5.11E+007	IGHV1-2	ARDSLFSRVDWYFDL	IGLV1-40	NSRDSSGNTVV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511G5	IGHV1-46	ARDGALYSNSPTEFDY	IGLV1-47	TTWDASRGGWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511B7	IGHV1-46	ARGGLVPAVMPALDY	IGLV1-47	AAWDDSLSGPV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511H7	IGHV3-23	ARGLQYYYDTSGYYKDSYYYGVDV	IGLV1-47	AAWDDSLSGPV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511B11	IGHV3-7	AGLFWYGGYFDY	IGLV1-40	QSYDRSLSVLYV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59B11	IGHV3-13	ARGTQDRVELMVGSPYYYYYMDV	IGKV1-39	QQSYITTMYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59D6	IGHV4-34	ARHRRDYITMIVRPTRLWAFDY	IGLV1-40	QSYDSALVV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59A1	IGHV3-66	ARELGPVGGTDQ	IGKV1-39	QQSHSTPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59A2	IGHV3-66	ARDLPLHGDYFDY	IGKV1-33	QQSDNVPVT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59H6	IGHV3-30	ARETLGGYCNGGSCYDAGYFDY	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59G12	IGHV3-33	ARDGVDFGMVTLFDY	IGKV1-39	QQSYNTPPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B1E6	IGHV4-4	ARVQGLIDY	IGKV1-NL1	QQYYSTPPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B1B1	IGHV5-51	ASQAAAGYYYYMDV	IGKV1-39	QQSYNILWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B1H12	IGHV3-23	AKQTDYGVGWFDP	IGKV1-33	QQYDNFSLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B1E11	IGHV1-69	AVLPLHSSYNWYYFDY	IGKV3-11	QQRSNWPPGMYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2F2	IGHV2-5	AHQRHSNSWYVSAWFDP	IGLV1-40	QSYDSSLSGNFV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5A6	IGHV3-33	AKGGWYSSKWYYFDY	IGKV2-28	MQALQMGT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2D5	IGHV3-13	ARGSDTVTTAFDI	IGKV1-39	QQSYTTPGLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2H8	IGHV3-53	AREAPNSRGSGTNFDY	IGKV1-39	QQSYSTPPYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2D11	IGHV3-33	AKNGYSYAYPRQYFDY	IGKV1-33	QHYDNLKVT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2E4	IGHV4-31	ARVSRYTMVRGVIFDY	IGLV2-23	CLYAGHSTYVV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2G6	IGHV4-38-2	ARVGVATILGVDY	IGLV6-57	QSYDSSWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2E12	IGHV3-30	AKGGGYISAWSTRYYAMDV	IGLV2-14	SSYTSSSTWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B3E9	IGHV3-23	AESSSLTGNFNY	IGLV3-21	QVWDTAWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5A1	IGHV3-13	ARGFDTTTGFYFDY	IGKV1-NL1	QQDYNFPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5B6	IGHV1-69	ARTEYSYDSGSSRAYSMDV	IGKV1-39	QQTHSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5E5	IGHV7-4-1	ARVGPSSSWPS	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5C1	IGHV3-33	AKGGWYSSKWYYFDY	IGKV2-28	MQALQMGT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5F7	IGHV3-7	ARDLGVLWFGDPY	IGKV1-NL1	QQYYSAPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4G4	IGHV2-5	AHSPDHRYFDVLTGYFNSERFYFDY	IGLV1-51	GTWDSSLSAGV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4A7	IGHV4-39	ARIPRHLGQDHYYYVMDV	IGLV2-23	CSYAGIFV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4D9	IGHV3-30	AKAAGGGYSYIYWGGDY	IGLV6-57	QSYDSSNLWV	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4E1	IGHV4-61	AREYFVSLPAAQTLYYYGIDV	IGKV3-15	QQYKNWPPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4H2	IGHV1-8	ARGLWFGDLTRTKYNWFDP	IGKV3-20	HQYDSSPLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4A3	IGHV1-46	ARDPPSGNYDNIDEWTRSENHYNYGMDA	IGKV3-11	QQRSNWPYLT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4C5	IGHV3-11	ARDGSAVAGPMSYFDY	IGKV1-NL1	QQYYSIPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4E5	IGHV2-70	AREVAGAVHLDY	IGKV1-39	QQSFSTPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4B6	IGHV3-7	ARDLGVLWFGDLLF	IGKV1-NL1	QQYYSDPPRT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4E11	IGHV4-59	ARGGYYYGPPRDFDY	IGKV3-20	QHYGSSPQYT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
13G9	IGHV1-58	AAPYCSSTSCRDGFDI	IGKV3-20	QQYGRSPWT	RBD	-	SARS-2_infection	Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
HL CV01-101	IGHV3-74	ARGSSNLFDI	IGLV1-44	AAWDDSLNGWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-102	IGHV3-21	ARSGGYSGYDYSHRIDY	IGLV2-14	SSYTLDSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-103	IGHV1-69	ASGWGMEYSSSSADY	IGKV3-11	QQRSNWPPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-104	IGHV1-18	ARADETMVQGVIPNFDY	IGLV2-8	SSYAGSNNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-107	IGHV3-74	ARGRDCGGSSCYGYPYYGMDV	IGKV2-28	MQALHTPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-109	IGHV3-7	ARAGSVGVVDY	IGKV2-30	MQGTHWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-110	IGHV3-7	VRDRGYCVGDVCYTVLDY	IGKV1-6	LHDYNYPPT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-111	IGHV3-15	TTWFYYDIRDH	IGKV3-11	QQRSNWPPFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-112	IGHV1-18	ARADDTMVQGVIPNFDY	IGLV2-8	SSYAGSNNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-113	IGHV3-15	ASIYYDF	IGKV1-17	LHYNSVPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-114	IGHV1-2	ARGDAVARTLNLDY	IGLV1-44	AAWDDSLNGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-116	IGHV3-7	ARAGNIGAVDY	IGKV2-30	MQGTHWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-117	IGHV3-49	GLSYYYDNGGYYSVPPIDV	IGLV2-8	SSYADSNNLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-118	IGHV3-9	AKNSPSCADAVCYFDV	IGKV4-1	QQYYSAPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-120	IGHV4-30-4	AREGVLITIFGVARDAFDI	IGKV3-20	QQYGSSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-121	IGHV4-38-2	SIWGGVQGVLQDY	IGKV3-15	QQYNDWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-122	IGHV3-7	ARAGSIASVDY	IGKV2-30	MQGTHWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-123	IGHV3-7	AKGGWRYFDY	IGKV3-11	QQRSSWPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-124	IGHV3-23	AKYGSITIFGVVIIGYFYFDY	IGKV3-20	QQYGSSPAT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-125	IGHV1-18	ARADYTMVQGVIPNFDY	IGLV2-8	SSYAGSNNVL	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-126	IGHV5-51	AGHVRYCISTNCYHYGMDV	IGLV5-45	MIWHTSAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-128	IGHV3-7	ARAGDRGAVDY	IGKV2-30	MQGTHWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-129	IGHV1-18	ARADYTMVQGVIPNFDY	IGLV2-8	SSYAGSNNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-130	IGHV3-7	ARPGYSGNNWGEAFDI	IGKV4-1	QQYYDTLWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-132	IGHV4-59	ARDRGYNWNYYYYYGMDV	IGKV3-20	QQYGSSPST	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-133	IGHV3-7	ARAGSRGSVDY	IGKV2-30	MQGTHWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-134	IGHV3-30	AKEKLDCSSTSCYFGFIYYYYYMDV	IGKV1-12	QQANSFPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-135	IGHV3-11	ARESYEGSSFDY	IGLV6-57	QSYDSSNRRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-137	IGHV3-7	ARDYGRCGDY	IGKV3-11	QQGGNWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-138	IGHV4-39	ARHGYITIFGVVIIPGWFDP	IGKV3-15	QQYNNWPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-139	IGHV4-39	ARHPDNELLPFDY	IGLV3-21	QVWDSSSDSYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-140	IGHV3-30-3	ARDPRNYCHSNTCPVWYFDL	IGKV3-20	QQYGSSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-141	IGHV3-33	AREGNYGDYGGSFDY	IGLV3-10	YSTDSSGNHRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-142	IGHV4-30-4	ARGPRITIFGVVIYWYFDL	IGLV1-40	QSYDSSLSGSGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-144	IGHV3-30	ARRDRIFEFGATREALDF	IGLV1-40	QSYDSSLSGYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-145	IGHV3-23	AKVTWTTTGDS	IGKV1-5	QQYNSYPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-146	IGHV3-7	ARAGDRGAVDY	IGKV2-30	MQGTQWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-147	IGHV3-30-3	ARERVNGRWLQLLTP	IGKV1-5	QQYDAYLS	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-148	IGHV3-7	ARAGDRGAVDY	IGKV2-30	MQGTHWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-149	IGHV1-18	AGYPRYNWNYDNRYYFDF	IGKV1-39	QQSYSAPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-151	IGHV1-18	ARADDTMVQGVIPNFDY	IGLV2-8	SSYAGSNNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-152	IGHV1-3	ARGVGATIPYYYYYYMDV	IGKV1-5	QQYNSYSWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-153	IGHV4-4	AKVGGGNADHGPGYYYYYMDV	IGKV1-9	QELNRYPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-154	IGHV3-9	AKNSASCADDLCYFDI	IGKV4-1	QQYYSGPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-155	IGHV3-11	ARALPGGITIFGVVITEYYFDY	IGKV3-20	QQYGSSSYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-158	IGHV3-21	ARGDDYGEYTGAFDA	IGLV3-1	QAWDSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-159	IGHV1-46	ARGGETQQRLVWDQKTDD	IGKV1-17	LQYNSYPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-163	IGHV3-7	ARAGSVGTVDY	IGKV2-30	MQGTHWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-166	IGHV3-15	TTEKGRYHLGGVFAN	IGKV4-1	QQYYSTPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-168	IGHV5-51	VWTSRGYFDH	IGLV7-43	LFYYGGAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-169	IGHV3-30	ARDLSSGWSLDS	IGLV2-14	SSYTSSNTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-170	IGHV4-4	ARYCSSTSCYGYYYYGMDV	IGLV2-8	SSYAGSISYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-171	IGHV4-4	AKGGGSGWYYDAFDI	IGKV3-15	QQYNNWLRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-174	IGHV1-18	ARDDWNYARGNFDY	IGLV2-14	SSYTSSSSVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-175	IGHV3-7	ARAGGVGTVDY	IGKV2-30	MQGTLWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-176	IGHV1-18	ARADHTMVQGVIPNFDY	IGKV2-28	SSYTGRKNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-180	IGHV3-7	ARCDMAGTTDY	IGKV2-30	MQGTLWPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-181	IGHV3-21	ARDLEGVETIFGVVIIPAYWYFDL	IGKV2-28	MQALQTRLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-182	IGHV3-23	AKDLKIGTLGWYYDFWSGYLPDPSNKIFDY	IGLV1-40	QSYDSSLSGWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-183	IGHV3-73	TRVNPIQGAFYDALDI	IGLV1-51	GTWDSSLSVVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-184	IGHV4-59	ARFSSAAGVWALDH	IGKV4-1	QQYYTTPFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-185	IGHV1-69	ACDMVQGVAVLDV	IGLV2-14	SSYTSSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-186	IGHV4-59	ARHGKSIPYSNYDWFDP	IGKV1-39	QQSYSTLPFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-188	IGHV3-72	ARDLGANGDRFGN	IGKV4-1	QQYYSTPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-193	IGHV3-15	ATDLGDYGDYMRS	IGKV1-12	QQANSFPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-194	IGHV4-59	AKKADPHSAFDY	IGLV2-11	CSYAGSYTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-195	IGHV3-7	VRELVVGRAEYFQD	IGLV1-44	AAWDDSLNGRV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-196	IGHV3-30	AKDPGMLYPSAFDM	IGKV3-15	QQYNNWPPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-197	IGHV3-23	AKDQDGHYGGNPDMDH	IGLV2-8	SSYAGSNKMV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-198	IGHV3-15	ATLTYGYSPY	IGLV2-14	SSYTSSTTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-199	IGHV3-74	ASNFNRNDGY	IGKV2-30	IQSTHWPPN	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-202	IGHV4-30-4	ARMGNMFGYSVVDF	IGKV1-39	LQTYSAPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-203	IGHV3-30	AKSEGKFYFYGVDV	IGLV1-47	AACDDSLSGHV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-205	IGHV5-51	AREARWSFPSWFDP	IGKV3-15	QQYNNWPRF	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-211	IGHV5-51	ARLSSGWYGGFNFDY	IGKV3-20	QQYGSSPVYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-212	IGHV3-30	AKCSYTSICKGWDGAH	IGLV2-14	SSFTTSYTLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-213	IGHV3-64	ARLQGTGYLDY	IGKV3-20	HQYGSSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-215	IGHV3-48	ARQWAVNWFVP	IGLV2-14	SSHTSSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-220	IGHV3-48	ARDVGTYESTSTGMDV	IGKV3-11	QQRGNWPPAT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-221	IGHV3-30-3	ARGAPVDY	IGLV2-8	-	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-222	IGHV3-23	AKPGGEWYSSGWRFDY	IGLV1-47	AAWDDSLSGPV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-223	IGHV3-23	AKCGRTSCRVDAFDI	IGLV8-61	VLSMGGGVWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-225	IGHV3-53	ARDGGGSYPHRAFDI	IGLV2-14	SSYTSSSTSDVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-226	IGHV4-39	ARHATGTPPYYYYYMDV	IGLV3-1	QAWDSSTACV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-227	IGHV3-30	AKGSPLLGFGGVDY	IGLV5-39	AIWYSSSLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-228	IGHV3-7	ARVGASDYDYVWGTRTLDS	IGKV4-1	QQCLTTPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-229	IGHV5-51	ARPYGAGTAHYFDY	IGKV4-1	QQYYGTPHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-231	IGHV4-39	ARHFHPGNYYYYYMDV	IGLV3-1	QAWDSSTYVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-232	IGHV4-39	ARKYGDLHFDY	IGLV8-61	VLYMGSGISV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-233	IGHV4-39	ARSDARFLEWLFPDAFDI	IGLV2-23	CSYAGSTTFVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-234	IGHV3-30	ARGSPFGGIRSGLGP	IGKV1-27	QKYNSAPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-238	IGHV4-39	ARHPTGSGSYQYYYYYIDV	IGLV3-1	QAWDSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-241	IGHV3-66	ARDRGYDSSGYTAADAFDI	IGKV1-5	QQYNSYST	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-242	IGHV4-31	ARGGYRNWFDP	IGLV2-11	CSYAGSYTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-244	IGHV5-10-1	ARLKGSVPPYYYNYMDV	IGKV2-28	MQGLQTPFI	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-249	IGHV3-30-3	ARHNRAQGPSFDV	IGKV1-39	QQTYSVPTT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-254	IGHV3-7	ASLLGGTVVNDY	IGKV4-1	QQYYSTQYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-257	IGHV3-48	ARHPWDDYGDYYYYYMDV	IGKV3-20	QQYGSSLNT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-258	IGHV4-59	ARAVHGVDTGMVTYYYHYYMDV	IGLV3-21	QVWDNSIDHVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-260	IGHV1-8	ARGREYYDFWSGYYN	IGLV2-14	SSYTRSNTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-266	IGHV3-15	TSERWLDAFDI	IGKV1-39	QQSYRSPPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-273	IGHV4-4	ARGWGKGPPLGY	IGLV2-23	YSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-274	IGHV3-30	AKDNGDYACFDY	IGKV4-1	QQYYSTPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-276	IGHV1-2	ARDPFEYYDFWSGYYRGGMDV	IGLV2-14	SSYTSSSTRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-101	IGHV1-2	ARGLITWYYYYDSSAVDY	IGKV3-20	QQYGSSPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-103	IGHV3-21	ARDPDGHRSGWFDWFDP	IGKV1D-12	QQANSFPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-104	IGHV1-18	ARDSHYYDSSGYYYLYYYYGTDV	IGLV3-25	QSADSSGTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-106	IGHV4-31	ARGRTIFGVVSGAFDI	IGKV3-20	QQYGSSPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-107	IGHV4-31	ARGRTIFGVVSGAFDI	IGKV3-20	QQYGSSPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-108	IGHV3-15	TKTKNPPAYDFWSGYYRGRPPYYKYGMDV	IGLV1-40	QSYDNSLSEYDDV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-109	IGHV5-10-1	ARHVGVGATHSPPFDY	IGLV1-40	QSYDSSLSGPTV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-110	IGHV3-48	ARDLGSWYYLLDFDY	IGKV1-5	QQYNSYPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-112	IGHV3-48	GRSSSWRYNWFDP	IGKV3-15	QQYNNWPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-113	IGHV3-15	TTDPYYEISSGYSPDY	IGLV2-11	-	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-116	IGHV4-59	ARVQGRGSGSYYSAYYYGMDV	IGLV1-40	QSYDSSLSGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-117	IGHV1-46	LRDGISTFGVVNHYYAMDV	IGLV2-14	SSYTSSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-118	IGHV1-46	ARDGISTFGVVKHYYAMDV	IGLV2-14	SSYTTTTTLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-120	IGHV3-21	ARDSLITIFGVVIEAPDDYGMDV	IGLV2-14	SSYTSSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-121	IGHV3-23	AKDYFVIPPAALYDY	IGLV1-51	GTWDSSLSAGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-123	IGHV3-23	VKELDDQLTLGGWFDP	IGLV2-23	CSYVGTATVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-124	IGHV5-51	ASSVRYFDWFDFDY	IGLV1-44	AAWDDSLNGYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-129	IGHV1-69	ARARRPTYSSSWGTFDY	IGKV1-39	QQSYSTPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-130	IGHV4-59	ASGTYGGPYLFDY	IGKV1-5	QKYNTYPGT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-131	IGHV3-11	ARAGDMIVVAAFDY	IGKV3-20	QQYGSSPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-132	IGHV3-7	ARGPQMVYALFPYYYYYGMDV	IGKV1-27	QKYNSAPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-135	IGHV3-64	VMELYGSDVFDL	IGKV1-39	QQSYSTSWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-138	IGHV3-74	ASYTWGRI	IGLV2-14	SSYTRSSTLVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-139	IGHV4-39	ASQGPLPPILYDILTGYYLGDYYYGMDV	IGKV2-28	MQALQTPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-140	IGHV3-49	TRDAYYYGSGSYSEGGH	IGKV3-11	QQRSNWPPLFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-141	IGHV4-38-2	ARDVTGYDNEDYYYYYGLDV	IGKV4-1	QQYYSSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-142	IGHV3-53	AREGPDSGYLDY	IGLV4-69	QTWGTGIRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-143	IGHV3-48	ARDSGFWSGYYPGNFNY	IGKV1-33	QQYDNLPPLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-144	IGHV1-18	ARDPWIELRPPRNYYYNGMDV	IGKV2-28	MQALQTPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-145	IGHV1-46	ARDSSDCSGGSCYRFDY	IGLV1-44	AAWDDSLNGYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-146	IGHV3-23	AKDRTVTKTGLFYLDDC	IGKV1-39	QQSYSTPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-147	IGHV3-23	ASQTGTGEVDY	IGLV3-1	QAWDSSTGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-148	IGHV3-23	AKGPRLLWFGELSPFDY	IGLV1-51	GTWDSSLSALV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-150	IGHV3-23	VKGSGDIERMVSTLRYYFYGLEV	IGLV1-47	AVWDDSLSAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-151	IGHV3-23	VKGSGDIERMVSTLRYYFYGLDV	IGLV1-47	AVWDDSLSAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-152	IGHV3-30	AKSGEVFWFGRFRRDYLDY	IGLV1-44	AAWDDRLNGVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-153	IGHV3-74	ARDSCTSTSCYESMK	IGKV1-5	QHYNSYPWM	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-154	IGHV1-24	ATSTVIAAAGTVHYYYYYGMDV	IGKV2-24	MQATQFPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-155	IGHV3-33	ARDEKAYDFWSGYLSYYYYGMDV	IGKV2-30	MQGTHWPPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-156	IGHV5-10-1	ARLLYYYDSSGYYLPSPIDY	IGKV1-33	QQYDNLLLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-158	IGHV3-23	VKGSGDIERMVSTLRYYFYGLDV	IGLV1-47	AVWDDSLSAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-160	IGHV5-10-1	ARLGADSSGYYLPSGGIGY	IGLV1-40	QSYDSSLSGSKV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-161	IGHV4-39	ARQRKGWLQLRGNWYFDL	IGLV3-10	YSTDSSGNQVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-162	IGHV3-74	ARGGGTVVTPGPDY	IGLV4-69	QTWGIGTHDVI	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-163	IGHV3-23	VKGSGDIERMVDALRYYFYGMDV	IGLV1-47	AAWDDSLSAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-166	IGHV4-4	TRLYCSSGACYLGP	IGKV3-20	QQYGRSPT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-167	IGHV1-46	ARGRDWFDP	IGLV2-23	CSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-168	IGHV1-69	AREAFYDILTGYSSTPNHYYYGMDV	IGKV2-28	MQALQTPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-169	IGHV3-74	ARDFYYDSSGFDY	IGKV1-39	QQSYSTPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-170	IGHV4-4	ARDTIGGHAFDI	IGLV3-21	QVWDSSSDHRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-172	IGHV1-24	ATSTLFSSVVPASWFDP	IGLV2-14	SSYTSSSTPVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-173	IGHV1-2	ARILPSDYFWSGYYSIQETDAFDI	IGKV1-5	QQYNSYSSS	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-174	IGHV5-51	ARQVFIAVAGTGFDY	IGKV2-28	MQALQTPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-175	IGHV4-31	ARDFVSGPLMTENVPIYDSSGYYLTRYNWFDP	IGLV1-51	GTWDSSLSAVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-177	IGHV3-23	AKDSGSYLLN	IGLV3-1	QAWDSSTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-179	IGHV1-2	AREDGSSPLGGGMDV	IGLV3-1	QAWDSSTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-180	IGHV3-23	VKGSGDIERMVSSLRYYFYGLDV	IGLV1-47	AVWDDSLSAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-181	IGHV1-69	ASTGHHQDASDY	IGKV3-11	QQRSNWPPRVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-182	IGHV1-2	ARERLAAAGTDFDY	IGLV1-40	QSYDSSLSDYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-183	IGHV3-23	VKGSGDIERMVSSLRYYFYGLDV	IGLV1-47	AVWDDSLSAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-185	IGHV4-4	ARRGHTLLWYYYYGMDV	IGLV1-51	GTWDSSLSAGAV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-186	IGHV3-48	ARGQRGLPFYYYYGMDV	IGLV1-40	QSYDSSLSGSV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-188	IGHV3-23	VKGSGDIERMVSTLRYYFYGLDV	IGLV1-47	AVWDDSLSAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-190	IGHV4-4	ARGMGYDFWSGYSSYYGMDV	IGKV1-16	QQYNSYPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-191	IGHV3-11	ARDLGYNRRFDY	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-192	IGHV3-15	TTDPLRYYDSSGYLYYGMDV	IGKV2-28	MQALLTPST	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-193	IGHV3-53	ARGGSWPNVFDI	IGLV8-61	VLYMGSGIWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-195	IGHV1-18	ARDRLRVRGVIKYYYYGMDV	IGLV3-25	QSADSSGTHWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-101	IGHV3-30	AKDRGYSSSWFSYLDS	IGKV3-20	QQYGSLRLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-102	IGHV1-3	AREDTFSVFGVVTRGNAYDV	IGKV3-20	QQYGVSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-104	IGHV5-51	ARLGRSLQPNLGFDL	IGKV2-30	MQGSHWPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-107	IGHV3-21	ARDSESAWNRIGNFYFDL	IGKV3-15	QQYNDWLIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-108	IGHV5-10-1	ARHHLKRGYATRYGMDV	IGKV1-39	QQSYSTPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-109	IGHV4-31	ASLEGPYCSDTTCYEGGQGLDY	IGKV3-11	HQRGNWWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-110	IGHV1-3	AREDTFSVFGVVTRGNAYDV	IGKV3-20	QQYGVSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-111	IGHV3-33	ARDLDGDYVTYYYGMDV	IGLV2-14	SSYTSSSTPVV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-113	IGHV3-30	ASGDGYRNFWYFDI	IGKV2-28	MQALQTPT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-114	IGHV3-30-3	ARTVGDYGDY	IGLV3-1	QAWDSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-115	IGHV3-48	ARDRGGYSGYGPYYYGMDV	IGKV1-39	QQSYSTPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-116	IGHV4-38-2	-	IGLV2-23	CSYAGAGSSNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-117	IGHV3-23	AKEKTSWLVAYYYGLDV	IGKV1-9	QQVNSHPHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-118	IGHV4-31	ARDYPFCGADCPWVDVFDI	IGKV3-15	QQYSNWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-119	IGHV3-30	AKPVGSSGYYEGGKPIDY	IGKV1-5	QQYNSYWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-119	IGHV3-30	AKPVGSSGYYEGGKPIDY	IGLV3-21	QVWDSSSDHWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-120	IGHV5-51	ARNRAGVIDY	IGLV6-57	QSYDSSNLWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-121	IGHV1-8	VRERIDYDHSGVSTSAFEF	IGLV1-44	GGWDDSLNGYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-122	IGHV3-23	AKGGYCSGGNCKMAHSYYGLDV	IGLV1-47	AAWDDSLSGHWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-125	IGHV4-39	ASSNTASTMIVVVVQRNWFDP	IGKV3-15	QQYNNWPPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-126	IGHV3-48	ARDRARAKWLAYSNYFDY	IGKV3-15	QQYNNWPL	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-127	IGHV3-33	ARDRVSSWEYYFDY	IGLV3-10	YSTDSSGNHRGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-129	IGHV4-59	ARDRVSGGMDV	IGLV3-21	QVWDSSSDHVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-131	IGHV3-23	ARGYIGYCSGSTCTTNGGGDY	IGLV1-51	VTWDSSLSAGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-134	IGHV3-23	AKAGIRGGISMVRAHFDI	IGLV2-8	SSYAGSNNFV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-135	IGHV3-33	AREDTAMVQRFDY	IGKV1-39	QQSYSTHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-135	IGHV3-33	AREDTAMVQRFDY	IGLV3-1	QAWDSSNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-136	IGHV1-69	ARGRDIVVESTDQDPMDV	IGKV4-1	QQYYSTSSIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-138	IGHV4-31	ARDYPFCGADCPWVDVFDI	IGKV3-15	QQYNNWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-139	IGHV3-23	AKDFSGANGDYYYYGMDV	IGLV3-25	QSADSSGTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-140	IGHV4-59	AAGGGSGFYYF	IGKV1-5	QQYKSSSST	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-143	IGHV4-59	ARDRVAAGVDY	IGLV3-21	QVWDSSSDHVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-144	IGHV3-30-3	ARTPGDGMDV	IGLV3-10	-	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-145	IGHV5-10-1	ARHAIYCSGGSCYAYFDY	IGLV1-41	-	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-146	IGHV4-31	ARDYPFCGADCPWVDVFDI	IGKV3-15	QQYNNWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-148	IGHV4-39	ARQRTHTIFGVVVHFDY	IGKV4-1	QQYYSTPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-149	IGHV4-59	ARGWGFPGSTNVHFYFYGLDV	IGKV1-9	QQLNSYRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-151	IGHV4-59	AAGEVVTAISYYYYGMDV	IGLV3-1	QAWDSSSVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-152	IGHV3-15	TTERIYDYVWGSYRYSDY	IGKV3-20	QQYGSSPVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-153	IGHV4-4	ARDLNV	IGKV3-15	QQYVNWPFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-155	IGHV1-2	ARALRITMIVVVTHYGMDV	IGKV3-20	QQYGSSPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-157	IGHV3-48	ARDKSDFWSGNFDY	IGKV1-33	QQYDNLLVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-159	IGHV4-38-2	ARDKVDYYPYYFDY	IGLV3-21	QVWDSSSDHRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-162	IGHV3-21	ARDQWSGTTVTSMGH	IGKV1-5	QQYDSNWYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-163	IGHV1-2	AREVMVRGALPPYGMDV	IGKV3-11	QQRSNWPPVT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-164	IGHV4-31	ARDYPFCGADCSWVDVFDI	IGKV3-15	QQYNNWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-165	IGHV3-74	AREGGDGFDY	IGKV1-5	QQYQSYPLA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-167	IGHV1-69	ARGVEMATILPDDAFDI	IGKV3-15	QQYNNWPPVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-169	IGHV1-69	ARGSTHNNLFVMDY	IGLV7-46	FLSYSGVRGLFVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-170	IGHV1-2	ARVDTTGTTFWLYYYYGMDV	IGLV3-1	QAWDSSTALVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-171	IGHV4-30-4	ARLHGDYYYFDY	IGKV1-39	QQSYSTHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-171	IGHV4-30-4	ARLHGDYYYFDY	IGLV3-1	QAWDSSVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-172	IGHV4-30-4	ARLSMTTVTRGNWFDP	IGKV1-39	QQSYSTHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-174	IGHV1-2	ARDLSNSGSSFDY	IGLV3-1	QAWDSSTADVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-175	IGHV1-46	VQDLGVRGGRRALDV	IGKV2-28	FQALQTPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-176	IGHV3-53	ARGYPGGP	IGKV1-33	QQYDNLLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-178	IGHV3-23	AKDALGFCSGTSCYGEGAFDI	IGKV1-5	QQYNSYPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-178	IGHV3-23	AKDALGFCSGTSCYGEGAFDI	IGLV2-23	CSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-181	IGHV3-30-3	ARDLQYYDFWSGYLGTPGRYYYYGMDV	IGKV3-20	QQYGSSPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-182	IGHV4-59	ARDRVSGGMDV	IGLV3-21	QVWDSSSDHVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-183	IGHV3-30-3	ARDLRFLEWLFNVPYYYYYGMDV	IGKV1-9	QQLNSYPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-183	IGHV3-30-3	ARDLRFLEWLFNVPYYYYYGMDV	IGLV2-23	CSFAGGITLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-185	IGHV3-15	TTDRTYDYVWGSYRYRDY	IGKV1-39	QQSYSTLPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-187	IGHV3-73	TTIGSGYGFGH	IGKV1-39	QQSYSTHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-187	IGHV3-73	TTIGSGYGFGH	IGLV2-11	CSYGGTYVL	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-189	IGHV3-9	AKAHSDPNYDFWSPDYYGMDV	IGLV2-14	SSYSTSSTKEV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-190	IGHV3-30-3	ARGVYGDSGVDY	IGLV3-21	QVWDSSSDHLYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-191	IGHV3-11	ARDTSQSHMDV	IGKV2-30	MQGTHWPPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-192	IGHV1-3	AREDTFSVFGVVTRGNAYDV	IGKV3-20	QQYGVSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-194	IGHV3-74	ARDRHTYSLEYFQH	IGLV6-57	QSYDSSNQV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-195	IGHV3-30	AKEGSKGWLQSSCYFDY	IGLV3-25	QSADSSGTYQV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-102	IGHV1-18	ARDLARVGWTWWYYYYGMDV	IGKV2-30	MQGTHWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-103	IGHV3-23	AKVYGSNTHTPVDY	IGLV2-8	SSYAGSNNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-104	IGHV3-7	ARDAARYYGMDV	IGKV1-39	QQSYSTPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-107	IGHV3-23	AKDRRTMIVVVITNKYYYGMDV	IGKV1-5	QQYNSYPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-108	IGHV3-15	TTDADTSPVV	IGLV4-69	QTWDTGIRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-110	IGHV3-48	ARSLRMG	IGKV3-20	HQYGSIPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-113	IGHV4-59	ARASFKMGTNYHYGMDV	IGKV1-27	QNYNSVPFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-114	IGHV1-2	TTLTAVVTPLGY	IGKV2-30	MQGTHWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-118	IGHV3-15	TTDEQRNYCTSPNCRGGAFDI	IGLV4-69	QTWGTGIRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-121	IGHV4-39	MRQGDWNYSYYFDA	IGKV2-30	VQGTLWPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-127	IGHV4-39	ARHPLALITIFGVSRQYGMDV	IGKV1-12	QQANSFPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-128	IGHV3-30-3	ARELGTSGTLDS	IGLV2-14	LSHSTFTTPQWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-129	IGHV3-48	ASIASYDYVWGTNRPNDAFDI	IGLV2-23	CSYGGPRNLYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-132	IGHV4-4	ARDRQYRGSDYNYYFDY	IGLV1-44	ATWDDSLNGRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-133	IGHV4-39	ARHQRPVTTFIDY	IGKV3-15	QHYKDWPPFFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-134	IGHV3-23	AKVMRDDFWSGYYNDYYYGMDV	IGKV3-20	QQYGRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-136	IGHV4-59	ARDNYSSRRYYYYYGMDV	IGKV3-20	QQYGSSPTWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-137	IGHV4-30-4	ARLSMTTVTRGNWFDP	IGLV1-47	AAWDDSLSGWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-138	IGHV3-23	VKDFPFGGCTSTTTNCDLFFAL	IGKV2-24	MQATQFPRA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-139	IGHV4-59	AGYLRNDNLDP	IGKV3-11	QQRSDWPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-140	IGHV3-64	AREYYGLLTGYYLDL	IGKV1-39	QQSYSIPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-143	IGHV3-23	AKEFSIGWGLFDS	IGKV3-11	QQRNNWPVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-147	IGHV1-2	ARDLYYDILTGYYMPMDV	IGKV3-11	QQRGNWPPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-151	IGHV1-58	AADPGGVGYCSGGSCYRAFDI	IGKV3D-15	QQYNNWPPALT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-152	IGHV1-69	ARLRVPLTAHDAFDI	IGLV1-40	QSYDSSVGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-154	IGHV1-69	ARAYCSGGSCYSYYYGMDV	IGLV3-1	QAWDSSTA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-155	IGHV4-59	ARVPREWLSPLYYG	IGKV1-5	QQYNSYQWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-156	IGHV3-9	VKDNARTRRGSFDY	IGLV2-23	CSYAGSNTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-159	IGHV3-48	AREGELSNYDAFDI	IGLV2-11	CSYAGTHSYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-161	IGHV3-30	AKEGSKGWLQSSCYFDY	IGKV2-28	MQAFEPPAIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-163	IGHV3-33	ARDWAVAGNFDY	IGKV3-20	QQYGASPPTT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-164	IGHV1-46	ARDGSHWDFDY	IGLV2-14	SSYVSSDAWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-165	IGHV3-53	ARRAASGWNFDY	IGLV2-23	CSYLGSATYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-166	IGHV1-18	ARDTWDIVIVPAASAYYGMDV	IGKV2-28	MQALQTHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-172	IGHV3-15	TTDRTYDYVWGSYRYRDY	IGKV1-39	QQTFSSPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-173	IGHV3-30	SKGFLEWLLRRYYYGMDV	IGKV1-9	QQLNSYPFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-176	IGHV5-51	ARHFGGSGSYYNGHWIPAYYYHGMDV	IGKV2-28	MQARQTPPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-176	IGHV5-51	ARHFGGSGSYYNGHWIPAYYYHGMDV	IGLV2-8	SSYAGSTNLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-178	IGHV4-31	ARDRTMVVWNAFDI	IGKV1-39	QQSHSPSRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-179	IGHV3-7	ARESRLGIAIFDRRLRSWFGA	IGLV2-14	SSYTSSSTRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-180	IGHV3-15	TTQHYDFWSGNYKPFAF	IGKV2-28	MQALQTLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-181	IGHV3-33	ARDEAAEYYFDY	IGLV3-25	QSADSSGTFWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-183	IGHV3-30	AKEGSKGWIQNSCYFDY	IGKV4-1	QQYYSTPPT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-185	IGHV3-23	VKDPNWANGY	IGKV2-30	VQGTHWPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-186	IGHV1-46	AKGRSTIFGVIVNQGDCYDY	IGKV1-27	QKYNSAPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-189	IGHV3-23	AKDPHFDFWSGNYFDY	IGKV1D-12	QQANSFPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-190	IGHV4-31	ARDRGVTIFGVVIIDAFDI	IGKV3-20	QQYGSSPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-191	IGHV1-18	SREGDLTIFGSVTNAYYYFGMDF	IGKV1-39	QQSYSTPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-196	IGHV1-2	ARDLGIGVAGNLDH	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-199	IGHV4-59	ARDRDSSGWYPNWFDP	IGKV1D-16	QQYNSYPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-200	IGHV1-2	ARGPFYYDNSGTLGGLDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-201	IGHV1-2	ATDRLVNTGVYTTGSMDV	IGLV2-23	CSYGGSSDYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-202	IGHV3-53	ARDLYYYGMDV	IGKV1-9	QQLNNYSVT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-203	IGHV1-2	ARKQQPSSLSYYYYGMDV	IGLV1-40	QSYDSSLSGSWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-204	IGHV4-39	ALCGYSYGSNYYYYGMDV	IGLV6-57	QSYDSSIWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-205	IGHV3-23	AKEYGYDSSGSGGDY	IGKV1-39	QQSYSTPNT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-205	IGHV3-23	AKEYGYDSSGSGGDY	IGLV2-23	CSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-206	IGHV1-2	AREGYYDFWSGYYTVYYYGMDV	IGKV1-5	QQYNSYWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-206	IGHV1-2	AREGYYDFWSGYYTVYYYGMDV	IGLV2-14	SSYTSSSTRV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-208	IGHV1-2	ARGPFYYDSSGTLGGMDV	IGLV2-14	SSYTSRNTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-209	IGHV3-11	ARDGVIPPRFDY	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-210	IGHV3-21	VSSGNYRFHY	IGLV2-14	SSYMSSSTPYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-213	IGHV1-8	ARGPSWNGYYYYFDY	IGLV1-44	ASWDDRLNGVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-214	IGHV6-1	AREENAFDI	IGKV3-15	QQYSNWLLYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-215	IGHV3-48	AREGHAFDI	IGKV3-20	QQYGSSPSWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-216	IGHV3-7	VAWGTTPLGTSENN	IGKV2-30	MQHTHWPHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-217	IGHV1-8	ARGPSWNGYYYYFDY	IGLV1-44	ASWDDSLNGVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-218	IGHV3-23	AKRMGGNRFNPPVEY	IGLV1-40	HSYDSSLSASV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-219	IGHV3-11	ARDGIGQLWDDSYYYGLDV	IGKV2-30	MQGAHWPPYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-221	IGHV3-30	AKKAGYSSGWYTDYYYNGMDV	IGLV1-40	QSYDSSLRGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-222	IGHV1-2	ARGPYYYDSSGSLGAFDI	IGLV2-23	CSYAGGSTSYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-223	IGHV1-8	VRGPSWNGYYYYFDY	IGLV1-44	ASWDDSLNGVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-224	IGHV5-51	ARLGPYYSSSSNGMDV	IGLV2-23	CSYAGSSTRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-225	IGHV4-31	ARDTPPGYNWNYGPYGMDV	IGKV3-15	QQYNNWPPGYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-226	IGHV3-30	AKKAGYSSGWYTDYYYNGMDV	IGLV2-8	SSYTASNRG	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-230	IGHV3-9	AKEISGYYFDY	IGLV4-69	QTWGTGIHWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-231	IGHV3-30	AKKAGYSSGWYTDYYYNGMDV	IGLV1-40	QSYDSSLRGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-235	IGHV3-23	AKSTYGDYYYYYGMDV	IGLV2-14	NSYTSNSSLGV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-236	IGHV3-53	AREYSSGWYDY	IGKV3-15	QQYNNWPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-237	IGHV1-2	ARGPFYYDSSGTLGGMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-238	IGHV1-8	ARTNWNYYYYYYGMDV	IGLV1-44	AAWDDSLNGYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-239	IGHV4-34	ARGRWYHDNNGYRSDAFDV	IGLV1-44	AAWDDSLNEV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-241	IGHV3-74	ITSMFNNGFY	IGLV2-11	SSYAGSYTV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-242	IGHV3-15	TTLWRLDP	IGLV7-46	LLTHTDSRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-249	IGHV1-2	ARDLGIGVAGNLDH	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-250	IGHV1-18	AGSDNYGFPYNGMDV	IGLV2-8	SSYAGNNDFV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-251	IGHV3-23	AKEFSIGWGLFDY	IGKV3-11	QQRNNWPVT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-252	IGHV1-46	ARDKHWNNANYYYYGMDV	IGKV1-5	QQYNSYL	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-254	IGHV1-2	ARDQGGAALVGHSNY	IGLV2-23	CSYAGSSTWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-255	IGHV1-2	ARDSRFSYVNGEFDY	IGLV2-23	CSYAGHSTWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-262	IGHV1-2	ARVGWYDFGTPGDYYYYYGMDV	IGLV2-23	CSYAGTSTFV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-263	IGHV1-2	ADSGYWGSHYYYGMDV	IGKV2D-29	MQSIQLPLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-264	IGHV1-2	ARDLGIGVAGNLDH	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-265	IGHV3-48	ARRRYSSSWYYYYGMDV	IGKV1-9	QQLNSYPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-266	IGHV1-2	ATDRLVNTGVYTTGSMDV	IGLV2-23	CSYGGSSDYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-267	IGHV1-2	ARVFGPGLDCSSTSCYTYGMDV	IGLV2-23	CSYAGSSSWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-270	IGHV3-11	ARARGSSGWYRIGTRWGNWFDP	IGLV2-14	SSYTSSSNVV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-271	IGHV1-2	ARVPFAYCSSTSCDRGTPYYYYYGMDV	IGLV2-14	SSYTSSSTLV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-272	IGHV3-64	ARGLDNNGYYSGY	IGKV3-20	QQYGSSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-274	IGHV1-2	ARDQKNDILTGLGDY	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-275	IGHV3-66	ARDYYDSSGYYSSGGLGY	IGLV2-8	SSYAGSNNFV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-280	IGHV1-2	ARGPFYYDSSGTLGGMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-281	IGHV1-2	ARGPFYYDSSGTLGGMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-283	IGHV1-2	VRGPFYYDSSGPLGGMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-284	IGHV5-51	ASGGDYPYGMDV	IGLV1-44	AAWDDSLSAWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-285	IGHV1-2	ARGPFYYDNSGTLGGLDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-286	IGHV3-9	AKGGRYCSGTNCYEYYFFAMDV	IGLV2-8	SSYAGSNNNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-287	IGHV1-58	AAPYCSSTNCYDAFDI	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-289	IGHV1-2	ARGAAMVTGYTYYYGLDV	IGKV3-20	QQYGSSPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-290	IGHV1-2	ARDQKNDILTGLGDY	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-292	IGHV1-2	ARDQKNDILTGLGDY	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-293	IGHV3-11	ARCNGGGACFYGMDV	IGKV4-1	QQYYSTLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-293	IGHV3-11	ARCNGGGACFYGMDV	IGLV2-14	SSYTISSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-294	IGHV1-2	ARGPFYYDSSGTLGGMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-297	IGHV3-53	ARRSASGWNFDY	IGLV2-8	SSYAGSNNLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-299	IGHV5-51	ATSHGYSGYELGY	IGLV2-14	SSYTSSSTVWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-301	IGHV1-2	ARVDTTGTTFWLYYYYGMDV	IGKV2D-29	-	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-301	IGHV1-2	ARVDTTGTTFWLYYYYGMDV	IGLV2-23	CSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-302	IGHV3-9	AKDKGPYYYYGMDV	IGKV2D-29	MQSIQLPQT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-303	IGHV1-2	ARDLGIGVAGNLDH	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-304	IGHV1-2	ARVFGPGLDCSSTSCYTYGMDV	IGLV2-23	CSYAGSNSWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-305	IGHV1-2	ARDLGIGVAGNLDH	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-306	IGHV1-2	ARGTLYYDILTGSPNPPKLDY	IGKV1-39	QQSYSTPWT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-307	IGHV1-2	ARGPFYYDNSGTLGGLDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-309	IGHV1-2	ARGPFYYDNSGTLGGLDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-310	IGHV1-2	ARGPFYYDSSGTLGGMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-312	IGHV1-2	ARIPIFGVVSTPGQYYYYGMDV	IGLV2-14	ISYTSSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-313	IGHV1-2	ATDRLVNTGVYTTGSMDV	IGLV2-23	CSYGGSSDYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-315	IGHV3-9	AKDFLWDLHPPRYYGMDV	IGKV1-39	QQSYSTHA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-315	IGHV3-9	AKDFLWDLHPPRYYGMDV	IGLV1-51	GTWDSSLNGV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-316	IGHV1-2	ARGPFYYDSSGTLGGMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-317	IGHV1-2	ARDQKNDILTGLGHY	IGLV2-8	SSYAGSNNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-319	IGHV1-2	ARGPFFFEVVVAEGFGWFDP	IGKV3-15	QQYNNWPPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-319	IGHV1-2	ARGPFFFEVVVAEGFGWFDP	IGLV2-8	SSYAGSNVYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-323	IGHV1-2	ARVFGPGLDCSSTSCYTYGMDV	IGLV2-23	CSYAGSSSWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-324	IGHV1-2	ARGPFYYDSSSTLGGMDV	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV23-101	IGHV3-30	ARDWEYYGSGTKAFDY	IGKV1-13	QHFNSYPLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-103	IGHV1-2	-	IGLV2-14	SSYTRSTAVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-113	IGHV5-51	ATTRGYSDYEFAY	IGLV2-8	SSYAGSNNFPWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV23-114	IGHV4-31	ARDLGPRSDFGSGSGVGVIDP	IGKV3-15	QQYHNWPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-115	IGHV1-2	ARGYYDILIGYATTHDAFDL	IGLV2-14	SSYTDSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV23-116	IGHV3-21	ARASLVTMVRGAGNYMDV	IGKV3-11	QQRSNWPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-116	IGHV3-21	ARASLVTMVRGAGNYMDV	IGLV2-23	CSYAGSRV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-121	IGHV1-2	ARELGSWDGRFDY	IGLV2-23	CSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV23-126	IGHV4-59	ARDTTSYCSGGSCYYNYGMDV	IGKV2-28	MQALQTPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-198	IGHV1-2	ARDLAYSMVRGISGI	IGLV2-23	CSYAGSNTWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-201	IGHV1-2	ARDLAYSMVRGISGI	IGLV2-23	CSYAGSNTWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-220	IGHV3-48	ARDRGSGWSLDESYFDH	IGKV1-39	QQSKSIPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-223	IGHV4-39	ARLRWLRGEFDY	IGLV6-57	QSYDSSTYWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-226	IGHV4-39	ARLRWLRGEFDY	IGLV6-57	QSYDSSTYWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-236	IGHV3-49	IRGGYGGNSGFDY	IGLV1-51	GTWDSSLSAVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-243	IGHV3-7	ARLYSGNYFDY	IGLV4-69	QTWDTAIWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-247	IGHV3-48	ARGFYDILTGYYSFHFDL	IGKV1-5	QQYNTYWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-248	IGHV3-33	ARREGVADYYYYYGMDV	IGKV1-6	LQVYNYPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-249	IGHV1-18	AREYDYSNPNYYYYYGMDV	IGLV3-27	YSAADNMGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-252	IGHV3-74	VRVSGPFHDYFLYAMDV	IGKV3-20	QHYSAATWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-253	IGHV1-2	ARVFHGVITPFDY	IGLV5-37	MIWPSSAVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-255	IGHV4-34	ARGRLGFEELFRGVFFYYFDY	IGKV1-39	QQTFNSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-256	IGHV3-49	TRAQEEKITMIRRIISWFDP	IGKV3-20	QQYGSSPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-260	IGHV4-59	ARLLKSCTGGICQTYFYYAMDV	IGLV1-40	QSYDGSLSESAV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-262	IGHV4-31	ARGTTYTIFGVVISPFDY	IGKV3-20	QQYGSSPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-265	IGHV4-34	ARGAPGT	IGKV1-5	QHYSTFPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-268	IGHV3-9	TTGYCRSNNCLTFYAF	IGKV1-39	QQSYRAPVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-269	IGHV4-31	ARDYFGRSGSGSSLYYYYGMDV	IGLV3-1	QAWDSSTV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-271	IGHV3-21	ARVAAAGQKYYFDY	IGKV1-9	QQLNS	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-275	IGHV3-30	AKVANVFMLYPRGSWGMDV	IGLV1-47	AAWDDSLSGWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-280	IGHV3-48	AAGSSTSPSPV	IGKV3-15	QQYNNWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-282	IGHV3-23	AKDRGRRLTHLGVAPDV	IGKV1-39	QQSYTTPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-283	IGHV3-66	CGGYGSSWYLDY	IGKV3-11	QQRSNWPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-284	IGHV4-31	ARGGLSSRNGGNRSYSSSSFPLGRQDY	IGLV2-14	SSYTSSSTLYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-285	IGHV5-51	ARFLSFVTSPTRYDY	IGLV2-14	SSYTSSSTLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-286	IGHV1-69	ARHLPLSGYYAFDV	IGKV3-20	QQYGSSPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-287	IGHV3-23	AKDRSGGILAGGSGGALDI	IGKV1-5	QQYSSYSRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-290	IGHV4-39	ARASEDISLERAYNYGLTIDF	IGLV3-9	QVWDSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-293	IGHV3-7	ARENYDSSGYYYAYYYYGMDV	IGLV3-25	QSADSSGTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-294	IGHV3-9	ARGDLGIRYFDY	IGKV3-15	QQYNNWPPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-294	IGHV3-9	ARGDLGIRYFDY	IGLV2-23	CSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-296	IGHV1-18	-	IGKV4-1	QQYHSTPPA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-296	IGHV1-18	-	IGLV2-23	CSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-298	IGHV3-33	ARGWGGDGYTVDAFDV	IGKV2-28	MQALQPPYI	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-301	IGHV1-46	ARSLYSGSYGAYNWFDP	IGKV3-11	LQRINWLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-309	IGHV4-61	AREQVLDPGLYYGIDV	IGKV1-39	QQSYSTHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-309	IGHV4-61	AREQVLDPGLYYGIDV	IGLV3-1	QAWDSDTVI	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-310	IGHV1-2	ARVFHGVITPFDF	IGLV5-37	MIWPSSDVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-311	IGHV1-2	ARGADIFITIFGVVIKENDY	IGLV2-18	SSYTSSSTLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-314	IGHV3-30	ARGKNYGYSDDDLFQHFDY	IGLV7-43	LLHYGSSQLGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-316	IGHV1-69	ARALGLSGHGMDV	IGKV1-39	QHSYSTPHT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-317	IGHV4-4	AKESWLELWLQGAGFDI	IGLV2-11	CSYGGSYTFVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-319	IGHV1-46	ARDLWMEYEYNDSGIQKTADQGMDV	IGLV3-1	QAWDINTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-321	IGHV3-33	ARDMVRGPNDASDI	IGKV1-12	QQANSFPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-322	IGHV4-39	ARQRTHTIFGVVVHFDY	IGLV3-25	QSADSSGTYDV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-323	IGHV3-49	TRAQEEKITMIRRIISWFDP	IGKV3-20	QQYGSSPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-325	IGHV3-49	TRAQEEKITMIRRIISWFDP	IGKV3-20	QQYGSSPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-329	IGHV3-33	ARDMVRGPNDASDI	IGKV3-15	QQYNNWPPVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-330	IGHV3-49	TRAQEEKITMIRRIISWFDP	IGKV3-20	QQYGSSPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-331	IGHV3-23	AKEVPDIIVVAVAVGMDV	IGLV1-47	ASWDDSLSGVL	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-332	IGHV1-2	ARETRETYYDILTGYPFYYYFGMDV	IGLV1-51	GTWDGSLSAAV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-333	IGHV3-15	SSDLPKWGSGMADY	IGLV8-61	VLYMGSDIWA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-336	IGHV3-49	TRAQEEKITMIRRIISWFDP	IGKV3-20	QQYGSSPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-344	IGHV3-33	ARREGVADYSYSCGMDV	IGKV1-6	LQVYNYPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-346	IGHV1-69	ARSDDSSGYYYLKEENDAFDI	IGKV2-30	MQGTHWREYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-347	IGHV1-2	ARDRLYCSSTSCYTPYYYYYYGMDV	IGLV3-25	QSADSSGTYGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-102	IGHV3-23	AKVETRGVGFDL	IGLV3-1	QAWDSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-103	IGHV3-11	ARDWNLSGYYGGGR	IGKV1-16	QQYNSYPLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-105	IGHV3-74	ARQRVARRRGFGESPFYYGLDV	IGKV1-6	LQNYNFPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-107	IGHV1-2	ARDGAQYILTGDFDY	IGLV2-8	SSYAGSNNYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-113	IGHV3-53	ARGGRLADAAGDY	IGKV1-33	QQYDNLPSWT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-114	IGHV5-51	ARAGNDNSLDY	IGKV1-39	QQSYTTPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-114	IGHV5-51	ARAGNDNSLDY	IGLV9-49	GADHGSGSNFVQKV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-115	IGHV3-7	ARDLYYYDSSGNGVNWFDP	IGLV1-40	QSYDSSLSGSYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-117	IGHV4-30-4	ARVTRIYGSGSYCFDY	IGLV2-23	CSYVGSSTFVV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-118	IGHV4-59	ARAWSSSWYLDY	IGKV3-11	QQRSNWPPVT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-119	IGHV4-4	ARAWNFDY	IGLV2-23	CSYAGSSNWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-122	IGHV3-23	AKVLDI	IGLV2-14	SSYTSSSTPYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-124	IGHV4-59	ATYYYDSSGYPYGMDV	IGKV1-9	QQLNSYPG	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-125	IGHV5-51	ARHQGYSSSSLGY	IGLV9-49	GADHGSGSNFVYM	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-127	IGHV3-33	ARDPEIVVGGVDY	IGKV2-30	MQGTHWPYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-128	IGHV3-11	ARDWNLSGYYGGGR	IGKV1-39	QQSYTTPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-129	IGHV4-31	ARDQGASASWDAFDI	IGKV3-20	QQYGSSLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-131	IGHV3-11	ARDHSVRFLEWLLPY	IGKV1-9	QQLNSYPWT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-132	IGHV4-31	ARAERSITIFGVVTSAFDY	IGKV4-1	QQYYSTPYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-134	IGHV4-34	ASSGWYYPDY	IGKV3-20	QQYGSSPNT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-135	IGHV3-23	AKVTGLGNAFDI	IGLV3-1	QAWDSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-136	IGHV4-4	ARSSGRGRVVALGSFDP	IGLV2-23	CSYAGSSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-139	IGHV3-53	ARGHYDLFDY	IGKV1-9	QQLNSYPPGT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-140	IGHV4-31	ARAYDSSGYYPDY	IGKV1-39	QQSYSTLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-142	IGHV5-51	ARIRGVYSSGWIGGDY	IGKV1-39	QQSYSTPRQWT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-143	IGHV1-2	ARDGAQYILTGDFDY	IGLV2-8	SSYAGSNNYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-146	IGHV1-69	ARAATYYYDSSGYTPNWFDP	IGKV1-39	QQSYSTLYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-147	IGHV3-9	AKDRRIAVAGTGEDYYFDY	IGLV3-21	QVWDSSSDQVV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-148	IGHV3-66	ARSAPLVGAYSGIYFDY	IGLV9-49	GADHGSGSNFVV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-149	IGHV1-69	ARAATYYYDSSGYTPNWFDP	IGKV1-39	QQSYSTLYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-150	IGHV3-30	AKSQWLVLRHAFDI	IGKV2D-29	MQSIQLWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-156	IGHV4-59	ARFSQYYYDSSGYDFDY	IGLV2-23	CSYAGSSSWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-158	IGHV3-15	TTDRWFGELFSAYYYYYGMDV	IGKV3-11	QQRSNWPPIFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-159	IGHV1-2	ARGNTVFWSGPPLDY	IGLV2-14	SSYTSSSTYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-160	IGHV3-23	AKVAGRGNAFDI	IGLV7-43	LLYYGGAL	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-165	IGHV4-4	ARRSLGNYDSSGYDH	IGKV3-15	QQYNNWPPAIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-165	IGHV4-4	ARRSLGNYDSSGYDH	IGLV1-44	AAWDDSLNGYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-173	IGHV3-30-3	ARDYGGYNYN	IGLV3-1	QAWDSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-177	IGHV3-9	AKDMVVVAIFGVGPFDY	IGKV1-6	LQDYNYPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-179	IGHV5-51	ARQRRPPGKRVLTMIVVVYNDAFDI	IGKV1-33	QQYDNLLFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-179	IGHV5-51	ARQRRPPGKRVLTMIVVVYNDAFDI	IGLV1-40	QSYDSSLSGSV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-180	IGHV4-4	ARRAAAGPRPYDY	IGLV2-23	CSYAGFSTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-181	IGHV1-2	ARDLGYSYLYGAFDI	IGKV3-11	QQRSNWPT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-182	IGHV1-69	AKELGYSGYGAHRYFDL	IGLV1-40	QSYDSSLSGVV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-183	IGHV3-53	ARGDGWDNYYYGMDV	IGLV1-40	QSYDSSLSGSV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-184	IGHV4-39	ARGLGWFDP	IGKV1-NL1	QQYYSTPPRT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-186	IGHV1-2	ARDQSPDILKSPFDY	IGLV2-23	CSYAGSSTFG	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-193	IGHV3-11	ARDISRNLHDFRPYYFDY	IGLV7-46	LLSYSGARV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-194	IGHV4-59	ARHDVYSSGWYGEGAFDI	IGLV1-40	QSYDSSLSGSWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-199	IGHV4-59	ARYYQDFDY	IGLV1-44	AAWDDSLNGPYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-201	IGHV3-30	AKDIVLVPAAIPVPIFDY	IGKV3-11	QQRSNWPPT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-202	IGHV3-33	ARDSSQQQLAYAFDI	IGLV3-1	QAWDSSIVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-205	IGHV4-30-2	ARDHYPYYYYGMDV	IGLV6-57	QSYDSSTVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-206	IGHV3-7	ARKGNAIDV	IGKV1-5	LQYNSYSWYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-207	IGHV4-30-4	AKIRVRAGFRWAFDI	IGLV2-14	SSYTNTNTLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-208	IGHV4-39	AHQSGNSGPWYFDL	IGLV8-61	VLYMGSGIVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-210	IGHV4-39	ARHVEPDYGGNSFDY	IGLV1-40	QSYDSSLSGYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-211	IGHV3-9	AKDISNKWLRLTQPYSYYGLDV	IGLV2-8	SSYAGSNIPYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-213	IGHV3-23	AKVLIRNGYDILTGYPYDAFDI	IGLV2-14	SSYTSSSTLV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-215	IGHV3-30-3	ARDGYSAYDFGY	IGLV8-61	VLFMGSGTWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-217	IGHV4-30-2	ASGPAWELFDY	IGKV3-15	QSYHNWPL	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-219	IGHV4-39	ARQMRIGTIVVVPAALDY	IGKV3-20	QQYYSSPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-221	IGHV3-66	ARGFGDYYFDY	IGKV3-20	QQLYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-222	IGHV4-30-4	ARDPWQVTIFGVVIRYGMDV	IGKV1-9	QQLNSYPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-225	IGHV3-11	ARDLWFGRYWGNWLDP	IGLV1-51	GTWDNSLSAAV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-227	IGHV3-66	ASEGRTTGTIVAYYYFAMDV	IGLV2-8	SSYAGRSNVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-228	IGHV4-31	AREKGTGDYYLDY	IGKV3-15	QQYNSWPRA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-229	IGHV4-30-4	AKIRVRAGFRWAFDI	IGLV2-14	SSYTNTNTLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-230	IGHV3-53	ARDNSSNWYYFDS	IGLV3-25	QSADSSGTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-231	IGHV3-33	ARDGLDDDYIWGSFKIRYYYMDV	IGLV2-8	SSYSGTTNFAQ	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-232	IGHV3-23	ASGTYRLGDY	IGLV1-44	AAWDDSLDGPV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-233	IGHV4-4	VTGGRWRFDP	IGLV2-11	CSYAGTYTYWL	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-235	IGHV3-23	VRDLSSSDPWYFDF	IGKV3D-20	QQYGDSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-236	IGHV3-64	ARGGYEIVVVPDYYYYGMDV	IGKV3-20	QQYKD	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-238	IGHV3-30	AKDPLNCSSTRCYTAWIYYYYGMDV	IGKV2D-29	MQSIQLPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-240	IGHV3-30	AKDSVKGYSSGWYYYYYGMDV	IGKV2D-29	MQSIQLPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-242	IGHV3-23	ARDLSSSDPWYFDF	IGKV3D-20	QQYGDSPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-243	IGHV3-21	ARDRSGWYRNLFDY	IGKV2-28	MQALQASIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-245	IGHV3-49	TRDFDHADSFDI	IGKV2-28	MQALHTPRYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-248	IGHV3-30	AKGFYDSGP	IGKV2-30	MQGTHWKT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-251	IGHV3-23	AKDQTVSFFYYGMDV	IGLV1-47	ATWDDSLSGYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-252	IGHV1-3	ARDNTNTWFGSIEY	IGKV4-1	QQNYATPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-255	IGHV3-9	VREATRGAHFDC	IGLV2-8	SSYVGFNNLDNFV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-257	IGHV4-34	ARRIYYGDLGNWNFDL	IGKV1-16	QQYNSYPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-259	IGHV1-69	ATLGYCSGGSCFPTGVFGY	IGLV7-46	LLSYSGARSWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-263	IGHV4-31	AREKGTGDYYLDS	IGKV3-15	QQYNSWPRA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-265	IGHV3-23	AKDGHSMVRGVTMWGEFYYYYGMDV	IGKV3-15	QQYNNWPPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-270	IGHV3-9	VRSRWQLTSSAFDM	IGKV1-9	QQLNKYPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-271	IGHV4-31	AREKGTGDYYLDP	IGKV3-15	QQYNSWPRA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-273	IGHV1-2	ARTYYYDSSGYRNYYYYGMDV	IGLV2-18	SLYTSSSTYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-275	IGHV3-15	TTDRGNSITIFGVVIIDRPY	IGKV3-20	QQYGSS	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-276	IGHV3-21	ARDEGSPGLDYYGMDV	IGLV2-14	SSYTSNTTLVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-278	IGHV4-30-4	AKIRVRAGFRWAFDI	IGLV2-14	SSYTNTNTLV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-281	IGHV3-11	ARDMNYKYYYDSSGYPLLDY	IGLV1-44	AAWDDSLNGWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-284	IGHV3-49	IRARYYYDSSATFDY	IGKV1-39	QQCYSLPST	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-286	IGHV3-30	AKDASSPVYDFWSGYYNHLGMDV	IGLV3-21	QVWDSSSDQGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-288	IGHV3-66	ARDYTVTTGGVDGMDV	IGKV3-11	QQRSNWPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-289	IGHV3-23	VSRAAVGQPEY	IGKV1D-12	QQAYTLPRVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV48-103	IGHV3-49	SRFYDYWNTFGLLLGSGLTFYHMDV	IGKV4-1	QQYCYTPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-104	IGHV1-69	ARDGQQLVRGWFDP	IGLV2-14	SSYTSSSTLYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-107	IGHV4-39	ASENDYGEHDY	IGKV4-60	ETWDSNTRKVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-109	IGHV3-30	VKGDTSAYWPSSLLIS	IGLV2-14	GSYATGSSPVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV48-110	IGHV3-33	ARDARYSAYELPDYFFDL	IGKV1-5	QQYKGSSWAT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-113	IGHV3-33	ARDGLDDDYIWGSFKIRYYYMDV	IGLV4-69	QTWGTGINVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-119	IGHV3-23	AKTDRHWNHCD	IGLV2-14	SSYTGSSTLVA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-123	IGHV1-3	ARNGGGLDQ	IGLV2-14	CSSTTSSTAV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-102	IGHV1-69	ARSPRPLIVVAEDGMDV	IGKV3-20	QQYGSSPFT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-109	IGHV1-2	ARGPLFWDTAMANFDY	IGLV2-14	-	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-111	IGHV3-49	NRELHNSVVVGVMGY	IGKV4-1	HHYYSPPYA	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-112	IGHV3-23	AKVGSGWYAFDY	IGKV3-15	QQYNKWPRT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-119	IGHV4-59	ARDRIMPLSYYYYYGMDV	IGLV1-44	AAWDDSLNGWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-126	IGHV3-53	ARDLSEGGMDV	IGKV1-12	QQANGFPPL	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-128	IGHV5-51	ARTYDFWSGFDYYGMDV	IGKV3-11	QQRSNWPT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-131	IGHV3-30	ARMATTYPEHDPSLY	IGLV3-21	QVWDSSSDHWV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-136	IGHV4-31	AAWRGFAATGFDS	IGKV1-9	QQLKSYPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-137	IGHV1-8	ATEGTILTTMTAGAFDL	IGKV1-12	QQTDNFPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-140	IGHV1-69	ARFGGTSQSSGYYGFDN	IGKV2-28	MQPLQTPYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-141	IGHV3-23	VTHDFPDWPPGGGMDV	IGLV6-57	QSYDWSNQGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-142	IGHV1-18	STRGMAPHDY	IGKV1-39	HQTYDTWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-143	IGHV3-11	ARDLGYSTRFDY	IGKV1-33	QQYDNLPLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-145	IGHV5-51	AREDLTGPDY	IGKV2-30	MQGTHWPNT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-146	IGHV3-23	ANNYYDNSGPDY	IGLV6-57	QSNDGSPSWV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-150	IGHV5-51	ARHLVCGGSCYPFDY	IGLV3-21	QVWDSSSDHQV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-153	IGHV3-33	ARDWFWRLGGVDY	IGLV8-61	VLYMGSGLVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-157	IGHV3-48	ATSYYDPSSAYSAHYAMDV	IGLV2-14	TSYTSLSPVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-164	IGHV1-2	ARSFGGFGGNYGMDV	IGKV1-39	QQSYSTPIT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-165	IGHV3-48	ARDPIGTGSDY	IGLV1-51	GTWDSSLNAGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-167	IGHV3-74	ARAHSTTLYGWFDP	IGKV3-20	QHYVSSPLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-171	IGHV4-34	ARGFRKGSTFN	IGLV2-14	SSYTTSNTRE	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-172	IGHV3-48	ARDRLTIFGVAIDYYGMDV	IGKV1-12	QQANSFPALT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-173	IGHV3-30	AKDYDSALCTGGTCTFDAFDF	IGKV1-27	QNYNSAPPWT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-174	IGHV3-21	ATVQGDYVAGRAYYYGMDV	IGLV3-1	QAWDSSTAV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-175	IGHV1-69	ARGLQGTHLDC	IGKV4-1	QQYYSTGFT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-177	IGHV3-30	ARAETPASEIDY	IGLV3-1	QAWDSSHVV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-178	IGHV3-49	TRDRPIDYGDLHIYYYGLDV	IGKV2-28	MQALQTPPT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-180	IGHV4-39	LKDRTLQGNWFDP	IGKV3-11	QQRRDWPPVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-183	IGHV3-30	ASKSPERGSFDY	IGLV2-14	SSYTNGSSLYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-188	IGHV4-4	AKGGGPIVA	IGKV4-60	ETWDSNTRL	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-189	IGHV3-23	AKGRRYYDFWSGPMPYGMDV	IGLV2-14	SSYTSSSTLGV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-190	IGHV3-30	ANTSPGRGSFDY	IGLV2-14	SSYTNSSTLYV	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-191	IGHV4-31	ARQLRFLEWQYFDY	IGKV1-33	QQYDNLLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-195	IGHV3-64	VKGWGVKASSLGGDY	IGKV3-11	HQRSDWPRLT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-103	IGHV3-15	TTWRLGQDWFDP	IGKV1-39	QQSYSAPLT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X2-105	IGHV3-73	TRRFDPNQRNDYYYALDF	IGLV1-44	SAWDDSLNGYV	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-106	IGHV1-69	ATRKETTVTTSLVYGMDV	IGKV1-39	QQSYSTPYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-107	IGHV3-66	ARGKVGATGFEY	IGKV3-20	QQYGSSPPMYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-108	IGHV3-66	ARGKVGATGFED	IGKV3-20	QQYGSSPPMYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-109	IGHV5-51	ARLAHYYDRSGYSRADDAFDV	IGKV3-15	QQYNNWPPVYT	RBD	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-117	IGHV3-66	ARGKVGATGFED	IGKV3-20	QQYGSSPPMYT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-118	IGHV3-30	AKTGGPYCSGGSCYSALMDY	IGKV1-33	QQYDNLPPT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-123	IGHV4-4	ARDRTREGYHDTLTGEFYFYGTDV	IGKV3-20	QQYAMSPVT	S1	-	SARS-2_infection	Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
COV2-2997	IGHV1-46	ARGAIPPNSRAEIDY	IGKV3-15	QQYYNWPLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-3012	IGHV3-13	ARVLYDSSGFYNWFDP	IGKV1-39	QQSYEIPPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2961	IGHV1-58	AAPYCSSISCNDGFDI	IGKV3-20	QHYGSSRGWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-3025	IGHV1-58	AAPYCSSISCNDGFDI	IGKV3-20	QHYGSSRGWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2046	IGHV3-9	AKAHSTGHQYYYGMDV	IGKV1-39	QQSYNTPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2196	IGHV1-58	AAPYCSSISCNDGFDI	IGKV3-20	QHYGSSRGWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2901	IGHV3-53	ARSYDILTGYRDAFDI	IGLV1-40	VAWDDSRNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2070	IGHV4-34	ARVGYSQGYYYYYMDV	IGKV1-39	QQSYTTLLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2132	IGHV3-53	ARDFLRWHDL	IGKV1-33	QQYDNLPPV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2911	IGHV4-39	ARMSRGYNYAYTFDI	IGLV2-23	CSYAGSVL	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2098	IGHV3-23	VKGLFDWFPL	IGKV3-15	HQYNNWPQT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2108	IGHV3-9	AKGVDYGGKLAYFDS	IGKV2-28	MQALQTPLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2114	IGHV1-69	ARGRGYSNYGASYYMDV	IGLV1-40	QSYDSSLSGSV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2304	IGHV3-21	ARDPVWVDGELLSGGIPFDY	IGLV1-44	AAWDDSLNGVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2078	IGHV1-69	ARVGVSGFKSGSNWYFDL	IGLV1-40	QSYDSSLSDSV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2299	IGHV3-30-3	ARDIDSGYDPTPVFDY	IGKV1-39	QQSYSTPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2351	IGHV5-51	ARRFYGPSSFDY	IGLV3-19	SSGDSSTDHHVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2318	IGHV2-70	ARGVVTYDY	IGKV1-39	QQSYSTPGT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2703	IGHV3-13	ARARGGYNWNFDY	IGKV1-39	QQSYSTPPIT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2277	IGHV3-30	ARDVPTTVTAFTVFTY	IGKV1-39	QQSYSTPGLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2068	IGHV3-53	ARSYDILTGYRDAFDI	IGLV1-40	QSYDSRLSGFVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2504	IGHV1-2	ARVVVLGYGRPNNYYDGRNVWDY	IGLV1-44	AAWDDSLNALV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2510	IGHV7-4-1	ARWGPDYGDYASNDY	IGLV3-27	YSAADNNRV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2308	IGHV3-23	VKGLFDWFPL	IGKV3-15	HQYNNWPQT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2391	IGHV1-8	ARMRSGWPTHGRPDDF	IGLV1-44	AVWDDSLNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2767	IGHV3-53	ARSYDILTGYRDAFDI	IGLV1-50	VAWDDSRNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2081	IGHV1-46	ARGAIPPNSRAEIDY	IGKV3-15	QQYYNWPLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2113	IGHV3-53	ARDFLRWHDL	IGKV1-33	QQYDNLPPV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2290	IGHV1-8	ARMRSGWPTHGRPDDF	IGLV1-44	LVWDDSLNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2130	IGHV3-15	TTAGSYYYDTVGPGLPEGKFDY	IGKV4-1	QQYYSTLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2050	IGHV1-2	ARVVVLGYGRPNNYYDGRNVWDY	IGLV1-44	AAWDDSLNALV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2064	IGHV1-8	ARMRTGWPTHGRPDDF	IGLV1-44	LVWDDSLNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2684	IGHV1-58	AAPHCNRTSCYDAFDL	IGKV3-20	QQYNNWWRT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2072	IGHV1-58	AAPHCNRTSCYDAFDL	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2539	IGHV1-8	ARMRTGWPTHGRPDDF	IGLV1-44	LAWDDSLNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2389	IGHV3-9	AKDIIRQGEDGMDV	IGKV1-39	QQSYSTPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2532	IGHV1-46	ARGFHVPAALRNWFDP	IGLV1-44	VAWDDSRNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2096	IGHV1-8	ARMRSGWPTHGRPDDF	IGLV1-44	AVWDDSLNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2051	IGHV2-70	ARGVVTYDY	IGKV1-39	QQSYSTPGT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2759	IGHV5-51	ARTPTLYNWFHP	IGLV1-44	AAWDDSLNGSWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2240	IGHV3-9	AKVGYTISRQWLVGEFDY	IGLV2-8	SAYAGSNNLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2413	IGHV1-8	ARMRSGWPTHGRPDDY	IGLV1-44	AVWDDSLNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2416	IGHV4-31	ASAKLVATISYFDY	IGLV1-36	AAWDDSLNGVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2399	IGHV3-66	ARDYRDWI	IGKV1-33	QQYHNLPRT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2756	IGHV3-23	AKWAGPIVMKYYLQY	IGLV1-40	QSYDISLGGWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2819	IGHV4-31	ARVVPTRGPVAWFDP	IGKV1-39	QQSYSTLLYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2381	IGHV1-58	AAPYCSRTSCHDAFDI	IGKV3-20	QHFGSSSQWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2628	IGHV3-9	AKDIIRQGEDGMDV	IGKV1-39	HQSYFTPQT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2909	IGHV1-69	ARGRGYSNYGASYYMDV	IGLV1-40	QSYDSSLSGSV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2353	IGHV5-51	ARLGVSKYCSGGRCLSGGSNWFDP	IGKV3-15	QQYNNWPPMYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2589	IGHV2-70	ARIQYQLNGMDV	IGKV1-39	QQSYSTPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2485	IGHV1-69	ARVGVSGFKSGSNWYFDL	IGLV1-40	QSYDSSLSDSV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2693	IGHV1-8	ARMRSGWPTHGRPDDL	IGLV1-44	AVWDDSLNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2762	IGHV4-39	ARHQRYCSSSSCHVWDY	IGLV2-23	CSYAGSSTWL	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2080	IGHV3-66	ARDLVTYGLDV	IGKV1-9	QLLNSHPLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2527	IGHV4-30-4	ARFRRSYGSGSYYNISFDY	IGLV2-23	CSYVGSSTYVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2618	IGHV3-20	ASVITFGGVIVRSY	IGLV1-44	AVWDDSLNGVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2531	IGHV4-59	ARATWLRDAFGI	IGLV6-57	QSFDSGNVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2919	IGHV2-70	ARTMATINAFDI	IGKV1-39	QQSFSTPRT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2037	IGHV3-53	ARDLNEHGLDV	IGKV1-12	QQTNSFPT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2780	IGHV4-34	ARLRYSSSGGHIFDY	IGKV1-33	QQYDNLPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2710	IGHV1-8	ARMRSGWPTHGRPDDH	IGLV1-44	VAWDDSRNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2097	IGHV3-9	AKDIIRQGEDGMDV	IGKV1-39	QQSYSTPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2243	IGHV4-39	ARQSRGYSYAWSFDY	IGLV2-23	CSYAGIVL	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2694	IGHV1-69	ARDHSGYYDSTSLMSPFFDY	IGLV1-40	QSYDSSLNGDV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2826	IGHV1-46	ARGYGFVPNVLYYFDY	IGLV2-23	CSYAGSSTWL	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2813	IGHV3-53	ARDALYYNGPGRDGMDV	IGKV1-33	QQYDNLPRT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2796	IGHV4-31	ARETYSAYEMPPYFDY	IGLV2-23	CSYARSSTRV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2812	IGHV3-53	ARDALYYNGPGRDGMDV	IGKV1-33	QQYANLPFT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2941	IGHV1-58	AAPYCSSISCNDGFDI	IGKV3-20	QQYGSSPPRYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2479	IGHV1-69	ARGVVAATPGWFDP	IGKV3-15	QQYNNFLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2790	IGHV3-53	ARSYDILTGYRDAFDI	IGLV1-40	QSYDSRLSGFVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2809	IGHV1-3	ASMTRMSEQTYYGMDV	IGKV1-39	QQSYTTLLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2891	IGHV1-46	ARGAAVPAAGEFDY	IGKV1-5	QQYNSYSYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2370	IGHV4-61	AGSPVPPTIVGASY	IGLV6-57	QSYDGINRWLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2952	IGHV3-66	ARDLVTYGLDV	IGKV1-9	QLLNSHPLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2562	IGHV1-8	ARMRTGWPTHGRPDDF	IGLV1-44	LVWDDSLNGLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2137	IGHV4-61	AGSPVPPTIVGASY	IGLV6-57	QSYDGINRWLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2631	IGHV4-39	ARHPVDGYNYGYSDL	IGKV3D-20	QQYGNSPFT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2768	IGHV3-30-3	ARDDNSPQGSGWYFYYYYAMDV	IGLV1-51	GTWDSSLSAYV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2434	IGHV3-53	ARHIPAWGYK	IGKV1-33	HQYDYLPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2752	IGHV3-53	ARDFLRWHDL	IGKV1-33	QQYDNLPPV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2832	IGHV3-66	ARGDGGYYSPFDY	IGKV1-39	QQSYSTPQT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2165	IGHV3-66	ARDLVTYGLDV	IGKV1-9	QLLNSHPLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2955	IGHV3-30	AKGGPNKEVLYFGELLDYGMDV	IGKV2D-29	MQSIQLPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2499	IGHV4-39	ARHTVDCGGDCFPNDAFDI	IGLV3-19	NFRDSSGHHPV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2751	IGHV3-9	ARDYCSSTTCPAETYYYMDV	IGLV3-21	QVWDGINDRVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2835	IGHV3-66	AREVVGYFDC	IGKV1-9	QQLNSYPGYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2268	IGHV2-5	ARHQIVVLFDM	IGLV2-14	SSYTSSSTLVL	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2760	IGHV2-70	ARATTFFYGMDV	IGLV1-47	AAWDDSLSGLI	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2632	IGHV1-2	ARVVVLGYGRPNNYYDGRNVWDY	IGKV3-20	QQYVEPPFT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2730	IGHV3-9	AKAGYYAYVWGSYRFEYFDN	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2039	IGHV1-46	ARGTLIPAHRGAFDI	IGKV3-20	QQYGNSPQ	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2518	IGHV3-9	AKDIIRQGEDGMDV	IGLV3-19	NSRDSSGNAVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2939	IGHV3-33	ARDLHQDWVVVVAANVYGMDV	IGLV3-19	NSRDSSGNPRW	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2807	IGHV2-70	ARETPVTAIDY	IGKV1-39	QQSYSTPRT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2838	IGHV1-58	AAPYCSSISCNDGFDI	IGKV3-20	QHYGSSRGWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2585	IGHV3-48	ARVDYYGSGSVYWYFDL	IGLV2-11	CSYAGIWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2110	IGHV3-30-3	ARDIDSGYDPTPVFDY	IGKV1-39	QQSYSSLSIT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2355	IGHV1-58	AAPHCNRTSCYDAFDL	IGKV3-20	QQYGSSPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2822	IGHV3-53	ARGPEPDAFDI	IGKV1-9	QQSYSNPSYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2733	IGHV3-53	ARGPEPDAFDI	IGKV1-9	QQLNSYSFET	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2841	IGHV4-59	ARLRWLRGGIDF	IGLV6-57	QSYDSNNQV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2789	IGHV1-46	ARGFHVPAALRNWFDP	IGLV1-44	ATWDDSLNGPV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2786	IGHV3-13	ARVLYDSSGFYNWFDP	IGKV1-39	QQSYEIPPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2853	IGHV1-46	ARGAIPPNSRAEIDY	IGKV3-15	QQYYNWPLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2352	IGHV1-46	ARGGEWRIVPGGRDYFDY	IGKV1-39	HQSYGVPIT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2801	IGHV1-46	ARERSGTYFFDY	IGLV1-44	AVWDDSLHSYV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2253	IGHV3-74	AGSPWLRGDIDY	IGLV6-57	QSYDGSNHAVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-3010	IGHV3-30-3	ARDLSTTWYLEMWGPDAFDI	IGKV1-5	QQYNSYPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-3013	IGHV3-30	AKNLGPYCSGGTCYSLVGDY	IGKV1-33	QQYANLPFT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2945	IGHV3-9	AKLDVGGYDFVSGHYYAFDI	IGKV2-30	MQGTHWPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2103	IGHV3-7	ARLGFYYGGADY	IGLV6-57	QSYDGINRAWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2111	IGHV3-13	ARVLYDSSGFYNWFDP	IGKV1-39	QQSYEIPPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2677	IGHV4-39	ARLLWLRGHFDY	IGLV6-57	QSYDSSNYWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2354	IGHV3-53	ASSSWLRGAFDI	IGLV6-57	QSYDSSKYVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2842	IGHV1-46	ARGYGFVPNVLYYFDY	IGLV6-57	QSYDSSDVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2734	IGHV4-61	AGSPVPPTIVGASY	IGLV6-57	QSYDGINRWLV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2821	IGHV1-69	TTTQGGDYGDNLYYLDY	IGLV3-21	QVWDSSSDRLYV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2358	IGHV3-30-3	ARDIDSGYDPTPVFDY	IGKV1-39	QQSYSSLSIT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2357	IGHV3-49	SRVRGSFYGSVGKNYGMDV	IGKV2-28	MQALQTPLYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2878	IGHV3-7	ARLGFYYGGADY	IGLV6-57	QSYDGINRAWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2464	IGHV4-31	ARDLGDGYNLRVPAYFDL	IGLV3-25	QSADSSGYV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2808	IGHV1-58	AAPYCSSISCNDGFDI	IGKV1-33	QQYDNLPLA	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2863	IGHV1-46	ARENDYGDYVEPRDYYYGMDV	IGLV3-25	QSADSSAAYVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-3029	IGHV3-43	AKDEMAYPPSHHYYYYYMDV	IGLV3-25	QSVDSSGTYPHVI	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2462	IGHV3-13	ARVLYDSSGFYNWFDP	IGKV1-39	QQSYEMPPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2083	IGHV3-30	AKNLGPYCSGGTCYSLVGDY	IGKV1-33	QQYANLPFT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2313	IGHV3-9	AKVSSITSLLGYYFDS	IGKV3-11	QHRSNWPPRLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2231	IGHV3-9	AKGRGAGYTSYMDV	IGLV3-21	QVWDSSSDHHVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2516	IGHV1-46	ARDQQIVPHADGFDI	IGKV3-11	QQRSNWPPRTWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2817	IGHV3-13	ARVFETKVIRGGRYYYYYYMDV	IGKV1-39	QQSYSNPSYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2331	IGHV4-39	ARILVIFTLNWFDP	IGLV6-57	QSYDSGNPI	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2765	IGHV3-9	AKGRGAGYTSYMDV	IGLV3-21	QVWDSSSDHHVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2758	IGHV3-13	ARGGDSGYDLGAWYFDL	IGKV1-39	QQSYSMPPIT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2944	IGHV3-30	AKKGGPYCGGGNCYAGYFDY	IGKV1-33	QQYDNLPLA	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2031	IGHV2-26	ARTEWLLSDNWFDS	IGLV3-25	QSSDSSGVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2329	IGHV3-23	ARVEGDWLLGGPYYHYYGMDV	IGLV1-47	AAWDDSLSSWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2783	IGHV1-69	ARGLTGSSAYKDEIYFDY	IGLV3-25	QSADSSGSR	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2894	IGHV3-30	AKGDGSYLMDYFDY	IGKV3-15	QQYDDWPPEVT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2794	IGHV3-7	ARVNDGRPNPLEYYFDY	IGLV3-25	QSADSSGTSVL	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2749	IGHV4-34	ARVGYSQGYYYYYMDV	IGKV1-39	QQSYTTLLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2709	IGHV3-30	AKNLGPYCSGGTCYSLVGDY	IGKV1-33	QQYANLPFT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2736	IGHV3-30-3	ARDLSTTWYLEMWGPDAFDI	IGKV1-5	QQYNSYPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2382	IGHV3-30	AKDLPPYASGWYEGGFDY	IGLV7-43	LLYYGGPWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2465	IGHV4-4	ARVDHVNVRDY	IGLV2-14	SSYTSSSIPYV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2705	IGHV3-30	ARDQGTVVTHFDY	IGKV1-39	QQSYSTPPWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2713	IGHV3-43	AKDEMAYPPSHHYYYYYMDV	IGLV3-25	QSVDSSGTYPHVI	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2848	IGHV3-30	ARDLAYHPYRDYGDDDYYYYYGMDV	IGLV3-25	QSADSSGTYRV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2678	IGHV3-20	AVIMSPIPRYSGYDWAGGAFDI	IGLV3-19	NSRDSSGNAVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2722	IGHV1-69	ARLSGSGWLGYAMDV	IGLV2-14	TSYTSSSTLNVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2258	IGHV3-20	ARARGPSEQYYDLLTGYYDAFDI	IGKV3-20	QQYGGSLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2753	IGHV3-13	ARVDFDILTGYYSN	IGKV1-39	QQSYSSEWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2797	IGHV5-51	ARDLIIESTIAARPGYYGMDV	IGLV3-25	QSADSRGAV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2032	IGHV1-46	ARGGLVPAARNAFDI	IGKV1-5	QQYNSYSWT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2740	IGHV3-30	AKKGGPYCGGGNCYAGYFDY	IGKV1-39	QQSSSSPIT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2287	IGHV1-8	ARGYGLTYYMDV	IGLV3-21	QVWDSSYYHPVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2514	IGHV3-20	AVIMSPIPRYSGYDWAGDAFDI	IGLV3-19	NSRDSSGNAVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2717	IGHV1-8	ARGPSILTGFYNPLDY	IGKV1-39	QQSYSTPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2417	IGHV4-34	ARVGGYYYYYMDV	IGKV1-39	QQSYTTLLT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2015	IGHV3-9	AMGPFGELLPYYFDY	IGKV3-11	QQRSNWPPYT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2461	IGHV4-31	ARGGSGSYSLFDY	IGKV1-33	QQYDNLYSVH	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2873	IGHV3-11	TGVVAAPAEYFQH	IGLV3-21	QVWDSSSDPFYV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2953	IGHV2-5	AHSGPPDLSPVLSQGWFDP	IGLV3-25	QSADSTGWV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2828	IGHV3-21	ARGGSILWWLIDY	IGLV6-57	QSYDSTSRVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2554	IGHV1-46	ARDVFWVPAASSFDY	IGKV1-9	QQLNSYLGT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2552	IGHV3-11	ARDPIRDGVWGLNENDY	IGLV4-60	ETWDSNTRV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2906	IGHV5-51	ARLGSESKIDYYYYGMDV	IGKV1-39	QQSYSTPPT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2007	IGHV3-30	AKVSATYYYYYYGMDV	IGKV1-33	QQYDNLLFT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2450	IGHV3-30	AKQGGLYCSGTNCWGGYLDY	IGKV1-33	QQYHNLPPIT	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2342	IGHV2-5	AHRPPSYHGWCYFDY	IGKV1-39	QQSYSTHMST	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2256	IGHV7-4-1	ARDPSYCSSTRCYTVGWFDP	IGLV3-21	QVWDSSSDPVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2834	IGHV2-5	AHRLPTPQLLPSFENWFDP	IGLV1-36	ASWDDSLIGPV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2082	IGHV3-20	AVIMSPIPRYSGYDWAGGAFDI	IGLV3-19	NSRDSSGNAVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2128	IGHV4-39	ARILVIFTLNWFDP	IGLV6-57	QSYDSGNPI	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2094	IGHV3-20	AVIMSPIPRYSGYDWAGDAFDI	IGLV3-19	NSRDSSGNAVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2055	IGHV3-9	AKGRGAGYTSYMDV	IGLV3-21	QVWDSSSDHHVV	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2158	IGHV4-31	ARGGSGSYSLFDY	IGKV1-33	QQYDNLYSVH	RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2016	IGHV1-24	AAAPAVMTAGWFDP	IGLV2-14	SSYTSSTTWV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2021	IGHV1-24	ATQPAAIGGTPPYY	IGLV1-47	AAWDASLSGHVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2026	IGHV1-24	ATSFPIRGDPSYYYYYYGMDV	IGKV1-16	QQYNSYPWT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2146	IGHV3-48	ARRSYRSSWYYYYGMDV	IGKV1-9	QQLNSYPVT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2150	IGHV3-30-3	ARDWAPTYYDMPSAFDI	IGLV3-21	QVWDSSSDHPGV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2190	IGHV3-48	AREARSRYFDWLPSYYFDY	IGLV2-14	SSYTSSSTHVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2199	IGHV1-24	ATGFAVFGRAAVPY	IGLV3-1	QAWDSSTVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2210	IGHV3-30-3	ARDQEWFRELFLFDY	IGKV1-12	QQANSFPPT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2212	IGHV3-21	ARVNGNSNWNFGSYYYYYMDV	IGKV3-11	QQRGNWWT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2215	IGHV3-21	ARWLQLRSDYYYFGMDV	IGKV3-15	QQCYNWPPWT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2222	IGHV4-59	ARAPRERLQWGEYYFDY	IGLV2-23	CSYAVSTTYVI	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2228	IGHV4-34	ARPPQAARIHYYYYMDV	IGKV3-15	QQYNYWPPLT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2251	IGHV2-26	ARIVLGASGTYPSPGFDP	IGLV7-43	LLYYGGAWV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2257	IGHV4-61	ARGHVAAWESCYY	IGKV2-28	MQALQTPQT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2260	IGHV3-23	AQMGPLGSTSSAADY	IGLV3-1	QAWDSSLVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2263	IGHV3-48	ARRSYRSSWYYYYGMDV	IGKV1-9	QQLNSYPVT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2293	IGHV3-23	AKNERITMLVVVTLFDY	IGLV1-51	GTWDSSLSAVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2305	IGHV4-39	AILWRGSSWADRHYYYYSMDV	IGLV1-44	AAWDDSLNGWV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2307	IGHV3-30-3	ARDLGRGLDP	IGLV3-1	QAWDSSTAV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2335	IGHV4-39	ARHDGSGEMDTITWGPIYYYMDV	IGLV2-14	SSYTSSTLNVL	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2346	IGHV4-34	ARPPQAARIHYYYYMDV	IGKV3-15	QQYNYWPPLT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2384	IGHV2-26	ARTTWGTWIQAWYFDI	IGLV2-23	CSYAGGNTFVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2394	IGHV3-21	ARWLQLRSDYYYFGMDV	IGKV3-15	QQCYNWPPWT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2405	IGHV4-39	ASLWFGDLYSFDY	IGKV1-27	QKYNSAPWT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2438	IGHV3-23	AKLLGSGITLDNDAFDI	IGKV1-39	QQTYSTPLYT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2444	IGHV3-23	AKDFGSGIVGATGFDF	IGLV3-25	QSADSSGTYVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2455	IGHV3-48	AREARSRYFDWLPSYYFDY	IGLV2-14	SSYTSSSTHVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2459	IGHV4-39	ARRGNYYDSKNWFDP	IGKV3-15	QQYNNWPPMYT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2466	IGHV3-21	ARVNGNSNWNFGSYYYYYMDV	IGKV3-11	QQRGNWWT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2489	IGHV4-39	ARQWKWFGEAWYFDL	IGKV3-20	QQYGSSPFT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2490	IGHV3-7	ARDPYDLYGDYGGTFDY	IGKV1-5	QQYNSYSLT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2495	IGHV1-69	AREDYYGSGSLVDPYYYYRMDV	IGKV3-15	QQYNNWWRT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2525	IGHV3-23	AKDPASGIVGPTHFDY	IGLV4-69	QSWDTGIGV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2526	IGHV1-24	ATGFAVFGRAAVPY	IGLV3-1	QAWDSSTVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2533	IGHV4-31	AREANDSGSFYNGPFDY	IGKV4-1	QQYYSTRT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2558	IGHV3-30-3	ARDQEWFRELFLFDY	IGKV1-12	QQANSFPPT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2563	IGHV4-34	ARGWGWGAVAGRAEYYFDY	IGLV2-23	CSYAGSSTWG	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2571	IGHV4-59	ARDQRQFQLLGRFGWFDP	IGKV3-15	QQYNNWPRT	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2622	IGHV4-4	ARGWYFDY	IGLV2-23	YSYAGSSTWV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2673	IGHV2-26	ARIVLGASGTYPSPGFDP	IGLV7-43	LLYYGGAWV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2769	IGHV3-30-3	ARDWAPTYYDMPSAFDI	IGLV3-21	QVWDSSSDHPGV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2816	IGHV4-59	ARAPRERLQWGEYYFDY	IGLV2-23	CSYAVSTTYVI	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2830	IGHV3-23	AKDSRSGIAGVDAFDI	IGLV3-21	QVWDSGSDHVV	NTD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2582	IGHV7-4-1	ARDQDSGYPTYYYYYMDV	IGKV2D-29	MQSIQPPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2248	IGHV3-30	ARDSGGNYGDSYFDY	IGLV3-25	QSVDRSGTYFNWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2245	IGHV3-33	AGSSGEGGLYYYYGMDV	IGLV3-25	QSGDSSGTYVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2418	IGHV3-23	AKPYGMDV	IGLV2-14	SSYTSTSTPWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2378	IGHV5-51	ARRDTDFDY	IGLV9-49	GADHGSGSNFVYVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2574	IGHV4-39	ARQWKWFGEAWYFDL	IGLV4-69	QTWGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2697	IGHV1-46	ARDLAGVPAALGCWFDP	IGKV3-11	QQRSNWPLIFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2488	IGHV3-74	AREVEQLAHMVDY	IGLV3-25	QSADSSGTSWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2368	IGHV5-51	ARRRGGIGIEYGMDV	IGLV3-25	QSTASSGTYVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2496	IGHV3-33	VRDLALFEVVIQQGV	IGLV3-10	YSTDSSGNHWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2400	IGHV2-5	AHNRFQYCSSTTCYTLLPFDY	IGKV1-9	QQLNSYPFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2445	IGHV3-20	ARRRSSSRYSSGWYMYYYYMDV	IGKV1-5	QQYNTYSGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2147	IGHV3-30-3	ARSTSGSYYYGMDV	IGLV2-14	SSYTSSSTLLYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2584	IGHV3-15	TTGGYSSYAASDY	IGLV2-14	SSFTSRGALVL	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2195	IGHV3-30	AKGGDGSGWAWDGDNPPTDY	IGKV4-1	QQYYTAPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2473	IGHV3-33	AREGQMAATTGIDY	IGLV3-10	YSTDTSGNHWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2586	IGHV3-9	AKVGWELSIDAFDL	IGKV3-20	QHYGSSRST	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2173	IGHV3-20	ARRRSSSRYSSGWYMYYYYMDV	IGKV1-5	QQYNTYSGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2369	IGHV3-30	AKDFGGDNTAMVEYFFDF	IGKV1-5	QQYNSYSPT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2427	IGHV4-4	ASRWGDYFDSSGAYDS	IGKV1-12	QQGNSFPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2191	IGHV3-20	ARRRSSSRYSSGWYMYYYYMDV	IGKV1-5	QQYNTYSGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2262	IGHV1-8	AREARYFDWIFEGSDYYYYGMDV	IGLV2-18	SSYTSSSLRV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2660	IGHV3-13	ARADPYQLLGQHYYYGMDV	IGKV3-20	QQYGSSPLIT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2054	IGHV1-69	ARGRGYSNYGASYYMDV	IGKV1-33	QQSDNLPMYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2226	IGHV5-51	ATHRCSGGFCYLAY	IGLV9-49	GADHGSGSNFVFVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2700	IGHV3-30-3	AKNLGPYCSGGTCYSLVGDY	IGLV1-40	QSYDSSLSGYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2386	IGHV3-33	AREGDFWSGYYTGWFDP	IGKV3-15	QQYNNWPRT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2521	IGHV3-30	AKDRTAVFLFFGLGDAFDI	IGLV3-21	QVWDSSSDHWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2675	IGHV3-30	AKDGSGSYYGWFDP	IGKV6-21	HQSSSLPPT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2942	IGHV2-70	ARATTFFYGMDV	IGLV3-25	QSVDSSGTYRV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2621	IGHV3-33	ARDYCNGVTCNSNY	IGKV4-1	QQYYSSHWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2300	IGHV4-4	ASRWGDYFDSSGAYDS	IGKV1-12	QQANSLPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2570	IGHV4-39	ARDPRVVVTARMYNWFDP	IGKV3-15	QQYNNWPPMYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2373	IGHV3-66	ARDPGSRYSGGWYDYYYAMDV	IGKV3-20	QQYGSSPPYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2872	IGHV3-33	AREGPFGDREASGAFDV	IGLV3-10	YSTDSSGKGV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2035	IGHV2-5	AHRRGILTEDAFDI	IGKV1-39	QQSYNTPRT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2383	IGHV3-30	AQGRGGYYSPFDD	IGKV3-15	QQYNNWPLA	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2454	IGHV3-33	AREGQGTYLDY	IGLV3-10	CSTDSSGNQRV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2676	IGHV1-69	ARSCGDCYSADLDF	IGKV3-11	QRRSNWPPFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2934	IGHV7-4-1	ARPGKAAAFDY	IGKV2-28	MQALQTPWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2241	IGHV5-51	ARRGEAAGIWYFDL	IGLV9-49	GADHGSGSNFEYVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2549	IGHV3-33	AREGQWPNQAFDI	IGLV3-1	QAWDSSTHVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2428	IGHV3-33	ARKGPLWRFDY	IGLV1-40	QSYDSSLSAWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2545	IGHV4-34	ARGPPVTTFFVFSLLFDP	IGLV1-47	AAWDASLSGWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2624	IGHV1-69	ARVEGEGVDSYYYGMDV	IGLV3-25	QSTDSSGSYVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2784	IGHV4-59	ARDGGNAYSSGWYRYYYHMDV	IGKV3-15	QQYNNWPYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2726	IGHV3-30	ARPSNWYFDL	IGLV2-23	CSYASSSIVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2718	IGHV4-39	ARRTYYDLWSAYSSTAYYCMDV	IGKV1-9	QQLNSYPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2474	IGHV3-15	TTLTYYYDSSAYLNDAFDI	IGLV3-10	YSTDSSGNHRV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2947	IGHV7-4-1	ARGLISLFRGAIFHYYYGMDV	IGLV2-11	CSYAGRYTWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2177	IGHV2-5	AHRLWFRDAFDI	IGKV1-39	QQTYSTFWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2420	IGHV3-30	ARDRSNLERLVMTFGGIIAGAFDI	IGKV3-15	QQYHVWPPIT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2818	IGHV4-34	ARCRQMGNFYYYYMDV	IGKV3-20	QQYGSSPPRYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2027	IGHV3-30	AIYGYYYYGLDV	IGLV3-25	QSADSSGTYFWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2451	IGHV2-5	VHRHVSGAFDY	IGLV3-1	QAWDSSTGGV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2546	IGHV3-30	AKEGEWELRGNALDI	IGLV3-25	QSVDGSGSSVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2643	IGHV3-30	ARGSAGNYYYGMDV	IGKV1-39	QQSYSTPGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2022	IGHV1-18	ARDQGPTYYYGSGSPHYGMDV	IGKV2-40	MQRIEFPWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2656	IGHV5-51	ARLTFGGSGSYYFYYNGMDV	IGKV3-20	QQYGRSSGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2529	IGHV7-4-1	VREYGSGHPLPI	IGLV3-25	QSADSSSHWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2553	IGHV3-30	ARSPPASYYNPSTGYFDY	IGKV1-39	QQSYSTPMHT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2611	IGHV3-33	ARESADISSRLDY	IGLV3-10	YSTDSSGNV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2238	IGHV2-5	AHRAVILNFDH	IGLV3-1	QAWDNDAGVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2207	IGHV5-51	ASALRERGVQLWSV	IGLV1-40	QSYDSSLGAL	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2143	IGHV3-66	AKEGGSGSLRYYYYGMDV	IGLV1-44	AAWDDSLNGYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2296	IGHV3-66	ARDPSAYYDILTGYSGDV	IGKV1-5	QQYSIYSWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2446	IGHV5-51	ATHRCSGGFCYLAY	IGLV9-49	GADHGSGSNFVFVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2197	IGHV5-51	ARPDYSSGWFSYWYFDL	IGKV3-20	QQYGRSPIT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2142	IGHV5-51	ARRGEAAGIWYFDL	IGLV9-49	GADHGSGSNFEYVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2274	IGHV3-48	ARDRGWNYGLDY	IGLV3-10	FSMDSSGDLRV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2614	IGHV2-5	AHRLWFRDAFDI	IGKV3-15	QQYNSYSLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2904	IGHV4-34	ARCRQMGNFYYYYMDV	IGLV1-40	QSFDIGRGGWI	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2681	IGHV3-30	ARALNKGFDP	IGKV4-1	QQYYSSPYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2371	IGHV3-30	AKGRGNYLTFFDS	IGKV3-15	QQYNNWPGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2639	IGHV3-30	ARAGGGSYRGPFDY	IGLV2-11	SAYAGSNNLV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2524	IGHV5-51	ASALRERGVQLWSV	IGLV1-40	QSYDSSLGAL	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2430	IGHV4-39	ARAPFQLLDKYYFFYYMDV	IGKV3-11	QQRSNWPPGVT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-3058	IGHV3-30	ARDRSGNYRDAFDI	IGKV4-1	QQYYSSYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2602	IGHV5-51	ARPDYSSGWFSYWYFDL	IGKV3-20	QQYGRSPIT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2685	IGHV1-46	ARDRLGDGSYLGGGYYGMDV	IGKV3-20	QQYGSSPRLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2041	IGHV4-61	ARARPDYYYYYAMDV	IGKV1-5	QQYNSYSTWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2814	IGHV3-30	AKDMVEPLFSHYYYYGMDV	IGLV1-40	QSYDSSLSGYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2266	IGHV3-49	IRDYDFWGGYYYHPLRAFDI	IGLV2-11	CSYAGSYTYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2387	IGHV3-30	AKDLTIVVIPAAPNFDY	IGLV2-14	SSYTSSSTPVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2281	IGHV3-30-3	ARVPVMVRGVYFDY	IGLV2-14	ISYTSSRTLV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2235	IGHV3-53	ARESTQ	IGKV1-5	QQYNTYSQT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-3057	IGHV3-7	ARLVTTVTTANGLYYYSYYYMDV	IGLV1-40	QSYASSLSAHVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2025	IGHV3-30	AKGGDSSGWAWDGDNPPTDY	IGKV4-1	QQYYTAPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2203	IGHV3-30	ARGSAGNYYYGMDV	IGKV1-39	QQSYSTPYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2453	IGHV7-4-1	ARARLLGYCSSTSCYTIGWGAFDI	IGKV1-33	QQYDNLPPGVSTT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2189	IGHV3-9	TKASRYCSSTICYWNWFDP	IGKV1-39	QQSYSTPT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2513	IGHV3-9	TKASRYCSSTICYWNWFDP	IGKV1-39	QQSYSTPT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2401	IGHV3-30	ARPYTGSYKSYMDV	IGKV4-1	QQYYSISWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2034	IGHV1-18	ARDLPIKVVVPAADYNWFDP	IGKV1-39	QQSYSTPPT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2322	IGHV3-30	ARGDGYRSQFDP	IGKV3-20	QQYGSSYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2933	IGHV3-30-3	ARGGATNFDY	IGLV3-21	QVWDSSSDHPEWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2388	IGHV3-23	AKDQARVQDYIWGSYRSYGMDV	IGKV2-28	MQALQTPRT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2151	IGHV1-69	ARIGSYPEYFQH	IGKV3-11	HYRSNWPPVLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2403	IGHV3-30	ARGDGDVYNFLLVRNWFDP	IGLV2-14	SSYTSSSTLYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2013	IGHV3-30	AKGGDSSGWAWDGDNPPTDY	IGKV4-1	QQYYTAPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2617	IGHV1-69	ARVSGYGDYGAYSDY	IGKV3-11	QQRSNWPPRLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2341	IGHV3-30-3	ARSTSGSYYYGMDV	IGLV2-14	SSYTSSSTLLYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2273	IGHV4-39	AGEEVRGVKLYYYYAMDV	IGLV2-14	SSYTSISTWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2337	IGHV2-5	AHRLWFRDAFDI	IGKV1-39	QQSYSTPGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2515	IGHV7-4-1	ARGLVGRIDP	IGKV1-33	QQYDNLLLFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2610	IGHV7-4-1	ARGRSYGLSLGY	IGKV1-33	QQYDNLLQFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2422	IGHV3-30	ARVNSGSYYSYFDY	IGKV4-1	QQYYSTPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2250	IGHV3-30	ARGSAGNYYYGMDV	IGKV1-39	QQSYSTPYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2844	IGHV3-30-3	ARAQGGNYYYGMDV	IGLV3-21	QVWDSSSDHHVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2520	IGHV3-7	ARDVGGYSGYDLGFDYYYYMDV	IGLV3-19	NSRDSSGYIWGWM	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2960	IGHV1-18	ARVQRRRLDY	IGKV2D-29	MQSIQLA	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2006	IGHV3-30-3	ARPQSGGYYAPLDY	IGKV3-20	QQYGSSPWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2333	IGHV3-7	ARLGGSSWHFDY	IGLV3-1	QAWSSSTAV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2458	IGHV3-30	ARDPSPLVLITSIDY	IGLV3-25	QSADTIGTYWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2009	IGHV3-30	ARDTATYVLLWSGDFNLDY	IGLV2-14	SSYTSSSTLWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2616	IGHV3-72	ASVITFGGVIVRSY	IGKV3-20	QYYGSSPFG	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2517	IGHV1-69	ARIGSYPEYFQH	IGKV3-11	HYRSNWPPVLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2397	IGHV3-7	ARLSGSSWDFDY	IGLV3-1	QAWDSSTGV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2325	IGHV2-5	AHRLWFRDAFDI	IGKV1-39	QQTYSTFWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2033	IGHV4-4	ARPTAGAGGAFDT	IGLV1-44	SVWDDSLNGPL	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2310	IGHV4-61	ATGYIGTYYYYMDV	IGKV1-39	QQSYSTLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2669	IGHV3-30	AKGGDGSGWAWDGDNPPTDY	IGKV4-1	QQYYTAPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2774	IGHV3-7	VRLGVSSWYFDY	IGLV3-1	QAWGSSRGV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2340	IGHV1-3	AMGPSAFSWLDP	IGLV1-40	QSYDSSLSGWSV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2811	IGHV3-30	ARELMSVG	IGLV1-40	QSYDSSLSGWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2239	IGHV3-30-3	ARPRSGSYYAYFDY	IGKV1-16	QQYNSHPPT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2429	IGHV3-53	ARESTQ	IGKV1-5	QQYNTYSQT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2883	IGHV3-30	AKDGSIAAADY	IGKV4-1	QQYYSTPWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2536	IGHV4-61	ARGGLLWFGGAGNYMDV	IGKV4-1	QQYYSTPPYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2028	IGHV3-30	AKGGDSSGWAWDGDNPPTDY	IGKV4-1	QQYYTAPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2017	IGHV4-59	VRGAMAWFDP	IGLV1-40	QSFDSSLSGSDV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2011	IGHV3-30-3	ARGHTGNYYYGMDV	IGKV1-39	QQSYSTFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2509	IGHV3-30-3	ARPRGGSYQTCFDY	IGKV3-15	QQYNNWPGT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2406	IGHV3-7	ARLGRSSWNFDY	IGLV3-1	QAWDSSTGV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2441	IGHV1-69	ARIGHFDSSGYYLDY	IGKV3-11	QHRTNWPPLFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2564	IGHV3-30-3	ARAQGGNYYYGMDV	IGLV3-21	QVWDSSSDHHVV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2776	IGHV3-7	ARVVVEVATNKGIHGVDYYYYYYMDV	IGLV3-19	NSRDNSGNLNWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2587	IGHV2-5	AHRLWFRDAFDI	IGKV1-39	QQSYSTPT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2551	IGHV4-39	ASGPPYMATFSYYFDY	IGLV2-14	SSYTSSSTPFV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2481	IGHV1-69	ARGWFGELLKGTYWFDP	IGKV4-1	QQYYSTPG	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2029	IGHV4-4	ARPTAGAGGAFDI	IGLV1-44	SVWDDSLNGPL	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2590	IGHV1-8	ARGRVGYVGSGSRGYYYYYDMDV	IGLV3-19	NSRDSSGNHLRV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2408	IGHV4-61	ARVGGISPYYYYYYMDV	IGKV1-9	QQLNSYPIT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2565	IGHV4-61	ARGAASFDY	IGKV2-28	MQALQTPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2641	IGHV3-30	AKSYNGNYYDAFDI	IGKV3-20	QQYGSSYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2449	IGHV3-30	ARASYNSNWSIGEYFRD	IGKV4-1	QQYYSPPWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2619	IGHV3-23	ARVEGDWLLGGPYYHYYGMDV	IGLV1-47	LVWDDSLNGLV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2367	IGHV1-69	ARTSHYDSSGSYFEY	IGKV3-11	HKRSNWPPSLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2343	IGHV1-18	ARVQRRRLDY	IGKV2D-29	MQSIQLA	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2270	IGHV1-69	AITYYYDSSGYWWDD	IGKV3-11	QQRSNWPPSYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2187	IGHV3-30-3	ARGGATNFDY	IGLV3-21	QVWDSSSDHPEWV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2478	IGHV3-9	AKGIYYDIFMPLLD	IGKV3-20	HQYGTSPYT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2820	IGHV3-33	ARDQSQGAYILTGYRGYGMDV	IGKV2-28	MQALQTPFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2620	IGHV3-30-3	ARADTMVRGTYFEY	IGLV2-14	SSYTSSRAVL	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2171	IGHV3-7	ARLSGSSWDFDY	IGLV3-1	QAWDSSTGV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2583	IGHV1-8	ARGGIYYLVRGFIIGYYGMDV	IGKV4-1	QQYYSTPLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2227	IGHV3-33	ARDQSQGAYILTGYRGYGMDV	IGKV2-28	MQALQTPFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2160	IGHV3-30-3	ARSTSGSYYYGMDV	IGLV2-14	SSYTSSSTLLYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2178	IGHV3-7	ARVGSSSWYFDY	IGLV3-1	QAWDSSTAV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2159	IGHV3-30-3	ARSTSGSYYYGMDV	IGLV2-14	SSYTSSSTLLYV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2166	IGHV1-69	ARIGHFDSSGYYLDY	IGKV3-11	QHRTNWPPLFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2224	IGHV3-30	AKDGSIAAADY	IGKV4-1	QQYYSTPWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2214	IGHV1-69	ARIGHFDSSGYYLDY	IGKV3-11	QHRTNWPPLFT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2218	IGHV3-30	ARPYTGSYKSYMDV	IGKV4-1	QQYYSISWT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2216	IGHV1-69	ARTSHYDSSGSYFEY	IGKV3-11	HKRSNWPPSLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2169	IGHV1-69	ARTSHYDSSGSYFEY	IGKV3-11	HKRSNWPPSLT	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2175	IGHV3-7	ARLSGSSWDFDY	IGLV3-1	QAWDSSTGV	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
COV2-2183	IGHV3-30-3	ARADTMVRGTYFEY	IGLV2-14	SSYTSSRAVL	non-RBD	-	SARS-2_infection	Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x
2-38	IGHV3-21	TRAGWELRLDAFDI	IGLV3-19	NSRDSSGIL	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
2-7	IGHV2-5	AHHKIERIFDY	IGLV2-14	SSYTTSSTV	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
1-87	IGHV1-24	ATGIAVIGPPPSTYYYYGMDV	IGLV2-14	SSYTSSSTYV	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
1-68	IGHV1-24	ATGWAVAGSSDVWYYYYGMDV	IGLV2-18	SSYTSSSTYV	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
2-51	IGHV1-24	ATGWAYKSTWYFGY	IGLV2-8	SSYAGSRMG	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
4-18	IGHV3-30	AKDSGYNYGYSWFDP	IGLV3-25	QSTDNSGTYPNWV	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
4-19	IGHV4-59	ARSAKHWLAPPGDYYYYMDV	IGKV1-9	QQLNSYLT	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
4-20	IGHV1-46	ARPGGGSYQEFDY	IGKV1-39	QQSYNTLQVT	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
2-36	IGHV4-61	AREVYYYDRSGYYASDGFDI	IGKV3-20	QQYGSSPQT	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
5-24	IGHV3-33	ARDPRDYYDFWSGYDYYYGLDV	IGKV3-20	QQYGSSGALT	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
2-4	IGHV1-2	ARDRSWAVVYYYMDV	IGLV2-8	SSYAGSNNLV	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
5-7	IGHV1-46	ARDREPHSDSSGYWDSLKYYYYYALDV	IGKV1-9	QQLNTYPFT	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
1-20	IGHV3-53	ARDLFYYGMDV	IGKV1-9	QQLNSYPC	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
2-15	IGHV1-2	ARGGSRCSGGNCYGWAYDAFDI	IGLV2-14	SSYTSSSTFV	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
2-17	IGHV1-69	ARGVGYRGVIPLNWFDP	IGKV3-15	QQYNNWPPFT	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
2-30	IGHV3-30	ARSILYGGGMDV	IGKV1-9	QQLNSYPLT	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
2-43	IGHV1-2	ARGLGVGCSGGNCYLDYYYMDV	IGLV2-14	SSYTSSSTWV	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
4-8	IGHV1-69	ASLQTVDTAIEKYYGMDV	IGLV3-1	QAWDSSTAV	NTD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
1-57	IGHV3-72	ARVHRWAYCINGVCFGAYSDY	IGKV3-20	QQYGSSPST	RBD	-	SARS-2_infection	Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
MnC4t2p1_F5	IGHV4-39	ARGVNYYDRNGYYRNDGFDI	IGKV1-17	LQHNTYPFT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC4t2p1_E6	IGHV3-9	AKDLRRQDYYADWYFDL	IGKV1-12	QQGNSFPFT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC2t1p1_C5	IGHV3-66	ATGARFGESPFDY	IGKV1D-12	QQANSFPGT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
FnC1t2p1_G5	IGHV7-4-1	ARSLRGANLVP	IGKV1-33	QQYDNLPLT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_D6	IGHV3-49	TRVRRLWFGSYYYGMDV	IGKV2-28	MQALQTPGT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_E12	IGHV3-49	TRVRRLWFGSYYYGMDV	IGKV2-28	MQALQTPGT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC4t1p1_D5	IGHV3-9	AKDINYDSGGYHKNYFDY	IGKV1-39	QQSYSNPLT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC1t3p1_G9	IGHV3-23	ALASGSYFGGANY	IGLV7-46	LLSYTGARV	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC4t2p2_A4	IGHV7-4-1	AKIGSRNSLGV	IGKV3-20	QHFGTSSVT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p1_F4	IGHV3-30	AKGGDYEWELLES	IGKV1-5	QHYHSFPLT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p1_G4	IGHV3-66	ARDFGDFFFDY	IGKV3-20	QQYGSSPRT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC2t2p1_C11	IGHV1-69	AREGGLDYFGSRNSGWTYTWFDP	IGKV1-39	QQSYSTLYS	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_B4	IGHV1-18	ARDGELLGWFDP	IGLV2-23	CSYAGSSTWV	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p2_B10	IGHV3-66	ARDYGDYFFDY	IGKV3-20	QQYGSSPRT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
FnC1t1p2_A5	IGHV1-8	ARATTDCSSTSCWSLDFWSGYYTGGREKIFDY	IGKV3-20	QQYGSSPGT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_B10	IGHV1-69	ARVSGYDSSGYWGDY	IGKV3-11	QQRSNWPPALT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC4t1p1_A11	IGHV3-48	ASSKGFCSGGSCSDY	IGKV3-20	HQYGSSPWT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC2t1p2_D9	IGHV3-33	ARAARRPVVTDTMAYYMDV	IGKV3-11	QQRSNWPPTWT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_G6	IGHV1-2	ARASVATITDFDY	IGLV2-23	CSYAGVRTVV	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_E8	IGHV1-2	ARASVSTITDFDY	IGLV2-23	CSYAGVRTVV	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC5t2p1_G1	IGHV1-58	AAPRCSGGSCYDGFDI	IGKV3-20	QQYGSSPWT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p2_C6	IGHV1-58	AAPYCSSTRCYDAFDI	IGKV3-20	QQYGRSPWT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p1_C6	IGHV1-58	AAPHCSSTICYDGFDI	IGKV3-20	QQYGSSPWT	RBD	Yes	SARS-2_infection	Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
REGN10934	IGHV3-15	TTARWDWYFDL	IGKV1-33	QQHDDLPPT	RBD	Yes	Veloimmune	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10964	IGHV4-59	ANMVRGVYEDDY	IGKV1-39	QQNYNTPLT	RBD	Yes	SARS-2_infection	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10977	IGHV1-69	ARTPFYYDSSGYYLDY	IGKV3-20	QQYVRSPRT	RBD	Yes	SARS-2_infection	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10954	IGHV3-66	ARDHGMAAAGYNY	IGKV1-33	QQYDNLPPA	RBD	Yes	SARS-2_infection	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10933	IGHV3-11	ARDRGTTMVPFDY	IGKV1-33	QQYDNLPLT	RBD	Yes	Veloimmune	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10986	IGHV3-66	ARALPYGDLHFDY	IGLV1-40	QSYDSSLSDSYV	RBD	Yes	SARS-2_infection	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10989	IGHV1-2	ARGSRYDWNQNNWFDP	IGLV2-14	SSFTTSSTVV	RBD	Yes	SARS-2_infection	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10984	IGHV3-66	ARGELGIPYGMDV	IGLV1-51	GTWDSSLSAGV	RBD	Yes	SARS-2_infection	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10987	IGHV3-30	ASGSDYGDYLLVY	IGLV2-14	NSLTSISTWV	RBD	Yes	SARS-2_infection	Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CV30	IGHV3-53	ARDLDVSGGMDV	IGKV3-20	QQYGSSPQT	RBD	Yes	SARS-2_infection	Hurlburt et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv. 10.1101/2020.06.12.148692
MD17	IGHV3-64D	VKDQDSSSWYDAFDI	IGKV1-39	QQSYTTPLT	RBD	Yes	SARS-2_infection	Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications. 11: 4303.
MD29	IGHV3-64D	VKDQDSSSWYDAFDI	IGKV1-39	HQTYTSPYT	RBD	Yes	SARS-2_infection	Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications. 11: 4303.
MD63	IGHV3-64D	VKDQDSNSWYDAFDI	IGKV1-39	QQSYSTPYT	RBD	Yes	SARS-2_infection	Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications. 11: 4303.
MD45	IGHV3-53	ARDLSVRGGMDV	IGKV3-20	QQYGVSPEII	RBD	Yes	SARS-2_infection	Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications. 11: 4303.
MD67	IGHV3-53	ARDLSVRGGMDV	IGKV3-20	QQFGSSPLT	RBD	Yes	SARS-2_infection	Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications. 11: 4303.
MD62	IGHV3-53	ARDLQYYGMDV	IGKV1-12	QQANSFPLT	RBD	Yes	SARS-2_infection	Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications. 11: 4303.
MD47	IGHV3-23	AKDLVTAPSYEAFDI	IGLV3-21	QVWDSSSHHHVV	RBD	Yes	SARS-2_infection	Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications. 11: 4303.
BD-236	IGHV3-53	ARDLGEAGGMDV	IGKV1-9	QQLNSYPPA	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-243	IGHV3-53	ARELRGYFDY	IGKV1-33	QQYDNLPSFT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-369	IGHV3-66	ARDLVAFGMDV	IGKV1-9	QQLNSDTPT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-396	IGHV3-53	ARDWGEYYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-397	IGHV3-53	ARDYGDLYFDY	IGKV3-20	QQYGSSPRT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-494	IGHV3-53	ARDLVVYGMDV	IGKV1-9	QQLNSYPFT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-495	IGHV3-66	ARDPIRNGMDV	IGKV1-33	QQYDNLPRT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-498	IGHV3-53	ARDLVVYGMDV	IGKV1-9	QQLNSYPLT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-501	IGHV3-53	ARDRVVYGMDV	IGKV1-33	QQYDNLPPT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-515	IGHV3-66	ARDRGLVSDY	IGKV1-33	HQYDNLPRT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-598	IGHV3-53	ARDLDYYGMDV	IGKV1-9	QHLNSYPPIT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-599	IGHV3-53	ARDLVVYGMDV	IGKV1-9	QQLNSYPLT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-600	IGHV3-53	ARDLDYYGMDV	IGKV1-9	QQLNSYGLT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-601	IGHV3-53	ARDLDYGGGMDV	IGKV1-9	QQLNSYPHRFT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-602	IGHV3-53	ARPIVGARSGMDV	IGKV1D-33	QQHDNLPVT	RBD	Yes	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-603	IGHV3-53	ARDLGTYGMDV	IGKV1-9	QQLNSYLYT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-604	IGHV3-53	ARDLGPYGMDV	IGKV1-9	QQLNSDLYT	RBD	Yes	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-605	IGHV3-53	ARDLGAYGMDV	IGKV1-9	QQLNSDLYT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-606	IGHV3-53	ARDLYYYGMDV	IGKV1-9	QQLDSYPL	RBD	Yes	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-607	IGHV3-53	ARDLDYYGMDV	IGKV1-9	QQLNSYLAIT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-608	IGHV3-66	ARDLDYYGMDV	IGKV1-9	QQLNSYPPFT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-609	IGHV3-53	ARDGYGMDV	IGKV1-9	QQLNSYPPA	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-610	IGHV3-53	ARGGAYYYGMDV	IGKV1-9	QQLNTYPPFG	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-611	IGHV3-66	ARDLDYMDV	IGKV1-9	QQLNSYPPMYT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-612	IGHV3-66	ARLPYGMDV	IGKV1D-33	QQYDNLPVT	RBD	Yes	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-613	IGHV3-66	ARLPYGMDV	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-614	IGHV3-66	ARARIYTYGPDY	IGKV1-33	QQYDNLPPV	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-615	IGHV3-66	ARVGDSRSWPFEY	IGKV1-33	QQYDNLPLFT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-616	IGHV3-66	ARAPYCSSRSCET	IGKV1-33	QQYDNLPIT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-617	IGHV3-66	AREIRVITPVEV	IGKV1D-33	HQYDNLPRT	RBD	Yes	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-619	IGHV3-53	ARERGGRFDY	IGKV1-33	QQHDNLPSFT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-620	IGHV3-66	ARDRPAAAIR	IGKV1-33	QQYDNLPPA	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-621	IGHV3-66	ARDYAGRV	IGKV1-33	QQYDNLPQT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-622	IGHV3-66	ARELSYSSSSGVGPKY	IGKV1-33	QQYDNLPPT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-628	IGHV3-53	ARDYGDYYFDY	IGKV3-20	QQYGSTPRT	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-629	IGHV3-53	ARDYGDYYFDY	IGKV3-20	QQYGSSPRT	RBD	Yes	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-631	IGHV3-53	ARSYGDYYFDY	IGKV1-9	QQLNS	RBD	-	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
BD-632	IGHV3-53	ARDYGDFYFDY	IGKV3-20	QQYDSSPRT	RBD	Yes	SARS-2_infection	Du et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. DOI: 10.1016/j.cell.2020.09.035
